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SUMMARY 
It is estimated that 6742 South African women are diagnosed with cervical cancer 
and 3681 women die from the disease every year. In 1993, The Centers for Disease 
Control declared cervical cancer an Acquired Immunodeficiency Syndrome defining 
illness. Apart from persistent human papillomavirus infection, HIV infection is the 
most common co-factor contributing to cervical cancer in South Africa. Studies have 
noted that in HIV positive women, there has been an occurrence of faster 
progression to more advanced stages of cervical cancer with high cases of treatment 
failure and recurrence. There is limited literature available regarding the prognosis of 
HIV positive women who suffer from cervical cancer. Women who are HIV positive 
and have cervical cancer have not been evaluated in detail regarding their response 
and adherence to cervical cancer treatment. Standard treatment protocols for this set 
of patients have not been defined. 
The aim of this study was to assess how HIV positive women who have been 
diagnosed with cervical cancer responded and adhered to cervical cancer therapy 
which includes: curative radiotherapy; curative chemotherapy; concurrent 
chemoradiation or palliative radiotherapy. The study also evaluated the effects of the 
concurrent use of antiretrovirals and cervical cancer treatment. This was done to 
determine whether invasive cervical cancer in women who were HIV positive could 
be managed using the same treatment protocols as patients who were HIV negative.   
A historical cohort design was employed for the study. The study was conducted at 
the Oncology Department of a tertiary level hospital located in the Eastern Cape 
Province, South Africa. The total sample consisted of 196 medical records of women 
diagnosed with cervical cancer between 2005 and 2008. One hundred women were 
HIV negative, 83 were HIV positive and the HIV status of 13 women could not be 
determined. The records were audited over a period of two years from the date of 
diagnosis. 
The term „complete response‟ referred to patients who had no recurrence of cervical 
cancer and no evidence of metastases after undergoing treatment. At one month 
following treatment there was a significant difference in the incidence of complete 
response between the HIV positive patients and the HIV negative patients (Chi2 = 
XIII 
 
16.4, d.f. = 1, p = 0.00005, Cramer‟s V = 0.31). The significant difference in response 
to treatment between the HIV positive patients and the HIV negative patients was 
maintained at six months after treatment (Chi2 = 15, d.f. = 1, p = 0.00011, Cramer‟s 
V = 0.34), 12 months after treatment (Chi2 = 20.5, d.f. = 1, p = 0.00001, Cramer‟s V = 
0.37), 18 months after treatment (Chi2 = 9.8, d.f. = 1, p = 0.00173, Cramer‟s V = 
0.28) and 24 months after treatment (Chi2 = 5.0, d.f. = 1, p = 0.02571, Cramer‟s V = 
0.26). At each of these intervals, cases of treatment failure and metastases were 
significantly higher in the HIV positive women than in the HIV negative women. 
Although there was no significant difference in the incidence of adherence between 
the HIV negative women, the HIV positive women who were on HAART and the HIV 
positive women who were not on HAART, there was a significant difference in the 
incidence of the various reasons for non adherence between the various groups. 
These reasons included: missed scheduled appointments (Chi2 = 2.9, d.f. = 2, p = 
0.02385, Cramer‟s V = 0.31); low blood count (Chi2 = 4.0, d.f. = 2, p = 0.01327, 
Cramer‟s V = 0.15); radiotherapy induced skin breakdown (Chi2 = 0.6, d.f. = 2, p = 
0.04581, Cramer‟s V = 0.16) and radiotherapy induced diarrhoea (Chi2 = 6.9, d.f. = 2, 
p = 0.03118, Cramer‟s V = 0.19). According to the 2004 National Antiretroviral 
Treatment Guidelines, cervical cancer patients would fall into the WHO stage IV 
category of HIV disease thus all patients with confirmed diagnosis of invasive 
cervical cancer should be commenced on antiretrovirals as soon as the cancer 
diagnosis is made regardless of their CD4 count. However, in the current study, 13% 
(n= 83) of the HIV positive women were not on antiretrovirals. 
The study concluded that HIV positive women had a higher incidence of both 
treatment failure and metastases to cervical cancer treatment. Standard radiotherapy 
and concurrent chemoradiation cervical cancer treatment protocols should be still be 
used in both HIV negative patients and HIV positive patients so as not to 
compromise tumour control. Furthermore, in accordance with the antiretroviral 
treatment guidelines, all HIV positive patients with cervical cancer should receive 
antiretrovirals irrespective of their CD4 count.  
Keywords: adherence; chemotherapy; concurrent chemoradiation; HIV positive; 
invasive cervical cancer; radiation therapy; response; toxicity. 
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Chapter 1  
INTRODUCTION 
1.1 INTRODUCTION 
Cervical cancer is the third most commonly diagnosed cancer and the fourth most 
common cause of cancer deaths in women worldwide, accounting for 9% (529 800) 
of the total new cancer cases and 8% (275 100) of the total cancer deaths among 
females in 2008. More than 85% of these cases and deaths occur in developing 
countries. In developing countries, the incidence rate of cervical cancer is five times 
higher and the mortality rate is 10 times higher than in developed countries. In South 
Africa, it is estimated that every year 6742 women are diagnosed with cervical 
cancer and 3681 women die from the disease. (WHO Organisation Databank, 2010) 
In 1993, the Centers for Disease Control (CDC) declared cervical cancer an 
Acquired Immunodeficiency Syndrome (AIDS) defining illness (Centers for Disease 
Control and Prevention, 1993:730). In the general population, invasive cervical 
cancer (ICC) appears at a mean age of between 44 and 52 years. Among Human 
Immunodeficiency Virus (HIV) positive women, ICC occurs at a mean age of 
between 30 and 40 years. (Chirenje, 2005:273)  
1.2 BACKGROUND 
Most cases of ICC can be prevented by screening.  Developed countries provide 
effective screening services which have reduced the incidence of ICC by about 70% 
to 90%. About 40% to 90% of women in developed countries are screened for 
cervical cancer; however, less than five percent of women in developing countries 
undergo cervical cancer screening. (WHO Organisation Databank, 2010) Although a 
national cervical cancer screening policy was developed and implemented in South 
Africa in 2000, statistics have shown that less than 20% of South African women 
have used this service (Department of Health, South Africa, 2000:2). Consequently, 
cervical cancer cannot be detected in its earlier stages and most women present 
with locally advanced disease.  
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There are three methods of treatment for patients with cervical cancer: surgery; 
radiation therapy (RT) and chemotherapy (CT). Currently, concurrent chemoradiation 
(CCRT), which is the concurrent use of radiotherapy and chemotherapy, is 
considered the standard treatment for locally advanced cervical cancer. However, 
around 30% of patients with ICC will die due to local tumour relapse or the 
development of distant metastases. (National Cancer Institute, 1999) 
Advances in Antiretrovirals (ARVs) continue to improve the prognosis of HIV positive 
individuals. Thirty six percent (971 556) of the 5.6 million HIV positive South Africans 
were receiving ARVs in December 2009 (UNAIDS, 2010:113). At present, women on 
ARVs have a higher life expectancy thus there should be a focus on long term 
management. Women who are HIV positive have a higher risk of developing AIDS 
defining illnesses such as cervical cancer. There is limited literature available 
regarding the prognosis of HIV positive women who suffer from cervical cancer. 
Women who are HIV positive and have ICC have not been evaluated in detail 
regarding their response and adherence to cervical cancer treatment. Standard 
treatment protocols for this set of patients have not been defined. 
1.3 RESEARCH AIM AND OBJECTIVES 
The aim of this study was to assess how HIV positive women who have been 
diagnosed with cervical cancer responded and adhered to cervical cancer therapy 
which includes: curative RT; CCRT or palliative radiotherapy (PRT). The study also 
evaluated the effects of the concurrent use of ARVs and cervical cancer treatment. 
This was done to determine whether ICC in HIV positive women could be managed 
using the same treatment protocols as ICC in HIV negative women.   
In order to achieve the aim the following objectives were required to be fulfilled: 
 The assessment of the patients‟ response to cervical cancer treatment. This 
involved the analysis of test results such as: laboratory tests; ultrasound; 
audiogram and cystogram. The clinician‟s rectal and vaginal physical examination 
results were included in the assessment.  
 The effects of the use of ARVs on the patients‟ response to cervical cancer 
treatment was also determined. This was achieved by assessing the response to 
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cervical cancer treatment in: HIV positive patients who were on ARVs; HIV 
positive patients who were not on ARVs and HIV negative women.  
 The patients‟ adherence to cervical cancer treatment was also determined in 
order to identify the extent to which tumour recurrence or metastases occurred 
due to failure to complete treatment. This was determined by looking at the 
patients‟ total number of prescribed doses, the number of missed doses and the 
reasons for missing the dose. 
 The relationship between patient response and several prognostic factors such 
as the patients‟ age, tumour size and the duration of cervical cancer treatment 
was also assessed.  
1.4 RESEARCH DESIGN 
A historical cohort study design was employed for the study. The study was historical 
because the events that were evaluated took place before the onset of the study. 
The cohort consisted of all women diagnosed with cervical cancer between 2005 and 
2008. Cohort studies are the most suitable for studying the course of a disease, for 
instance the course of cervical cancer. They possess the correct time sequence to 
provide the strong evidence for possible causes and effects, as in the effect of 
CCRT/RT in cervical cancer patients. (Dawson & Trapp, 2001:10-19) 
1.5 SAMPLE AND SETTING 
The study was conducted at the Oncology Department of a tertiary level hospital 
located in the Eastern Cape Province, South Africa. The Oncology Department at the 
study site treats about 200 cervical cancer patients annually (newly diagnosed and 
follow up cases) and provides RT and CT for curative or palliative purposes.  
The sample was a total sample in that it consisted of the medical records of all HIV 
positive and HIV negative women diagnosed with cervical cancer between 2005 and 
2008 who were older than 18 years of age at the time of diagnosis and received CT, 
RT, CCRT or PRT. The medical files of patients who only received surgical treatment 
and patients who were younger than 18 years of age at the time of diagnosis were 
excluded from the study. 
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1.6 DATA COLLECTION 
A researcher completed questionnaire, which was referred to as an audit form, was 
employed as the data collection tool. Data was collected by reviewing the patients‟ 
medical records and noting the information on the audit form. A pilot study was 
conducted on the 5th and 6th of August 2010. Ten medical records of women 
diagnosed with cervical cancer in 2004 were reviewed in order to test the reliability 
and reproducibility of the audit form. Data collection for the main study occurred over 
a three month period, from September to November 2010. A retrospective review of 
case records of women diagnosed with cervical cancer between 2005 and 2008 was 
performed. The record of each patient was audited for a two year period from the 
date of diagnosis.  
1.7 ETHICAL CONSIDERATIONS 
The research proposal was submitted to the Faculty of Health Science Research 
Technology and Innovative Committee and to the Research Ethics Committee- 
Human at NMMU in order to obtain ethical approval. Permission was also requested 
from the Head of the Oncology Department at the study site. The letter of approval 
from the Research Ethics Committee Human is included as Appendix 1 (ethics 
clearance number: H10-HEA-PHA-001) and the letter of approval from the Head of 
Oncology Department at the study site is included as Appendix 2. Confidentiality was 
maintained at all times during the study. No patient identifiers were linked to the 
data. The study was conducted in accordance with the ethical principles of the 
Declaration of Helsinki (World Medical Association, 2008).  
1.8 RELEVANCE OF THE STUDY 
With an estimated 5.6 million people living with HIV, of which 3 million were women 
above 15 years of age, South Africa‟s epidemic remains the largest in the world. 
Apart from persistent human papillomavirus (HPV) infection, HIV is the most 
common co-factor contributing to cervical cancer in South Africa. The adult (15 to 49 
years) prevalence rate of HIV is 18.1%, thus there is a large proportion of South 
African HIV positive women who are susceptible to cervical cancer. (UNAIDS, 
2010:30) Additionally, cervical cancer is the most common cancer in black South 
African females, with a risk of 1 in 26, compared with 1 in 83 in white females (WHO 
Organisation Databank, 2010). 
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Studies have noted that in HIV positive women, there has been an occurrence of 
faster progression to more advanced stages of cervical cancer with high cases of 
treatment failure and recurrence. (Silverberg et al., 2006:511-513) Therefore, there is 
a need to determine whether HIV positive women with cervical cancer should be 
managed in the same way as their HIV negative counterparts, as is the current 
practice or whether different protocols should be developed.   
1.9 OUTLINE OF THE STUDY 
The first chapter provides an outline of the background to the study, the rationale for 
the study and a list of the aim and objectives. The literature review of the study is 
outlined in chapters two and three. Chapter two entails a detailed discussion on 
cervical cancer and the link between HIV/AIDS and cervical cancer. The main focus 
of chapter three is the use of CCRT as the standard treatment for advanced cervical 
cancer in both HIV positive and HIV negative women.  
Chapter four contains a detailed outline of the study methodology. The limitations of 
the study are also outlined in chapter four. The results of this study are presented 
and discussed in chapter five. Chapter six summarises the chief findings of the study 
and provides recommendations, which are based on the most significant 
observations of this study.  
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Chapter 2  
HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER 
2.1 INTRODUCTION  
The human papillomavirus is the causative agent of many sexually transmitted 
diseases. About 75% of sexually active women and men in the world will probably be 
infected with at least one or several types of HPV during their sexual life. (Baseman 
& Koutsky, 2005:S16) Most HPV infections can be cleared within 14 months in 
immunocompetent women. However, persistent HPV infection occurs in 
immunocompromised women, resulting in cervical dysplasia and cancer. The HPV 
types are classified as either high risk or low risk depending on their propensity to 
disrupt the normal cell cycles and lead to the development of malignancy. There are 
more than 150 types of HPV. (Knodel, 2008:1929 and Firnhaber & Michelow, 
2009:23) Of these, 12 are classified as low risk (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 
81 and CP6108), three as probable high risk (26, 53 and 66) and 15 as high risk (16, 
18, 31, 33, 35, 39, 45, 51 52, 56, 58, 59, 68, 73 and 82). Infection with HPV-16 and 
HPV-18 causes approximately 70% of cervical cancer and 50 to 60% of cervical 
precancerous lesions (Table 2.1). Table 2.1 illustrates the proportion of cervical 
cancer caused by the different HPV types. (Smith et al., 2007:622) 
Table 2.1: The proportion of cervical cancer caused by the different HPV types 
HPV type Proportion of cervical 
cancer caused (%) 
HPV type Proportion of cervical cancer 
caused (%) 
16 54.6 59 1.1 
18 15.8 56 0.8 
33 4.4 51 0.7 
45 3.7 39 0.7 
31 3.5 73 0.5 
58 3.4 68 0.5 
52 2.5 82 0.2 
35 1.8 Not identified 5.2 
Source: Smith et al., 2007:622. 
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2.2 CERVICAL CANCER 
Cervical cancer is the third most commonly diagnosed cancer and the fourth most 
common cause of cancer deaths in women worldwide, accounting for 9% (529 800) 
of the total new cancer cases and 8% (275 100) of the total cancer deaths among 
females in 2008. (WHO Organisation Databank, 2010)Overall, cervical cancer is the 
second leading cancer in South African women and the leading cancer in black 
South African women. Up to 30% of these patients are HIV positive. (Mqoqi et al., 
2004:21-22) 
Table 2.2 outlines the HIV/AIDS and cervical cancer statistics from the United States 
of America (U.S.A.), the United Kingdom (U.K.), South Africa (S.A.) and Kenya. 
Cervical cancer ranks as the most frequent cancer in the developing countries, 
Kenya and South Africa and has a lower incidence ranking in the developed 
countries, U.S.A  and U.K. (13th and 11th respectively)  (Table 2.2). 
Table 2.2: HIV/AIDS and cervical cancer statistics, 2009 
 U.S.A. U.K. S.A. KENYA 
Population of women (millions) 122.84 25.51 16.84 10.32 
HIV prevalence (%) in adults aged 15-49 
years 
0.4 0.4 16.9 7.8 
Age standardised incidence rate 7.7 8.3 37.5 28.7 
Age standardised mortality rate 2.3 3.1 21 23.4 
Annual number of new cases 13162 3181 6742 2635 
Annual number of deaths 5214 1529 3681 2111 
Incidence ranking of cervical cancer (all 
ages)* 
13
th
 11
th
 1
st
 1
st
 
Mortality ranking of cervical cancer (all 
ages)* 
12
th
 11
th
 1
st
 1
st
 
Incidence ranking of cervical cancer (15-44 
years)* 
4
th
 2
nd
 1
st
 2
nd
 
Mortality ranking of cervical cancer (15-44 
years)* 
8
th
 2
nd
 1
st
 1
st
 
Most frequent HPV type among women with 
cervical cancer 
16 16 16 16 
Rates are per 100,000 women per year. 
*Ranking among all cancers 
Sources: UNAIDS, 2009.  
WHO/ICO Information centre on HPV and cervical cancer, 2010.  
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2.2.1 Development of cervical cancer 
Cervical cancer develops in four steps: HPV transmission, viral persistence, 
progression of persistently infected cells to precancer and invasion. The reverse 
process can also occur, for instance, clearance of HPV infection and regression of 
precancer to normality. (Schiffman et al., 2007:892) 
2.2.2 Classification  
There are two classification systems used to describe cervical carcinoma precursor 
lesions: the World Health Organisation (WHO) system and the Bethseda system. 
The WHO system uses the term, Cervical Intraepithelial Neoplasia (CIN) to describe 
the abnormal cervical lesions. Mild dysplasia is classified as CIN1, moderate 
dysplasia as CIN2 and severe dysplasia as CIN3. The Bethseda System is the most 
recent and widely used classification system. It divides all cervical epithelial 
precursor lesions into two groups: Low grade squamous intraepithelial lesions (LSIL) 
which corresponds to CIN1 and High grade squamous intraepithelial lesions (HSIL) 
which corresponds to CIN2 and CIN3. (Cancer Research UK, 2009) Precancer 
includes the diagnoses of CIN3, severe dysplasia or carcinoma in situ (Von Knebel, 
2002:2231).  
Non-carcinogenic types of HPV can sometimes produce CIN2, thus the diagnoses of 
CIN1 and CIN2 is not precancer. In addition, errors that might have occurred during 
the processing and interpretation of the cervical tissue biopsy might lead to CIN1 
diagnosis. Diagnosing CIN1 does not necessarily predict a higher risk of CIN3 than a 
negative biopsy. (Cox et al., 2003:1410) 
The time between infection and microscopic evidence of precancer is often within 5 
years. The average age of diagnosis of precancer is between 25 and 35 years and 
depends on the age at first sexual intercourse. (Herrero et al., 2005:1797)  In some 
cases, precancer has been diagnosed within 2 years of sexual debut (Woodman et 
al., 2001:1831). The strongest risk factor for precancer diagnosis is the HPV type. 
For instance, persistent HPV-16 infection has a 40% risk of a precancer diagnosis, 
after 3 to 5 years of persistent infection. (Khan et al., 2005:1075) A woman with 
several HPV types has a higher risk of precancer than a woman with any one of the 
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HPV types. However, it is unknown whether the total risk of precancer for the woman 
with several HPV types is greater than the sum of the risks of individual HPV types. 
(Herrero et al., 2005:1796-1802) 
Invasive cancer involves the integration of the HPV genome into the host genome. In 
the general population, ICC is observed in women between 44 and 52 years. The 
average time between HPV infection and development of precancer appears to be 
shorter than the time it takes for precancer to develop to ICC. (Peitsaro et al., 
2002:886-887) 
2.2.3 Signs and symptoms 
Symptoms usually do not appear until abnormal cervical cells become cancerous. 
The most common symptom in the early stages is abnormal vaginal bleeding which 
may start and stop between regular menstrual periods, or after sexual intercourse, 
douching, or a pelvic exam. Menstrual bleeding may last longer and be heavier than 
usual. In addition, bleeding after menopause or increased vaginal discharge may 
also be symptoms of cervical cancer. Symptoms of advanced disease include 
voiding problems, lower back pain, leg pain, lymphoedema, weight loss and uraemia. 
(American Cancer Society, 2009:22) 
On physical examination, an ulcerating tumour originating from the cervix can be 
seen. The tumour may be confined to the cervix but it usually grows into the vagina. 
Histological examination of the tissue biopsy confirms the diagnosis. (Ansink, 
2007:69)  
2.2.4 Risk factors 
Apart from persistent HPV infection, there are socio-cultural, socio-economic and 
biological risk co-factors for HPV infection (Table 2.3). The socio-cultural co-factors 
include: early marriage; polygamy and high parity. In addition, low socioeconomic 
status among HPV infected women might be a risk co-factor because poverty is one 
of the barriers that hinder effective prevention and treatment of cervical cancer. The 
biological co-factors include: family history of cervical cancer; HIV infection; Sexually 
Transmitted Infections (STI) (chlamydia, gonorrhoea, herpes type 2); and poor 
nutritional status. (Anorlu, 2008:42-43) Other risk co-factors for cervical cancer are 
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smoking and long term use of hormonal contraception (Firnhaber & Michelow, 
2009:23).  
Table 2.3: Co-factors contributing to cervical cancer 
Co-factor  
Socio-cultural factors Early marriage, polygamy, high parity 
Socio-economic factors Poverty 
Biological factors Family history, HIV infection, STI infection, poor nutritional 
status 
Other factors Smoking, long term use of hormonal contraception 
Sources: Anorlu, 2008:42-43 and Firnhaber & Michelow, 2009:23.  
2.2.5 Stages of cervical cancer 
The International Federation of Obstetrics and Gynaecology (FIGO) staging system 
is used for cervical cancer (Table 2.4).  Cervical cancer can spread through three 
ways. Firstly, by spreading directly into the cervical stroma, parametria and then into 
the vagina, uterus, bladder and the rectum. Secondly, cervical cancer can spread 
through the lymph nodes, first to the parametrial nodes then to the pelvic nodes and 
the para-aortic nodes. This is the main way that cervical cancer spreads. Finally, 
cervical cancer can spread through the blood, although this is unusual. (Ansink, 
2007:69)
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Table 2.4: FIGO staging for cervical cancer 
Stage 0 Carcinoma in situ, cervical intraepithelial neoplasia Grade III. 
Stage I 
 
IA 
The carcinoma is strictly confined to the cervix. (extension to the corpus would be disregarded) 
Invasive carcinoma which can only be diagnosed only by microscopy. All macroscopically visible lesions –even 
with superficial invasion-are allotted to Stage IB carcinomas. Invasion is limited to a measured stromal invasion 
with a maximal depth of 5.0 mm and a horizontal extension of not more than 7.0 mm. Depth of invasion should not 
be greater than 5.0 mm taken from the base of the epithelium of the original tissue-superficial or glandular. The 
involvement of vascular spaces, venous or lymphatic, should not change the stage allotment.   
Stage IA1 Tumour limited to the cervix, invasion of not greater than 3 mm in depth and extension of not greater than 7 mm 
Stage IA2 Tumour limited to cervix, invasion between 3 and 5 mm and extension of not greater than 7 mm  
Stage IB All larger tumours that are limited to the cervix or preclinical cancers greater than Stage IA. 
Stage IB1 Clinically visible lesions not greater than 4.0 cm 
Stage IB2 Clinically visible lesions greater than 4.0 cm 
Stage II Cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina. 
Stage IIA Tumour with extension to upper two thirds of vagina. No obvious parametrial involvement. 
Stage IIB  Tumour with extension to parametria, pelvic side wall is not involved 
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Stage III The carcinoma has extended to the pelvic wall. On rectal examination, there is no cancer free space between the 
tumour and the pelvic wall. The tumour involves the lower third of the vagina. All cases with hydronephrosis or 
non functioning kidney are included, unless they are known to be due to other causes. 
Stage IIIA Tumour with extension into lower one third of vagina, with no extension to the pelvic wall. 
Stage IIIB Tumour extended to pelvic side wall and/or hydronephrosis 
Stage IV The carcinoma has extended beyond the true pelvis, or has involved the mucosa of the bladder or rectum (biopsy-
proven). 
Stage IVA Invasion into bladder and/or rectum 
Stage IVB Distant metastases 
Source: Ansink, 2007:68-69. 
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2.2.6  Treatment 
2.2.6.1 Treatment of pre-invasive lesions 
The majority of pre-invasive lesions can be effectively treated by cryotherapy, large 
loop excision of the transformation zone (LEEP/LLETZ) or conisation. In cryotherapy, 
the abnormal cells are frozen and killed using a metal probe cooled with nitrous 
oxide. Carbon dioxide can be used as an alternative gas in remote areas because it 
is cheaper and is readily available; however, it often blocks equipment. Cryotherapy 
is suitable in low resource settings because it can be provided without local 
anaesthesia or electricity. This method‟s main disadvantage is that the patients 
require a few weeks to recover and might experience discharge with some possibility 
of infection. (Seamans et al., 2006:2) 
The LEEP or LLETZ procedure involves the use of a thin wire heated with electricity 
to remove tissue from the cervix. This method is often preferred as it can be done as 
an outpatient procedure with local anaesthesia and it removes a small amount of 
cervical tissue. Cold knife conisation is used when extensive tissue removal is 
needed. Hysterectomy would also be another appropriate treatment option if LEEP 
or cold knife conisation are not feasible and if fertility is not desired.  (Kyrgiou et al., 
2006:493) 
Cytology and HPV testing are used to assess the efficacy of the LEEP procedure. 
Patients who have been successfully treated test HPV negative. The women testing 
HPV negative four to six months after the LEEP procedure have no significant risk of 
recurrent CIN2 within the subsequent two or more years. The women who test HPV 
positive must be closely monitored in order to prevent the development of ICC. 
(Arbyn et al., 2005:S7-10) 
2.2.6.2 Treatment of invasive cancer 
In general, both immunocompetent and HIV positive women are managed in the 
same way. However, HIV positive women must be closely monitored for both 
therapeutic efficacy and unusual toxicity. (Msadabwe, 2009:34) Developing countries 
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lack adequate resources and skills thus standard treatment for cervical cancer as 
described in textbooks is not often feasible.  
2.2.6.3 Guideline recommendations for the management of cervical cancer 
The possible options recommended for the treatment of cervical cancer are 
summarised in Table 2.5. These recommendations were obtained from the 2008 
British Associated Guidelines for HIV associated malignancies and from the United 
States National Cancer Institute website. The British and the American guidelines 
are identical and are used to manage the various stages of cervical cancer (Bower et 
al., 2008:359-360 and United States National Cancer Institute, 2010). The South 
African Department of Health has not published guidelines for the management of 
cervical cancer, thus the study site used the recommendations from the British and 
American guidelines to manage the cervical cancer patients at the study site. 
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Table 2.5: U.K. and U.S.A. guideline recommendations for the management of cervical cancer  
Stage Treatment options 
IA 1. Total hysterectomy: if the depth of invasion is less than 3 mm and no vascular or lymphatic channel 
invasion is noted, Oophorectomy is optional and should be deferred for younger women.  
2. Conization: In women wishing to preserve fertility, if the depth of invasion is less than 3 mm, no 
vascular or lymphatic channel invasion is noted, and the margins of the cone are negative. 
3. Modified radical hysterectomy: For patients with tumour invasion between 3 mm and 5 mm and for 
patients where the depth of tumour invasion was uncertain because of invasive tumour at the cone 
margins.  
4. Intracavitary radiation therapy alone: For women who are not surgical candidates, if the depth of 
invasion is less than 3 mm and no lymphatic invasion is noted. The recommended dose is 100 Gy to 
125 Gy.  
 
 
IB/IIA 
 
1. Radiation therapy: External beam pelvic radiation therapy combined with two or more intracavitary 
brachytherapy applications. Radical hysterectomy and bilateral pelvic lymphadenectomy.  
2. Postoperative total pelvic radiation therapy plus chemotherapy following radical hysterectomy and 
bilateral pelvic lymphadenectomy: The recommended radiation dose is 50 Gy that should be 
administered for five weeks plus chemotherapy with cisplatin with or without fluorouracil (5-FU) for 
patients at high risk of recurrence including those with positive pelvic nodes, positive surgical margins, 
and residual parametrial disease. 
3. Radiation therapy plus chemotherapy with cisplatin or cisplatin/5-FU for patients with bulky tumours.  
 
IIB/III/IVA 
 
1. Radiation therapy plus chemotherapy: Intracavitary radiation therapy and external beam pelvic 
radiation therapy to the pelvis combined with cisplatin or cisplatin/fluorouracil. 
 
 
 
 
 
Radical hysterectomy with pelvic lymphadenectomy  OR 
Neoadjuvant chemotherapy + radical surgery  
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Stage Treatment options 
IVB No standard chemotherapy treatment that provides substantial palliation is available. Therefore, these 
patients are suitable candidates for clinical trials testing single agents or combination chemotherapy 
agents listed below or new anticancer treatments in phase I and II clinical trials. 
1. Radiation therapy may be used to palliate central disease or distant metastases.  
2. Chemotherapy.  
 Cisplatin (15%–25% response rate). 
 Ifosfamide (31% response rate).  
 Paclitaxel (17% response rate).  
 Ifosfamide/cisplatin. 
  Irinotecan (21% response rate in patients previously treated with chemotherapy). 
 Paclitaxel/cisplatin (46% response rate).  
 Cisplatin/gemcitabine (41% response rate).  
 Cisplatin/topotecan (27% response rate). 
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Stage Treatment options 
Recurrent 
disease  
No standard chemotherapy treatment that provides substantial palliation is available. Therefore, these 
patients are suitable candidates for clinical trials testing single agents or combination chemotherapy 
agents listed below or new anticancer treatments in phase I and II clinical trials. 
1. For recurrence in the pelvis following radical surgery, radiation therapy in combination with 
chemotherapy (fluorouracil with or without mitomycin) may cure 40% to 50% of patients. 
2. Chemotherapy can be used for palliation.  
 Cisplatin (15%–25% response rate).  
 Ifosfamide (15%–30% response rate). 
 Paclitaxel (17% response rate).  
 Irinotecan (21% response rate in patients previously treated with chemotherapy). 
 Bevacizumab (11% response rate). 
 Ifosfamide/cisplatin. 
  Paclitaxel/cisplatin (46% response rate).  
 Cisplatin/gemcitabine (41% response rate).  
 Cisplatin/topotecan (27% response rate).  
 Cisplatin/vinorelbine (30% response rate). 
 
Sources: Bower et al., 2008:359-360 and United States National Cancer Institute, 2010. 
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2.2.7  Prognosis 
There are several prognostic factors that influence the survival of cervical cancer 
patients. These factors include: patient characteristics (age, blood haemoglobin 
level); tumour characteristics (stage, lymph node involvement, size of tumour); and 
treatment characteristics (doses, duration of treatment). (Borowsky et al., 2005:E19)  
2.2.7.1 Patient characteristics: age and blood haemoglobin (Hb) level 
It is believed that cervical cancer in younger patients is more aggressive than in 
older ones (Brewster et al., 1999:1466). However, age is not an independent 
prognostic factor for the survival of cervical cancer patients due to the selection of 
different treatment options. Younger women with small tumours undergo surgical 
treatment, while women of the same age with bigger tumours usually receive 
radiotherapy. Therefore, poor prognosis cannot be related to age alone. (Ho et al., 
2004:461) 
Blood Hb level is an independent prognostic factor for the overall survival, disease 
free survival and the local control of the tumours. However, it has no prognostic 
value for distant metastases free survival. The link between anaemia, a condition 
associated with low Hb levels and poor prognosis in cervical cancer patients remains 
unclear. One theory suggests that anaemia is usually present at the moment of 
diagnosis in patients with poor prognosis. Therefore tumour related anaemia is a 
sign of tumour aggressiveness. In these cases, correction of the Hb level during 
treatment will have no impact on the effect of the treatment. (Grogan et al., 
1999:1528) 
Another theory suggests that the relationship between anaemia and poor prognosis 
of cervical cancer could be linked to poor tumour sensitivity to RT due to decreased 
oxygen supply.  In these cases, correction of the Hb level during treatment could 
have a positive impact on the effect of the treatment. (Grogan et al., 1999:1528) 
More severe anaemia develops in patients treated with CCRT than with RT alone, 
because of the additive myelosuppressive effect of chemotherapeutic drugs. 
Therefore, effective prevention and management of anaemia is essential in order to 
improve the prognosis of cervical cancer patients. (Kim et al., 2007:199) 
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2.2.7.2 Tumour characteristics: clinical stage and lymph node involvement 
Although clinical stage is one of the main prognostic factors in cervical cancer 
patients, it depends on other factors such as lymph node involvement and the 
selected treatment option (Waggoner, 2003:2217). It has been found out that rapid 
disease progression and a shorter survival occurs in patients whose lymph nodes 
are more than 10 mm before treatment (Ho et al., 2004:463). 
2.2.7.3 Treatment characteristics 
The prognosis of cervical cancer depends on when treatment is initiated. Detection 
and treatment of cervical cancer in its earliest stages significantly improves 
prognosis. This is due to the fact that treatment of local lesions is more effective than 
systemic treatments such as CT. (Committee on Practice Bulletins-Gynaecology, 
2002:857) With treatment, the five year relative survival rate for the earliest stage of 
invasive cervical cancer is 92% and the rate for all the stages combined is 72% 
(American Cancer Society, 2009:22). Approximately, 80% to 90% of women with 
stage I cancer and 50% to 65% of women with Stage II cancer who receive 
treatment are still alive five years after diagnosis. Only 25% to 35% of women with 
Stage III cancer and 15% or less of women with Stage IV cancer are alive five years 
after diagnosis. (Gershenson & Ramirez, 2008) 
According to literature, the longer the duration of chemoradiotherapy, the shorter the 
overall survival, disease free survival and local control of the tumour (Waggoner, 
2003:2223 and Taylor et al., 1990:97). The American Brachytherapy Society 
recommends that the total treatment duration for cervical cancer should be less than 
eight weeks (Nag et al., 2000:202). Prolonging the duration of treatment could 
interfere with the therapeutic effect of CCRT (Green et al., 2001:785 and Lukka et 
al., 2002:209). 
2.2.8  Prevention of cervical cancer 
There are primary and secondary prevention strategies. The primary prevention 
strategies include creating awareness, implementing safe sexual practices, smoking 
avoidance, good nutrition and HPV vaccination. Secondary prevention strategies 
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include cytology, visually inspecting the cervix and HPV deoxyribonucleic acid (DNA) 
testing. (Firnhaber & Michelow, 2009:24) 
2.2.8.1 Primary prevention strategies 
2.2.8.1.1 Creating awareness 
This involves educating women about the causes, risk factors, symptoms and 
prevention strategies of cervical cancer. (Firnhaber & Michelow, 2009:24) 
2.2.8.1.2 Implementing safe sexual practices and family planning methods 
It is important to adopt safe sexual practices such as the use of condoms. A study 
showed that regular use of condoms may increase HPV clearance and increase the 
rate of regression in HIV negative women. However, the impact of condom use on 
HPV transmission in HIV positive women remains unknown. (Holmes et al., 
2004:456) In addition, the rate of HPV transmission may be lower in circumcised 
males (Castellsague et al., 2002:1107). The tough keratinised epithelium of the 
circumcised penis might decrease male HPV infection and carriage. Supposedly, the 
mucosal epithelium of the uncircumcised penis is more susceptible to HPV infection 
and replication. The keratinised stratified squamous epithelium provides better 
protection from HPV infection than the mucosal epithelium. (Thompson et al., 
2004:1567-1571)   
Family planning is also important because it helps an individual to attain the desired 
number of children thus avoiding multiparity. A study conducted in Mali to determine 
the association between parity and invasive cervical cancer found that women with 
higher parity were more likely to have cervical cancer than women of lower parity, 
with the risk of cervical cancer increasing by 1.1 times for each additional birth. 
(Bayo et al., 2002:204) Other case control studies conducted by the International 
Agency for Research on Cancer (IARC) reported that women with HPV infection who 
had seven or more full term pregnancies were four times more likely to develop 
cervical cancer as compared to nulliparous women with HPV infection. Furthermore, 
a two-fold increased risk of cervical cancer was noted in women who had HPV 
infection and had one or two full term pregnancies. (Munoz et al., 2002:1096) Similar 
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results were also obtained in cohort studies conducted in Costa Rica, Thailand and 
United States (Castellasague & Munoz, 2003:20-28). 
It has been suggested that parity is a marker of the oestrogen-hormonal environment 
throughout the fertile years of women as well as a marker of repeated cervical 
trauma among women who are highly parous. Oestradiol has been noted to induce 
immortalization of HPV infected cells. (Bayo et al., 2002: 204) 
2.2.8.1.3 Smoke avoidance 
Cohort studies in Costa Rica, Portland, Copenhagen and Manchester were 
conducted to explore a link between cigarette smoking and cervical cancer. The 
participants were divided into „currently smoking vs. never smoked‟ women who had 
HPV infection. The studies indicated that women who reported that they had ever 
smoked were two times more likely to have cervical cancer than women who had no 
history of smoking. These studies provided evidence that cigarette smoking can 
increase the risk of cervical cancer in women with persistent HPV infection. 
(Castellasague & Munoz, 2003:20-28) This evidence was reviewed in 2002 by the 
monograph programme at IARC and cigarette smoking was found to be an 
independent risk factor for cervical cancer (IARC, 2002). 
Studies have suggested that chemicals such as benzopyrene from cigarette smoke 
damage the cervix and make it vulnerable to HPV infection (Plummer et al., 2003: 
810). There is some evidence that smoking cessation can resolve HPV induced 
cervical abnormalities (Prokopczyk et al., 1997:871). Health workers should advise 
women with cervical abnormalities to stop smoking in order to prevent the 
progression of precancer to ICC.  
2.2.8.1.4 HPV vaccination 
Two vaccines, Cervarix® and Gardasil® provide protection against some HPV types. 
Cervarix® provides protection against HPV types 16 and 18, while Gardasil® 
protects against HPV types 6, 11, 16 and 18.  Approximately 70% of cervical cancer 
is caused by HPV types 16 and 18. These vaccines target females between the ages 
of 9 and 26 years because the vaccine only works if given before HPV infection 
occurs. Therefore, the timing of HPV vaccination requires knowledge of the median 
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age of sexual debut in the population. Health workers are thus targeting females 
before they start having sex and become exposed to HPV or HIV. The vaccines are 
administered as three 0.5 ml intramuscular injections over a six month period.  The 
duration of protection is not yet known, but there is evidence of protection for at least 
five years after vaccination. (Sankaranarayanan, 2007:5-9)  Larger studies are 
currently being conducted in Nordic countries to evaluate longer term duration. 
(Firnhaber & Michelow, 2009:25) 
Multivalent vaccines which target a wide range of HPV types are being tested 
(Schiller & Nardelli-Haefliger, 2006:S148). There is also a therapeutic HPV vaccine 
that is in the early phases of testing. This vaccine will be given to women who are 
already infected with HPV to prevent the progression of the virus. (De Jong et al., 
2002:3456)  
Unfortunately, the vaccines are very expensive and very few countries have 
programmes to fund HPV vaccination (Table 2.6). Currently there are two vaccines 
that are available in South Africa, Cervarix® and Gardasil®. These vaccines were 
introduced in 2008 but are not yet available in the public health sector. (Harries et al., 
2009:39) Furthermore, cervical screening may still be required as 30% of cervical 
cancer is caused by HPV types other than 16 and 18. The use of the HPV vaccines 
in men and the duration of immunity is unknown. (Knodel, 2008:1929 and Firnhaber 
& Michelow, 2009:25) Vaccination could also increase the risk of irresponsible 
sexual behaviour because people might think that once they are vaccinated they are 
completely immune to developing cervical cancer (Rydstorm & Tornberg, 2006:301). 
The safety and efficacy of HPV vaccines in HIV positive women is still unclear 
because it is not known whether a sufficient antibody response to the vaccine will be 
obtained. (Firnhaber & Michelow, 2009:25) 
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Table 2.6: HPV vaccine programmes in U.S.A., U.K., S.A. and Kenya 
 U.S.A. U.K. S.A. KENYA 
Bivalent vaccine (Cervarix) No Yes Yes Yes 
Quadrivalent vaccine (Gardasil/Silgard) Yes Yes Yes Yes 
HPV vaccine schedule 11-12 years 12-13 years x 
3 
No No 
Introduction in entire or part of the 
country 
Entire Entire Part Part 
Source: WHO/Institut Catala d‟Oncologia (ICO) Information centre on HPV and cervical cancer, 2010.  
2.2.8.2 Secondary prevention strategies 
Cervical cancer, unlike other cancers, can be prevented but is fatal if left untreated.  
Screening programmes detect the disease at an early stage thus reduce the cases 
of cervical cancer. These programmes are based on cervical smears. There are 
three methods used to detect cervical abnormalities: cervical cytology; visual 
inspection using acetic acid (VIA) and HPV DNA testing. (Firnhaber & Michelow, 
2009:24) Although most cervical abnormalities clear without treatment, close 
monitoring is still needed as most precancers and cancers are diagnosed in women 
with abnormal cytological findings (Kinney et al., 2006:973).  
Usually women are screened and if any abnormalities are detected, the women are 
referred to a colposcopy centre for a colposcopic biopsy. The biopsy is used to 
diagnose precancer or to make distinctions such as CIN1, 2, or 3. The biopsy also 
provides information about the location and extent of disease which is important for 
choosing the most appropriate treatment option. (Ferris & Litaker, 2006:706-708) 
Once the diagnosis is confirmed, women are referred for treatment (Firnhaber & 
Michelow, 2009:24). 
Cervical cytology involves the use of the Papanicolaou test, or Pap smear for 
cervical cancer screening. Cells from the cervix are collected using a brush, put on a 
microscope slide and screened by a cytologist for abnormalities. It is the only proven 
method for reducing the incidence and mortality of cervical cancer in large-scale 
population screening.The range of sensitivities and specificities of conventional 
cytology for the detection of HSIL in screening studies are 40% to 86% and 88% to 
99%, respectively. However, in routine screening settings the estimated sensitivity 
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for HSIL is only 50% to 60%. Cytology is also associated with a significant false 
negative rate. (Firnhaber & Michelow, 2009:25) Pap smear screening involves 
people who are skilled in collecting the smears, cytologists, pathologists, laboratory 
services and an effective follow up system. These professionals are often lacking in 
developing countries. (Ansink, 2007:68)  
Precancerous lesions can be highlighted by VIA so that the lesions can be viewed 
with the naked eye. The cervix is inspected with the naked eye before and after 
application of acetic acid. The sensitivity for detecting HSIL ranges from 66% to 96% 
and the specificity from 64% to 98%. (Firnhaber & Michelow, 2009:25) 
The VIA method has several advantages: the results are available immediately thus 
avoiding the need for multiple visits in most cases, and reducing loss to follow-up; it 
can be taught to nurses, midwives and other health workers in a short space of time 
and it costs less than other approaches such as cervical cytology in routine use 
because no specimen transport, expensive laboratory equipment or highly trained 
professions are needed. (Firnhaber & Michelow, 2009:26) 
The disadvantages of VIA include: low specificity – a considerable number of women 
who test positive do not have disease, resulting in unnecessary anxiety and 
treatment; lack of standardised methods of quality control because there is no 
permanent record of the test and the results highly depend on the accuracy of the 
screener‟s interpretation. Moreover, the efficacy and cost-effectiveness of large scale 
VIA based population screening programmes in reducing the incidence of, and 
mortality from, cervical cancer are not known.  Most of the time, VIA has been 
evaluated as a once in a lifetime screening test, and its performance in periodic 
screening has not been assessed. (Firnhaber & Michelow, 2009:26) 
One advantage of the HPV DNA testing method is that this method does not require 
subjective interpretation of the results like the Pap smear and VIA (Knodel, 
2008:1929). Unfortunately, HPV DNA testing is expensive, it depends on reagents 
that are currently produced by very few commercial manufacturers, and has low 
specificity in younger women. In addition, the tests need to be transported to the 
laboratory and highly trained personnel are required to carry out the tests. The 
patients need to return to the clinic for results, so there is potential loss to follow-up. 
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The required resources are often not available in developing countries. A rapid HPV 
test, the HPV Digene Fast Test, has been developed for use in countries with low 
resources. The test eliminates the need for laboratories. (Firnhaber & Michelow, 
2009:26) 
The best method of screening in both HIV positive and HIV negative women has yet 
to be determined. Even though there is no evidence that VIA is more accurate than 
Pap smears, VIA might decrease the proportion of inadequate smears. Inadequate 
smears are not abnormal smears. They are observed in settings like the tropics 
where conventional smears are susceptible to air drying or where there is 
widespread cervical inflammation. Thus VIA may decrease the risk of interpreting 
inadequate smears as abnormal smears and avoid patient anxiety and unnecessary 
treatment. (Ronco et al., 2007:28) 
2.2.9 Barriers that prevent the early diagnosis, prevention or treatment 
of cervical cancer. 
Women in many developing countries experience barriers that hinder the early 
detection and treatment of cervical cancer. Approximately, 80% of cervical cancer 
cases occur in developing countries where screening only covers 5% of the female 
population. (Munoz et al., 2002:1093) About 60% to 75% of women who develop 
cervical cancer in sub-Saharan Africa live in rural areas. Many women with cervical 
cancer lack access to health care due to financial or geographical reasons. (Anorlu, 
2008:43) In a situational analysis for cervical cancer diagnosis and treatment in the 
East, Central and Southern African countries, it was found that, although 95% of 
health care facilities had the infrastructure for cervical screening, very few women 
were screened due to lack of policy guidelines, infrequent supply of basic materials, 
and lack of suitably qualified staff. (Chirenje et al., 2001: 129-131) 
2.2.9.1 Lack of education 
The lack of knowledge about cervical cancer and screening practices has been 
found to impede screening programmes in South Africa. Only 2% of women in rural 
South Africa, who were found to have a STI had sought medical attention. (Denny et 
al., 2006:73) This finding is consistent with other studies that revealed lack of public 
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awareness of HPV infection (Anhang et al., 2004:318-319; Kaiser Family 
Foundation, 2000; Katz et al., 2007:131; Mays et al., 2000:372-374 and Van Til et 
al., 2003:1116). In addition, various studies have shown that most health care 
workers lack the necessary skills required to screen for abnormal cervical 
abnormalities and to effectively educate patients about HPV infection. (Jain et al., 
2006:484 and Sussman et al., 2007:302) 
2.2.9.2 Inadequate human resources 
The management of cervical cancer involves a multidisciplinary team of cytologists, 
gynaecologists, oncologists, nurses and counsellors. These medical professionals 
are lacking in many developing countries and where the professionals exist they tend 
to work in isolation rather than in teams. (Anorlu, 2008:45) 
2.2.9.3 Lack of policy guidelines or lack of implementation of policy guidelines 
In South Africa, it is estimated that 1 in every 41 women will develop cervical cancer 
at some point in their lives, however, the national screening policy is yet to be fully 
implemented. There are few screening programmes throughout the rest of sub-
Saharan Africa. This is in contrast to developed countries, where the implementation 
of screening programmes has resulted in a decline in the incidence of cervical 
cancer over the last 40 to 50 years. (Wake et al., 2009:44-45) 
2.2.9.4 Lack of integration of cervical cancer and HIV management 
programmes 
There are very few facilities that offer both cervical screening services and HIV/AIDS 
management services. This means that the women have to sacrifice a lot of time and 
incur additional transport costs to visit different clinics for these services. Therefore, 
most HIV positive women do not adhere to the cervical screening recommendations. 
Women with HIV at highest risk for invasive cervical cancer are those receiving both 
inadequate screening and treatment for precancer and suboptimal antiretroviral 
therapy. (Wake et al., 2009:46) 
A study conducted in South Africa to determine HIV positive women‟s perceptions to 
cervical screening services found that cervical screening practices were not adherent 
to the screening recommendations. Only around 50 of the 100 surveyed women had 
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been screened during the last 10 years and less than a quarter had received a test 
within the previous year. Screening usually occurred at other health facilities and 
therefore, was not integrated with HIV management. (Wake et al., 2009:46-47) 
In summary, an integrated and coordinated approach in the management of both 
cervical cancer and HIV/AIDS would reduce cancer incidence, morbidity and 
mortality through prevention, early detection, treatment and palliation. 
2.2.9.5 Lack of follow up 
In sub-Saharan Africa, most centres for the management of cervical cancer are 
located in urban areas even though the majority of cervical cancer patients are 
located in rural areas. Consequently, follow up is poor because many of the women 
who live in rural areas may lack time, money or the means of transport to travel to 
urban centres for follow up after treatment. (Anorlu, 2008:45)  
2.2.9.6 Lack of support from male counterparts 
Findings from a study whose aim was to determine the knowledge, beliefs and 
attitudes of HPV and cervical cancer testing among Hispanic women in the United 
States showed that some participants preferred using condoms to prevent HPV 
infection. However, the participants reported some negative aspects of condom use 
such as: inconvenience; unreliability; stigma; and resistance by many Hispanic men. 
Many women said that they would be subjected to stigma or even physical abuse if 
they suggested using a condom with their husbands. These findings are consistent 
with other studies conducted in some African countries where women find it difficult 
to suggest the use of condoms to their partners. (Vanslyke et al., 2008:594) 
Moreover, the knowledge and attitude of men toward gynaecological diseases such 
as cervical cancer is important. In developing countries, men often influence the 
women‟s willingness to seek treatment for such diseases. Therefore, women are 
more likely to seek medical advice if they receive support from their male 
counterparts. (Singh et al., 1998:393) 
In summary, several factors hinder the prevention, early diagnosis and treatment of 
cervical cancer. These factors include: lack of education about HPV infection; lack of 
policy guidelines or lack of implementation of the policy guidelines; inadequate 
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integration of cervical cancer and HIV/AIDS management programmes; lack of follow 
up and insufficient support from male partners. 
2.3 THE LINK BETWEEN HIV/AIDS AND CERVICAL CANCER 
2.3.1 Introduction 
In 1993, the CDC declared cervical cancer an AIDS defining illness (Centers for 
Disease Control and Prevention, 1993:730). Apart from persistent HPV infection, HIV 
is the most common co-factor contributing to cervical cancer in South Africa. Though 
ARVs reduce AIDS mortality, HIV positive women could still die due to cervical 
cancer unless they acquire access to appropriate screening and treatment services 
(Castellsague et al., 2002:1110).  
Highly Active Antiretroviral Therapy (HAART) may increase the life expectancy of 
HIV positive women thus increasing their exposure to oncogenic HPV and 
significantly increase the risk for cervical cancer (Mbulaiteye et al., 2006:985). 
Furthermore, a significant number of HIV positive women are in the age group which 
has the highest cervical cancer rates (Ries et al., 2007).  In the general population, 
ICC appears at a mean age of between 44 and 52 years. Among HIV positive 
women, ICC occurs at a mean age of between 30 and 40 years. In South Africa, the 
adult (15 to 49 years) prevalence rate of HIV is 18.1% (UNAIDS, 2010:30). Thus 
there is a large proportion of HIV positive women who are susceptible to cervical 
cancer. Compared to HIV negative women, HIV positive women tend to have a 
higher prevalence of HPV, more HPV types, more HPV persistence and a higher 
prevalence of cytological abnormalities. Therefore, immune suppression caused by 
HIV infection results in poor prognosis of HPV infection. (Chirenje, 2005:273) 
2.3.2 The relationship between HIV and HPV viruses 
Cervical cancer and AIDS are both sexually transmitted diseases.  Local cervical 
immunity has an influence on the degree of cervical neoplasia. Consequently, the 
immune response affects whether HPV infection is cleared or persists to create a 
risk of cervical cancer. It has been noted that the changes that occur in the HPV cell 
are related to the functioning of the immune system. Thus, when an individual‟s 
immunity deteriorates or CD4 count lowers the HPV cell changes increase. In HIV 
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positive women, a high HPV load may indicate the reactivation of latent HPV 
infection and high HPV replication due to HIV induced immunosuppression. 
(Silverberg et al., 2006:511-513) However, studies have produced differing data 
regarding the influence of a patient‟s CD4 cell count and antiretroviral therapy on the 
course of HPV infection. This could be due to differences in the study design, study 
population and HAART use. (Committee on Practice Bulletins-Gynaecology, 
2002:858) 
2.3.3 The frequency of LSIL and HSIL in HIV positive women 
Various studies have reported that women who are HIV positive are at a higher risk 
of LSIL and HSIL (Schuman et al., 2003:129 and Hawes et al., 2003:555). A study of 
400 untreated HIV positive women who underwent HPV DNA testing, cytology, 
colposcopy, histology and a CD4 count every 6 months for 36 months showed that 
68% of women were positive for high risk HPV DNA, 35% had LSIL on Pap smear, 
and 13% had HSIL on Pap smear (Denny et al., 2008:1385-1387). Low CD4 counts 
and high viral loads are linked to abnormal cytology and high-risk HPV DNA. Another 
study in Kenyademonstrated HPV infection in 17% of HIV negative women and 49% 
of HIV positive women. The study also reported that LSIL was found in 6.9% HIV-
negative and 21% of HIV positive women, and HSIL in 0.6% of negative and 5.8% of 
positive women. High risk HPV types and low CD4 counts were linked to HSIL. 
(Yamada et al., 2008:847) 
The patients‟ CD4 count could also influence the rate at which HPV induces 
abnormal lesions in the cervix. In one study of 647 HIV positive women in Rwanda, 
abnormal cytological findings caused by HPV were observed in 91% of the women 
with a CD4 count below 200 cells/mm3, compared to 51% of women with a CD4 
count above 350 cells/mm3.  (Singh et al., 2009:1856) 
However, other studies have produced contrasting results. In a study conducted in 
Finland, 153 HIV positive participants were followed up for a mean of 5.6 years. 
Thirty three percent of the women were shown to have cervical neoplasia. The risk of 
cervical neoplasia was not associated with decreased CD4 counts, duration of HIV 
infection or use of antiretrovirals. (Lehtovirta et al., 2008:40-41) 
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The LSIL found in HIV negative women regress spontaneously. However, HIV 
positive women with LSIL have a lower rate of regression and a greater tendency to 
progression. Progression of cervical dysplasia was observed in 14% of HIV positive 
women compared with 7% of HIV negative women. Regression to normal was noted 
in 43% of HIV positive women and 66% of HIV-negative women. Cervical dysplasia 
regressed in only 45% of HIV positive women after two years, which was significantly 
lower than the regression rate in HIV negative women. (Ahdieh-Grant et al., 
2004:1076) 
In conclusion, HIV positive women are at higher risk of developing cervical 
abnormalities due to HIV induced immunosuppression. When compared to their HIV 
negative counterparts, LSIL or HSIL found in HIV positive women do not  regress 
spontaneously and  in fact tend to progress to invasive cervical cancer. 
2.3.4 The HPV oncogenic types found in HIV positive women from 
various countries 
It has been suggested that HPV types 16 and 18 account for 70% of high grade 
intraepithelial precursor lesions in HIV negative women (Smith et al., 
2007:630).However, data from various studies have shown that simultaneous 
infection with multiple HPV types occurs more frequently in HIV positive women. This 
observation has been linked to the mode of transmission of HIV and HPV, the 
inability to clear HPV infections and reactivation of latent HPV infections due to 
immune suppression. (Levi et al., 2004:228 and Strickler et al., 2003:1064-1065) 
 A study conducted in South Africa, with 148 HIV positive women as participants, 
indicated that 95% of the women had HPV. There was a median of three HPV types 
per participant, and 85% of women had one or more oncogenic HPV types (HPV 16 
accounted for 30%, followed by HPV type 35 and 53). (Firnhaber et al., 2009:10-12) 
Results from a study in Kenya indicated that the prevalence of HPV 16 was similar in 
HIV positive and HIV negative women with invasive cervical cancer (De Vuyst, 
2008:246). In Zambia, a 150 women study found that 98% of HIV positive women 
had at least one type of HPV (85% had a high risk HPV type), with a median of four 
types per participant. The most common oncogenic type was HPV 52. (Parham et 
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al., 2006:1020-1022)Data from South America and Asia also show a variety of 
oncogenic HPV types such as 16, 18, 33, 35, 52 and 81 (Bollen et al., 2006:263 and 
Cerquiera et al., 2007:80).  
Some low risk HPV types such as types 11, 53 and 61 have been detected more 
frequently in HIV positive women with HSIL than in HIV negative women with HSIL.  
This suggests that low risk HPV types that have little potential to cause oncogenic 
changes in HIV negative women may induce malignancy in HIV positive women. 
(Schiffman et al., 2005:79-81) This finding is consistent with a study that was 
conducted in South Africa to examine prevalence of HPV infection in HIV positive 
and HIV negative couples. The study revealed that oncogenic HPV types were 
dominant in 60% of the HIV negative female participants and in 73% of the HIV 
positive female participants. In addition, HIV positive women had non oncogenic 
HPV types (HPV types 11, 40, 67, 71, 72, 83 and 84) that were not detected in HIV 
negative women. (Mbulawa et al., 2009:1516) 
Data concerning the association between HIV induced immunosuppression and HPV 
type is important because currently available prophylactic vaccines target HPV type 
16 and 18 yet low risk HPV types have potential to cause neoplastic changes in the 
cervix of HIV positive women (Firnhaber et al., 2010:438). In North America and 
Europe, the prevalence of HPV 16 was more weakly associated with immune 
suppression (as determined by CD4 counts) than other types of HPV (Koshiol et al., 
2006:1628-1629).  A similar study by Firnhaber et al. (2010:433-443) was conducted 
among 1,010 HIV positive women in South Africa. Lower CD4 count was linked to 
increased cervical abnormalities. HPV type 16 was more prevalent in advanced 
cervical dysplasia. Women who were HIV positive with CD4 counts less than 200 
cells/mm3 had higher prevalence of overall HPV types. (Firnhaber et al., 2010:443) 
The study by Firnhaber et al. (2010:433-443) revealed that HPV 16 prevalence may 
be affected by the CD4 count. This was in contrast to the results obtained from the 
study conducted by Koshiol et al. (2006:1623-1629). Therefore, further studies need 
to be performed in both the developed and the developing countries. In summary, 
HIV positive women are often infected with more HPV types than HIV negative 
women and low risk HPV types have the potential to cause malignancy in the cervix. 
(Firnhaber et al., 2010:441)  
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2.3.5  Influence of Antiretroviral Therapy on HPV infection 
Antiretroviral drugs are linked to immune restoration and a reduction in the incidence 
and mortality from opportunistic infections. The use of HAART increases CD4 counts 
and decreases viral load thus partially restores immunocompetence. Research has 
produced conflicting data regarding the impact of antiretroviral therapy on the course 
of HPV infection. This could be due to differences in the study design, study 
population, the HAART regimen and variations in patient adherence. (Heard et al., 
2004:15-19) Some of the data suggests that the use of HAART positively impacts 
the course of CIN, by reducing the incidence of HSIL and increasing the regression 
rate from HSIL to LSIL. However, there has not been a HAART associated reduction 
in the incidence of cervical cancer. (Minkoff et al., 2001:2164) 
A systematic literature review by Bratcher & Sahasrabuddhe (2010:1-13) using the 
database PubMed®, investigated the impact of HAART on the development of CIN 
in HIV positive women. Twenty two articles were analysed based on the impact of 
HAART on: HPV incidence, persistence and clearance; progression and regression 
of cervical disease and the rates of invasive cervical cancer (Table 2.7). (Bratcher & 
Sahasrabuddhe, 2010:2) 
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Table 2.7: Review of trials used to investigate the impact of HAART on HPV infection 
 Impact of HAART 
Study Incidence Persistence Clearance Progression Regression ICC rate 
Heard  et al.,1998 N/A N/A N/A N/A Yes N/A 
Heard  et al., 2002 N/A N/A N/A N/A Yes N/A 
Heard  et al., 2006 No N/A N/A N/A N/A N/A 
Orlando  et al., 1999 N/A N/A N/A No N/A N/A 
Ellerbrock et al., 2000 No N/A N/A N/A N/A N/A 
Intl Collaboration on HIV 
and Cancer, 2000 
N/A N/A N/A N/A N/A Higher incidence post HAART, 
but stats not significant 
Dorucci et al., 2001 N/A N/A N/A N/A N/A Higher incidence post HAART, 
but stats not significant 
Minkoff et al., 2001 N/A N/A N/A No No N/A 
 Lillo et al., 2001 No No N/A No N/A N/A 
Moore et al., 2002 N/A N/A N/A N/A No N/A 
Schuman et al., 2003 No N/A N/A No No N/A 
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Ahdieh-Grant et al., 2004 N/A N/A N/A N/A No N/A 
Del Mistro et al., 2004 No No N/A No N/A N/A 
Clifford et al., 2005 N/A N/A N/A N/A N/A No 
Engels et al., 2006 N/A N/A N/A N/A N/A Higher incidence post HAART, 
but stats not significant 
Engels et al., 2008 N/A N/A N/A N/A N/A Lower incidence post HAART, 
but stats not significant 
Biggar et al., 2007 N/A N/A N/A N/A N/A Higher incidence post HAART, 
but stats not significant 
Soncini et al., 2007 Yes N/A N/A N/A N/A N/A 
Sirera et al., 2007 No N/A N/A N/A N/A N/A 
Sirera et al., 2008 No N/A N/A N/A N/A N/A 
Dal Maso et al., 2009 N/A N/A N/A N/A N/A Lower incidence post HAART, 
but stats not significant 
Paramsothy et al., 2009 N/A N/A Yes No No N/A 
Source: Bratcher & Sahasrabuddhe, 2010:4 
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The data on the impact of HAART on the incidence, progression and clearance of HPV 
infection obtained from the review was inconclusive. Comparison across studies was 
difficult due to differences in sample size, treatment regimens and limited availability of 
high quality methods used to assess the cervical samples. Most studies indicate that 
HAART did not reduce the incidence of cervical precancerous lesions or the 
progression from low to higher grade SIL/CIN. One theory proposed to explain this 
finding suggested that SIL/CIN represent oncogenic changes in the cervical cells 
caused by persistent HPV infection that may not be changed by the modification of the 
immune status induced in the short term by HAART. New studies need to be conducted 
that will follow up HIV positive women without cervical abnormalities while comparing 
differences in duration needed for development of these precancerous lesions. 
(Bratcher & Sahasrabuddhe, 2010:7-10) 
Data on the impact of HAART on the regression of cervical lesions also produced 
conflicting results. The definitions of the clinical endpoints of SIL/CIN differed in the 
studies thus there could have been misclassification of results. In the context of 
regression, the relationship between HIV, HPV and HAART was unclear. Enhancement 
of the HPV gene expression, which is important in SIL/CIN development, has been 
shown to occur in the presence of the HIV gene. (Olaitan et al., 1996:759-760) 
Moreover, HIV positive women seem to have decreased vaginal Langerhans cells which 
promote local cervical immunity (Bratcher & Sahasrabuddhe, 2010:10). There is some 
data that indicates that some HAART drugs such as protease inhibitors may have an 
anti-tumour effect that is independent of increased immunocompetence, however, this 
has not been proven in clinical studies. (Monini et al., 2004:868)  
There is also mixed evidence of the impact of HAART on the rates of ICC. All of the 
studies were conducted in industrialised countries where early detection and high 
quality treatment options may have prevented ICC among the HIV positive women. In 
addition, it was difficult to interpret the significance of the studies in the pre and post 
HAART eras. (Bratcher & Sahasrabuddhe, 2010:11) 
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Therefore, studies which assess the impact of HAART on the incidence, progression, 
regression of SIL/CIN and development of ICC should be conducted in developing 
countries. This is vital not only for scientific purposes but also for appropriate resource 
allocation and programme implementation. (Bratcher & Sahasrabuddhe, 2010:13) 
In 2009, a prospective cohort study was conducted to assess the influence of 
adherence and effective ARV use on CIN and cervical cancer in HIV positive women. 
The participants were assessed prior to and after HAART initiation. The oncogenic HPV 
prevalence rates were compared before and after HAART initiation. The average 
prevalence of oncogenic HPV infection decreased 36% in adherent women and 12% in 
non-adherent women. (Minkoff et al., 2010:684) 
Adherence to HAART was also associated with a reduction in the incident detection rate 
of oncogenic HPV infection. In adherent women, the rate of incident detection 
decreased 33% from a mean of 5.4/100 person visits to 3.4/100 person visits, whereas 
in non adherent women it decreased 9% from 6.1/100 person visits to 5.6/100 person 
visits. In terms of HPV clearance, adherent HAART users had marginally greater 
clearance of HPV after HAART compared with before HAART, whereas there was no 
relationship with non adherent users. (Minkoff et al., 2010:685) 
Women who were adherent to HAART had a reduction in SIL prevalence after HAART 
initiation.  However, the incidence of SIL was not lower among adherent women 
compared to non adherent women. (Minkoff et al., 2010:688) 
In conclusion, adherent and effective use of HAART was significantly linked to reduced 
HPV infection and SILs among HIV positive women. Therefore, HAART adherence and 
effectiveness should be considered when determining the impact of HAART on HPV 
infection and cervical neoplasia. 
2.3.6 Social factors that impact on cervical cancer and HIV 
There are social factors that increase the risk of women contracting both HIV and 
cervical cancer. For instance, cervical cancer and HIV are diseases of poverty and 
inequity. These conditions are more prevalent in developing countries than the 
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industrialised countries. The developing countries have insufficient resources that would 
be used to manage these conditions. (Jewkes et al., 2001:742) Furthermore, the high 
rate of violence against women has increased the risk of women contracting sexually 
transmitted infections such as HIV and HPV. Sexual abuse has been linked to high risk 
HPV infection and cervical squamous intraepithelial lesions in women. (Kahn et al., 
2005:363)  
2.3.7 Methods to improve the integration of cervical cancer and HIV/AIDS 
management 
Cervical cancer is an AIDS defining illness, thus a link exists between these two 
conditions. There is a need to integrate cervical cancer services within HIV/AIDS 
management services. This would require: the adequate allocation of financial and 
human resources to HIV/AIDS and cervical cancer management services; appropriate 
cervical cancer education programmes for both health care workers and women; policy 
development; providing HPV vaccinations for both teenage girls and boys; and 
developing effective follow up systems for cervical cancer patients. 
2.3.7.1 Increase funding 
Governments must recognise that cervical cancer and HIV are serious public health 
problems and adequate resources need to be allocated to prevention and treatment 
services (Anorlu, 2008:46). Sexual and reproductive health services should be 
considered during the allocation of funds for HIV/AIDS management. Resources should 
be invested in providing essential equipment and supplies. Increased funding would 
allow for scale up of laboratory and radiation services and procurement of expensive 
chemotherapeutic drugs. The HPV vaccine, which has proven to be effective, could also 
be made available in the public sector health services. Most South African women are 
not able to access this vaccine due to its cost as it is available only in the private sector.  
(Bourke, 2007) 
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2.3.7.2 Increased human resources 
World Health Organisation statistics for 2006 put South Africa‟s doctor to patient ratio at 
77 doctors for every 100,000 people (WHO, 2006).  Africa bears 24% of the global 
burden of disease but has only 3% of the global health workers.  In addition, most of the 
health workers are situated in urban areas, leaving people living in the rural areas with 
limited access to health care. Therefore, health ministries in Africa should increase the 
number of health workers, particularly those trained in the management of cervical 
cancer such as oncologists and gynaecologists. (Jewkes et al., 2001:736-737) 
2.3.7.3 Communication and education 
Previous findings have shown that South African women lack awareness of cervical 
cancer as a disease. Women and health care workers need to be educated on the link 
between HIV/AIDS and cervical cancer. Women should be made aware of the current 
cervical cancer screening policy. Women should be educated about the causes, risk 
factors, symptoms and prevention strategies of cervical cancer. Women should also be 
aware of their rights with regards to the cervical cancer screening policy. (Maree & 
Wright, 2007:55-58 and Lartey et al., 2003:315-316) 
The low levels literacy levels in South Africa could have a negative influence on the 
cervical cancer awareness programmes. The Department of Health found that eight 
million of the South African population would not benefit from written health promotion 
material due to low levels of literacy. (Department of Health, South Africa, 2007) 
Therefore, cervical cancer and HIV management programmes need to be tailored to the 
literacy levels of women (Paul et al., 2003:2932). 
Cultural beliefs may influence women‟s perceptions of cervical cancer. Abnormal 
vaginal bleeding, one of the signs of cervical cancer, is believed to be caused by 
witchcraft. Therefore, to avoid stigma, women who experience abnormal vaginal 
bleeding might not disclose their condition. Influential people such as community 
leaders and traditional healers should be educated about cervical cancer so that they 
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can relay accurate information to the other members of the community. The women 
would then be willing to seek treatment. (Vorobiof et al., 2001:S125-127) 
In addition, health workers also need training on how to provide services safely and 
effectively for instance, how to conduct smears properly. The quality of observations 
and interpretations made by cytotechnologists depends on their training and 
experience. Due to the shortage of health care professionals in the public sector, task 
shifting must be considered. For instance, the Department of Health could be 
responsible for HPV vaccination in schools and community health workers could 
perform services like cervical cancer screening follow up. (Bourke, 2007) Women‟s 
health days can be created, where health facilities are dedicated to screening for 
cervical cancer and performing HPV vaccinations (Reeler et al., 2009:524). Mobile 
clinics should also be established to target women in remote areas as most women who 
suffer from cervical cancer live in the rural areas (Bourke, 2007). 
2.3.7.4 Policy development 
The extent to which women participate in organised screening is linked to the structure 
of the population and how the screening programme is organised (Fylan, 1998:1509). In 
2000, a national cervical cancer screening policy was developed and implemented in 
South Africa. If the programme achieves over 75% coverage, it is expected to reduce 
the incidence of cervical cancer by half. Screening occurs by performing three free Pap 
smears for women at the ages of 30, 40 and 50. Statistics have shown that less than 
20% of women have used this service in South Africa. (Department of Health, South 
Africa, 2000:2) 
In 2010, the South African Department of Health revised the clinical guidelines for the 
management of HIV and AIDS in adults. The guidelines stipulate that women who are 
HIV positive should be offered cervical cancer screening on diagnosis and if the test is 
normal, it should be repeated every three years, irrespective of ART status. Abnormal 
Pap smears will be managed according to the result (Table 2.8). (Department of Health, 
South Africa, 2010:31) 
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Table 2.8: 2010 South African guidelines for the management of abnormal Pap smears in 
HIV positive women 
Abnormal pap smear result Management 
ASCUS Repeat in one year and if still ASCUS, refer baseline colposcopy. 
LSIL Repeat in one year and if still LSIL, refer baseline colposcopy. 
HSIL Refer colposcopy 
Carcinoma in situ Refer immediately 
ASCUS, atypical squamous cells of undetermined significance; LSIL, low grade squamous intraepithelial 
lesions; HSIL, high grade squamous intraepithelial lesions. 
Source: Department of Health, South Africa, 2010:31. 
An organised nationally coordinated programme that integrates the management of HIV 
and cervical cancer should monitor quality controls and ensure the implementation of 
the most cost effective therapies and routines (Bourke, 2007). Single or twice in a life 
time cervical cancer screening models have been proposed to improve cost 
effectiveness and efficiency in some developing countries such as India, Peru, Kenya, 
South Africa and Thailand. These computer based cervical cancer screening models 
target women between the age of 40 and 59 years. The model uses HPV DNA testing 
as the primary screening test followed by cytology. In low resource areas, HPV DNA 
testing is followed by VIA. The women who have cervical abnormalities but do not 
present with invasive cervical cancer are then treated using cryotherapy or loop 
electrosurgical excision procedure in the same screening session. This model estimates 
a 25% to 36% reduction in the lifetime risk of cancer. (Goldie et al., 2005:2165-2168) 
2.3.7.5 HPV vaccination for boys 
Vaccinating girls can only reduce the efficacy of the HPV vaccine if unprotected sex 
occurs between a vaccinated girl and unvaccinated boy. Hence, HPV vaccination for 
boys should also be considered. (Bourke, 2007) 
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2.3.7.6 Research 
In 2000, it was reported that less than 20% of the world population were covered by 
cancer registries. Therefore, the majority of the world‟s health ministries lack the basic 
data that is required to allocate resources to HIV/AIDS and cervical cancer 
management programmes. The health ministries should establish cancer registries to 
determine the extent of cervical cancer cases in their countries. This will ensure 
effective planning. South Africa has a National Cancer Registry, however, the cervical 
cancer statistics were last recorded in 2001 and are outdated.  (Bourke, 2007) 
Research should be undertaken in order to understand the local perceptions of cervical 
cancer as well as to establish the experiences faced by women diagnosed with cervical 
cancer. This might promote community engagement and support, thus ensuring 
effective service delivery through collaboration between the health care system and the 
community. (Reeler et al., 2009:524) 
2.3.7.7 Effective follow up systems 
In the developing world, most of the cervical cancer patients are found in the rural areas 
thus have limited access to health care centres due to geographical or financial 
reasons. Consequently, good monitoring and evaluation systems need to be instituted 
in order to determine the efficacy of the integrated HIV and cervical cancer 
management programmes. (Reeler et al., 2009:523) 
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Chapter 3  
CONCURRENT CHEMORADIATION 
3.1 INTRODUCTION 
Concurrent chemoradiation refers to the simultaneous use of two forms of therapy of 
cervical cancer, namely radiation therapy and chemotherapy. Previously, the therapies 
have been administered sequentially. Radiation therapy uses high energy photons to kill 
the cancerous cells. There are two forms of radiation therapy: external beam radiation 
therapy (EBRT) and intracavitary (ICT) brachytherapy. Radiation produces secondary 
charged particles and free radicals that interact with nucleic acids and kill cells. In 
EBRT, the photons are given externally in a procedure that is similar to a diagnostic x-
ray. The dose can be increased according to the volume of the tumour while sparing 
normal tissues. This treatment usually takes six to seven weeks to complete. In 
brachytherapy or internal radiation therapy, a capsule of radioactive material is placed in 
the vagina near the tumour, or the radioactive material may be placed in thin needles 
that are inserted directly in the tumour. This treatment takes a few days to complete. 
Brachytherapy permits the delivery of high doses of radiation to the tumour with minimal 
radiation of the surrounding tissue thus reduces toxicity. (Harries & Botha, 2007:66-67) 
Chemotherapy involves the use of cytotoxic agents that are administered orally or 
intravenously. The cytotoxic agents used in combination with radiotherapy include: 
cisplatin; carboplatin; 5-fluorouracil; hydroxyurea; misonidazole; mitomycin; bleomycin; 
etoposide; ifosfamide; epirubicin and the taxanes. (Serkies & Jassem, 2004:204) 
3.2 MECHANISM OF ACTION OF CONCURRENT CHEMORADIATION 
The objectives of combining chemotherapy and radiotherapy are to increase local 
tumour control, decrease distant metastases and improve survival with minimal impact 
to normal tissue (Fu, 1985:2123). Several mechanisms of interaction between 
chemotherapy and radiotherapy have been proposed (Table 3.1). 
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Table 3.1: Possible mechanisms of interaction between chemotherapy and radiotherapy 
Proposed mechanism 
Modification of the slope of the dose response curve. 
Decreased accumulation of or inhibition of repair of sublethal damage. 
Inhibition of recovery from potentially lethal damage. 
Perturbation in cell kinetics with an increase of the proportion of cells in sensitive cell cycle phase and 
proliferative state. 
Decrease in tumour bulk, improved blood supply, reoxygenation and recruitment and increased 
radiosensitivity and chemosensitivity. 
Increased drug delivery and uptake. 
Source: Fu, 1985:2125 
The slope of the dose response curve is altered when CCRT is employed. 
Chemotherapeutic agents that intercalate the DNA such as cisplatin increase the slope 
of radiation dose response curves thus enhancing the effects of radiation on both the 
tumour and normal tissues. (Fu, 1985:2123) Concurrent chemoradiation results in 
decreased accumulation or inhibition of repair of sublethal damage. Chemotherapeutic 
agents such as cisplatin inhibit the repair of sublethal radiation damage. (Fu, 
1985:2125) 
The use of CCRT may cause perturbation in cell kinetics which is beneficial as the 
effect of chemotherapeutic agents and RT may be dependent on the phase of the cell 
cycle. Chemoradiotherapy can induce synchrony in tumours and in normal tissues. For 
instance, hydroxyurea, a chemotherapeutic agent that kills cells in the S phase, partially 
synchronises and blocks cells at G1/S phase of the cell cycle. If radiation therapy is 
administered after treatment with hydroxyurea during the sensitive phase as the cells 
emerge from the block, an enhanced effect may be expected. (Fu, 1985:2126) 
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A decrease in tumour bulk, improved blood supply, reoxygenation and recruitment and 
increased radiosensitivity and chemosensitivity are consequences of CCRT. This is 
beneficial as the response to CCRT is tumour size dependent and the cytotoxic effect of 
agents such as cisplatin reduces the bulk of tumours which improves blood supply to 
the tumour. Reoxygenation of the tumour then occurs and the tumour shifts into a 
radiosensitive phase of the cell cycle. Increased drug delivery and uptake has been 
reported following CCRT. Increased drug delivery and uptake may be as a result of 
tumour shrinkage and improved blood supply after radiation. (Fu, 1985:2126) The 
chemotherapeutic agents used in the treatment of cervical cancer have been shown to 
display one or more of the mechanisms of interaction (Table 3.2).  
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Table 3.2: Mechanism of cytotoxicity and enhancement of radiation effects of some chemotherapeutic drugs used in the 
treatment of cervical cancer 
Drug Mechanism of cytotoxicity  Possible mechanism of enhancement of radiation 
effects 
Bleomycin Causes single and double strand breaks in DNA, 
inhibits DNA synthesis, and preferentially kills cells in 
G2 and M phases 
Inhibition of recovery from potentially lethal damage 
and perturbation in cell kinetics  
Cisplatin Causes DNA intrastrand crosslinks and changes in 
DNA conformation and inhibits DNA synthesis, causes 
delay in S phase 
Reduces the repair of sublethal and potentially lethal 
damage induced by radiation therapy 
Increases the slope of hypoxic cell radiation dose 
response curves 
5-Fluorouracil Binds and inhibits thymidylate synthetase and inhibits 
ribonucleic acid (RNA) processing and function 
Perturbation in cell kinetics  
Increases the slope of hypoxic cell radiation dose 
response curves 
Hydroxyurea Inhibits ribonucleoside diphosphate reductase and 
DNA synthesis, selectively kills cells in S phase 
Perturbation in cell kinetics  
Mitomycin C Causes intrastrand and interstrand crosslinks in DNA 
by alkylation and inhibits DNA synthesis 
Additive cytotoxicity 
Source: Fu, 1985:2127. 
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3.3 CONCURRENT CHEMOTHERAPY AND RADIOTHERAPY 
In 1999, the United States National Cancer Institute recommended that CCRT should 
be considered for all patients with advanced cervical cancer (National Cancer Institute, 
1999). This recommendation was based on five randomised controlled trials (Keys et 
al., 1999; Morris et al., 1999; Rose et al., 1999; Whitney et al., 1999 and Peters et al., 
2000) (Table 3.3). Each of these trials showed a significant improvement in survival 
rates and progression free survival among women with locally advanced cervical cancer 
treated with concomitant cisplatin based chemotherapy and radiotherapy (Table 3.4). 
These guidelines have been adopted worldwide and CCRT is now considered the 
standard treatment of advanced cervical cancer. (Cairns et al., 2008: 565) 
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Table 3.3: Randomised controlled trials that provided evidence for the decision that concurrent chemoradiation should be 
considered for patients with locally advanced cancer 
Trial Eligibility No. of 
participants 
  Investigational group Control group 
Keys et al., 1999 IB ( tumours >4cm) 369 CDDP 40mg/m
2
/wk (6 
cycles) 
EBRT and intracavitary 
radiation 75Gy and 55 Gy 
Hysterectomy 
EBRT and intracavitary radiation 
75Gy and 55 Gy 
Hysterectomy 
Morris et al., 1999 IB-IIA >5cm IIB-IVA 403 CDDP 75mg/m
2
 
5FU 4mg/m
2
/96h (3 cycles)  
Pelvis and para-aortic 
nodes  RT 45Gy 
Pelvis and para-aortic nodes RT 
45Gy 
Peters et al., 2000 I-IIA after radical 
hysterectomy with nodes, 
margins or parametrium 
positive 
268 CDDP 70mg/m
2
 
5-FU 4g/m
2
/96h (2 
concurrent & 2 adjuvant 
cycles) 
RT 49.3Gy 
RT 49.3Gy 
Whitney et al., 1999 IIB-IVA 368 CDDP 50mg/m
2
 
5-FU 4mg/m
2
/96h  
Standard whole pelvic RT 
Standard whole pelvic RT 
HU 3g/m
2
 (2xweekly) 
48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CDDP, cisplatin; EBRT, external beam radiation therapy; 5-FU, 5-Fluorouracil, HU, hydroxyurea; Gy, Gray; RT, radiation therapy 
Source: Green et al., 2001:782 
Rose et al., 1999 IIB-IVA 526 CDDP 40mg/m
2
/wk (6 
cycles) 
RT 
OR 
CDDP 50mg 
5-FU 4g/m
2
/96hrs (3 
cycles) 
HU 2g/m
2
 (2x weekly) 2 
cycles 
RT 
RT 
HU 3g/m
2 
(2x weekly) 
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3.4 SURVIVAL OUTCOME MEASURES 
Various survival outcome measures were used in the randomised controlled trials. 
Overall survival refers to the time from randomisation until death by any cause. 
Locoregional disease free survival is defined as the time from randomisation until 
locoregional recurrence or progression or death by any cause. Metastases free survival 
refers to the time from randomisation until first metastasis or death by any cause. 
Overall disease free survival is the time from randomisation until locoregional 
recurrence, metastasis or death by any cause. Time to metastases is defined as the 
time from randomisation until first metastases. (Chemoradiotherapy for Cervical Cancer 
Meta-analysis Collaboration (CCCMAC), 2010:3) 
Table 3.4: Survival outcomes of the five randomised controlled trials used by the 
National Cancer Institute as a basis for using concurrent chemoradiation as treatment for 
locally advanced cervical cancer 
Trial Conclusion 
Keys et al., 1999 Overall survival was significantly higher in the CCRT group at 3 years. 
Morris et al., 1999 The 5 year survival rate was 73% in the CCRT group and 58% in the radiation 
group. The disease free survival rates at 5 years was 67% in the CCRT group 
and 40% in the radiation group. The rate of distant metastasis and locoregional 
recurrence were significantly higher in the radiation group. 
Peters et al., 2000 Overall survival was significantly higher in the CCRT group. The 4 year survival 
rate was 81% in the CCRT group and 71% in the radiation group. 
Whitney et al., 1999 Overall survival was significantly higher in the CCRT group. 
Rose et al., 1999 Both groups that received cisplatin had a higher progression free survival than 
the group that received hydroxyurea alone. 
Source: Cairns et al., 2008: 566-568. 
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Although these five randomised controlled trials, (Keys et al., 1999; Morris et al., 1999; 
Rose et al., 1999; Whitney et al., 1999 and Peters et al., 2000) favoured the use of 
CCRT, a negative trial was also conducted by Pearcey et al., (2002:966-972). This 
negative trial randomised 259 patients with stage IB to IVA cervical cancer. The 
investigational group received radiotherapy (EBRT and brachytherapy) plus weekly 
cisplatin chemotherapy 40 mg/m2/wk (6 cycles) and the control group received 
radiotherapy alone (external beam radiotherapy and brachytherapy). No significant 
difference in progression free survival or 3 and 5 year survival rates were noted. 
(Pearcey et al., 2002:966-972) 
The five randomised controlled trials and the negative trial had various limitations 
because they differed in terms of the local and experimental treatments used and the 
stages of disease included. Moreover, the negative trial questioned the value of adding 
cisplatin to radiation therapy. Therefore, a systematic review of 19 trials done between 
1980 and 2000 was performed in order to summarise the effects of CCRT based on all 
the trials (Table 3.5). (Green et al., 2001:781-786) 
Of the 19 trials, 16 compared CCRT with the same radiotherapy, one trial compared 
CCRT with extended field radiotherapy and two trials compared cisplatin based CCRT 
with hydroxyurea based CCRT. Cisplatin was used in 10 of the trials, either weekly as a 
single agent or every two to six weeks in combination with 5-fluorouracil, vincristine or 
bleomycin. The other seven trials used 5-fluorouracil either as a single agent or in 
combination with mitomycin C, or mitomycin C either as a single agent or in combination 
with bleomycin or epirubicin. These trials included 4580 women who mostly had stage 
IIB to IVA cancer, but some trials included or were confined to women with stage IA to 
IIA. (Green et al., 2001:781-786) 
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Table 3.5 : Characteristics of trials reviewed by Green et al., (2001) 
Trial Eligibility Number of 
participants 
      Investigational group Control group 
Platinum based trials:  
Wong et al., 1989 IIB-IIIB 64 CDDP 25mg/m2/wk for 4 weeks + RT 
OR 
CDDP 50mg/m2/wk for 4 weeks + RT 
RT 
Lira-Puerto et al., 1990 IIB-IV 24 CDDP 20mg/m2 /wk (9 cycles) + RT RT 
Whitney et al., 1999 IIB-IVA 368 CDDP 50mg/m2 
5-FU 4mg/m2/96h + RT 
HU 3g/m2 (2xweekly) + RT 
Tseng et al., 1997 IIB-IIIB 122 CDDP 50mg/m2 
VCR  1mg/m2  
BLM 75mg/m2 every 21 days (4 
cycles) + RT 
RT 
Morris et al., 1999 IB-IIA >5cm 
IIB-IVA 
403 CDDP 75mg/m2 
5FU 4mg/m2/96h (3 cycles) + RT 
RT 
Peters et al., 2000 I-IIA  268 CDDP 70mg/m2 
5-FU 4g/m2/96h (2 concurrent & 2 
adjuvant cycles) + RT + S 
RT + S 
Keys et al., 1999 IB(tumours 
>4cm) 
369 CDDP 40mg/m2/wk (6 cycles) + RT 
+S 
RT +S 
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Rose et al., 1999 IIB-IVA 526 CDDP 40mg/m2/wk (6 cycles) + RT 
OR 
CDDP 50mg/m2 
5-FU 4g/m2/96hrs (3 cycles) 
HU 2g/m2 (2x weekly) 2 cycles  
+ RT 
HU 3g/m2 (2x weekly) + RT 
Hong Wei et al., 1997 IIB-IIIB 120 CDDP 60mg/m2 
5-FU 1500mg/m2 
VCR 2mg/m2 every 21 days (2 
cycles) 
+ RT + hyperthermia 
RT + hyperthermia 
Pearcey et al., 2000 IB2-IIA>4cm, 
IIB-IVA 
259 CDDP 40mg/m2/wk (5 cycles) + RT RT 
Pras et al., 1985 cited in 
Green et al., 2001 
IB-IIA> 4cm, 
IIB-IVA 
52 CDBCA 300mg/m2 
5-FU 2400mg/m2 every 28 days (2 
cycles) 
+ RT 
RT 
Leborgne, 1995 cited in 
Green et al., 2001 
IB2-IVA 153 CDDP 80mg/m2 
5-FU 2400mg/m2 every 28 days (2 
cycles) 
+ RT 
RT 
Non-platinum based trials:  
Singh et al., 1985 IIB-IVA 560 MMC 4mg/m2 and BLM 15mg/m2 RT 
Hernandez et al., 1999 III 27 MMC 30mg/m2/wk (5 cycles) before 
RT 
OR 
MMC 30mg/m2/wk (5cycles) after RT 
RT 
Thomas G.M., 1999 IB-IVA>5cm 234 5-FU 1000 mg/m2/day for first and RT 
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last 4 days of  RT 
Lorvidhaya et al., 2003 IIB-IVA 673 MMC 10 mg/m2, 5-FU (oral) 4200mg 
every 28 days (2 cycles) + RT 
OR 
MMC 10 mg/m2, 5-FU (oral) 4200mg 
every 28 days (2 cycles) + RT+ 
Adjuvant CT:  5-FU (oral) 5600mg 
every 28 days (3 cycles) 2 weeks rest 
every 6 weeks. 
RT 
OR 
RT + Adjuvant CT:  5-FU (oral) 
5600mg every 28 days (3 cycles) 2 
weeks rest every 6 weeks  
Wong et al., 1999 IA, IIA>4cm, 
IIB-IIIB 
220 EPI 60 mg/m2 on day one of RT + 
Adjuvant CT:  EPI 90mg/m2 every 28 
days (5 cycles)  
RT 
Fernandez et al., 1995 IIB, IIIB bulky 82 5-FU, MMC RT 
Roberts et al., 2000 IB2, II-IVA 212 MMC 30 mg/m2 every 42 days (2 
cycles) + RT 
RT 
BLM, bleomycin; CBDCA, carboplatin; CDDP, cisplatin; CT, chemotherapy; EPI, epirubicin; HU, hydroxyurea; MMC, mitomycin C; RT, radiation 
therapy; S, hysterectomy and pelvic lymphadenectomy; VCR, vincristine; 5-FU, 5-fluorouracil; Source: Green et al., 2001:782. 
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Approximately, 11 to 13 of the trials were available for meta-analysis. The results 
showed a 29% reduction in the risk of death and an absolute improvement in survival 
of 12% with CCRT compared to radiotherapy alone. Furthermore, CCRT significantly 
improved disease free survival. An absolute improvement of progression free 
survival of 13% and a reduction of local and distant recurrence rates was also noted 
with the use of both platinum and non platinum CCRT groups.  The most prominent 
finding in the meta-analysis was the significant reduction of distant metastases in the 
CCRT group. This suggested that, at the doses and the schedules used, the 
chemotherapeutic agents exerted a systemic effect. Therefore, the increase in local 
control may have been due to independent cell death by radiation and cytotoxic 
agents. Agents such as cisplatin and mitomycin might also have had a synergistic 
effect with radiation thus help to improve local control and survival. (Green et al., 
2001:786) 
The trials reviewed by Green et al. (2001:781-786) also provided information about 
toxicity caused by the use of CCRT. Toxicity can be classified as acute or late. Acute 
toxicity is defined as adverse events which occur during treatment and up to 90 days 
after completion of chemotherapy or radiotherapy.  Acute adverse events are of a 
short duration and normally diminish with medical management, while late adverse 
events are difficult to reverse and may permanently impair the patient‟s quality of life. 
Late toxicity appears nine months to five years after treatment. Chemotherapy 
toxicity might be detrimental if radiotherapy is prolonged. This is because local 
control falls by up to 1% per day if treatment continues for more than 7 weeks (Perez 
et al., 1995:1277). Therefore, toxicity caused by CCRT complicates treatment. 
(Green et al., 2001:785) 
Only a few trials reported acute toxicity in detail and different scales of measurement 
were employed. Thus, the toxicity data from the trials was classified as 
haematological, gastrointestinal, genitourinary, dermatological or neurological. Acute 
toxicity was reported in detail in eight published trials (Wong et al., 1989; Tseng et 
al., 1997; Keys et al., 1999; Morris et al., 1999; Rose et al., 1999; Whitney et al., 
1999; Wong et al., 1999 and Peters et al., 2000) and one unpublished trial 
(Leborgne, 1995 cited in Green et al., 2001). (Green et al., 2001:785) 
55 
 
Severe or life threatening haematological toxicity, particularly leucopenia, was noted 
more frequently in patients in the CCRT group than in the control group. Pelvic 
irradiation and chemotherapy can have a significant effect on the bone marrow thus 
cause haematological toxicity. In contrast, genitourinary toxicity was lower in the 
CCRT group than in the control group. Neurological and dermatological toxicity was 
not significantly different between the groups. (Green et al., 2001:785) 
Usually haematological toxicity is self limiting or resolved with medical management. 
On the contrary, gastrointestinal side effects like diarrhoea and faecal incontinence 
may become chronic (Kirwan et al., 2003:220). The bladder and the gastrointestinal 
tract were the main systems affected by late toxicity. Toxicity was not significantly 
different between the groups. However, long term follow up was not available. Seven 
deaths due to toxicity were reported, one in the control group (fistula), five in the 
investigational group (chemotherapy related death) and one due to complications. 
(Green et al., 2001:785) 
This systematic review and meta-analysis had several limitations. Heterogeneity was 
evident in the results for overall survival, progression free survival and local 
recurrence. Differences in the platinum based trials were also observed, particularly 
in the type and timing of local and systemic treatments. In addition, the length of 
follow-up and analyses of the various outcomes varied between trials. Another 
limitation was the fact that only a small proportion of the participants had advanced 
stages of cervical cancer, stage III and IV. Therefore, extrapolation of the results to 
patients with advanced stages of cervical cancer may lead to invalid conclusions. 
(Green et al., 2001:785) 
A subsequent systematic review and meta-analysis by Lukka et al. (2002:203-212) 
investigated the effects of the use of cisplatin based CCRT to treat cervical cancer. 
Eight randomised controlled trials were evaluated (Wong et al., 1989; Tseng et al., 
1997; Keys et al., 1999; Morris et al., 1999; Rose et al., 1999; Whitney et al., 1999; 
Pearcey et al., 2000 and Peters et al., 2000). The meta-analysis was conducted 
using four-year mortality rates from survival curves from six of the trials. These were 
combined with the three-year mortality rates reported by Pearcey et al. (2000:378) 
and the number of deaths by the end of the trial that was conducted by Wong et al. 
(1989). (Lukka et al., 2002:208-209) 
56 
 
The meta-analysis by Lukka et al. (2002:203-212) demonstrated that the use of 
cisplatin based CCRT resulted in the absolute reduction of the risk of death by 11%. 
The relative risk of death was similar in the studies that used different treatment 
interventions (cisplatin alone or cisplatin plus 5-FU) and different control 
interventions (RT alone or RT plus hydroxyurea). Six of the trials also showed a 
reduction in both local and distant metastatic rates. (Lukka et al., 2002:210) 
The systematic review and meta-analysis conducted by Lukka et al. (2002:203-212) 
showed increased acute toxicity, particularly haematological and gastrointestinal in 
the CCRT groups. This finding is consistent with the systematic review and meta-
analysis conducted by Green et al. (2001:781-786). Late toxicity rates were not 
significantly different between the experimental groups and the control groups. 
(Lukka et al., 2002:211) 
Although the systematic review and meta-analysis by Lukka et al. (2002:203-212) 
confirmed the benefit of the use of cisplatin based CCRT, several issues were 
raised. The use of protracted radiotherapy or suboptimal doses of RT may lead to 
poor local control (Fyles et al., 1992). Several authors (Thomas, 1998:137-145 and 
Pearcey et al. 2000:378) have observed the relatively low doses of RT used in the 
trial by Keys et al. (1999:1154-1161) and the low total dose of RT and protracted 
treatment time in the trial by Rose et al., (1999:1144-1153). Therefore, the potential 
benefit of the concurrent use of cisplatin and an optimum RT regimen remains 
unclear. (Lukka et al., 2002:211) 
The randomised controlled trials used in the systematic review and meta-analysis by   
Lukka et al. (2002:203-212), used different chemotherapeutic agents and regimens 
as well as different control treatments. Consequently, there were difficulties that were 
encountered during the interpretation of the effects of cisplatin based CCRT. 
Nevertheless, the reduction of the relative risk of death for cisplatin based CCRT 
appeared to be comparable to that for concurrent cisplatin plus 5-FU with 
radiotherapy. (Lukka et al., 2002:211) 
Although the systematic reviews and the meta-analysis by Lukka et al. (2002:203-
212) and Green et al. (2001:781-786) showed a benefit of CCRT for all stages of 
disease, only a small proportion of the participants had advanced stages of cervical 
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cancer, stage III and IV. Therefore, the data did not sufficiently represent the cervical 
cancer population in developing countries, where many women present with 
advanced disease at diagnosis. Arandomised controlled trial was initiated in India 
which compared cisplatin based CCRT with RT alone in 160 women with stage IIB to 
IVA cervical cancer. All the patients received EBRT (5000 cGy) and brachytherapy. 
Patients in the CCRT arm received 30mg/m2 of cisplatin. Cisplatin, which is readily 
available and affordable, was administered weekly for five weeks during the course 
of external radiotherapy. The complete response rate was 83% in the CCRT arm and 
73% in the RT arm. The adherence rate was similar in both arms. At 54 months, the 
overall survival rate had increased from 47% to 56% and the disease free survival 
had increased from 37% to 51% in the CCRT arm. Neutropenia was the major dose 
limiting toxicity and was observed more in the CCRT arm. Radiation proctitis was the 
most common late toxicity that was reported.  (Mitra et al., 2006:432-436) 
Both reviews (Lukka et al., 2002:203-212 and Green et al., 2001:781-786) noted that 
it was difficult to interpret the benefits of CCRT due to the different treatments 
employed in the included studies. The authors concluded that a meta-analysis of 
individual patient data (IPD) was required to fully review all the existing evidence. 
The IPD meta-analysis would: explain the heterogeneity observed in the evaluated 
trials and give more consistent analysis with respect to progression free survival, 
local and distant recurrence and CCRT induced toxicity. (Lukka et al., 2002:203-212 
and Green et al., 2001:781-786)   
A further meta-analysis was initiated and coordinated by the U.K. Medical Research 
Council Clinical Trials Unit and was carried out by the Concomitant 
chemoradiotherapy in Cervical Cancer Meta-Analysis Collaboration (CCCMAC). 
Although 18 trials were identified, only 15 were eligible for the meta-analysis. Of the 
15 trials, 13 trials compared CCRT versus the same radiotherapy. In the other two 
trials, chemotherapy was administered after CCRT. (Chemoradiotherapy for Cervical 
Cancer Meta-analysis Collaboration (CCCMAC), 2010:3) 
The meta-analysis was limited to include trials that compared CCRT and radical RT 
(with or without surgery) with the same radical RT (with or without surgery). The 15 
trials were conducted between May 1987 and June 2006. Table 3.6 shows the 
regimens that were used in the experimental arms of the trials. The prescribed EBRT 
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dose used in the trials was between 40 and 61.2 Gy. (Chemoradiotherapy for 
Cervical Cancer Meta-analysis Collaboration (CCCMAC), 2010:3) 
Table 3.6: Regimen used in the experimental arms of the trials included in the meta-
analysis conducted by The Chemoradiotherapy for Cervical Cancer Meta-Analysis 
Collaboration (CCCMAC) 
Regimens used in the 
experimental arm 
Number of 
trials 
Trials 
Platinum based 
chemoradiotherapy 
11 Leborgne, 1995; Pras, 1995; Chen et al., 1997; 
Keys et al., 1999; Onishi et al., 2000; Peters  et 
al., 2000; Pearcey et al., 2002; Cikaric et al., 
2005; GaripaAYaoAYlu et al., 2004; Kantardzic 
et al., 2004 and Lal et al., 2004 
Non- platinum based 
chemoradiotherapy: 5-FU OR 
mitomycin-C OR  5-FU plus 
mitomycin-C 
3 Thomas et al., 1998; Roberts et al., 2000 and 
Lorvidhaya  et al., 2003. 
Cisplatin based or 5-FU based 
chemoradiotherapy 
1 Lanciano et al., 2005 
Source: Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC), 2010:6. 
The CCCMAC meta-analysis found that the type of CT (platinum based or non 
platinum based), the planned RT dose and the total planned duration of radiation did 
not affect the effect of CCRT. Similarly, for the ten cisplatin based trials, the effect of 
CCRT was not affected by the dose of cisplatin or the cycle length. 
(Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC), 
2010:8) 
In terms of survival, there was a significant difference between the 13 trials that used 
CCRT and the two trials that used additional CT after CCRT was administered. A 
54% reduction in the risk of death and an absolute survival benefit of 19% at 5 years 
was observed in the two trials that used adjuvant CT after CCRT. In the other 13 
trials that used CCRT only, a 19% reduction in the risk of death and an absolute 
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survival benefit of 6% at 5 years was observed. Data on disease free survival and 
metastases free survival was also obtained from the 13 trials (Table 3.7). 
(Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC), 
2010:8) Thus from the 13 trials it can be summarised that there is an improvement in 
the 5 year survival rate when CCRT is used instead of RT and that the two trials 
where CT was administered after CCRT had a larger survival benefit. 
Table 3.7: Absolute survival benefit at 5 years (%) after administration of CCRT 
Outcome Absolute survival benefit at 5 years (%) 
Overall disease free survival 8% 
Locoregional disease free survival 9% 
Metastases free survival  7% 
Source: Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC), 2010:8. 
Data on toxicity was obtained from all the trials. Serious gastrointestinal toxicity was 
noted in the trials that used platinum based CCRT and the trials where additional CT 
was administered after CCRT. Increased cases of acute haematological toxicity were 
observed in the groups that received CCRT as opposed to RT. (Chemoradiotherapy 
for Cervical Cancer Meta-analysis Collaboration (CCCMAC), 2010:14) 
Most of the trials analysed by CCCMAC did not record late toxicity thus it was 
difficult to assess the effect of the type of treatment on late toxicity. Late rectal 
toxicity was recorded in seven trials, late bladder toxicity was recorded in five trials 
and late intestinal and vaginal toxicity was recorded in four trials. Nine deaths were 
recorded. (Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration 
(CCCMAC), 2010:14) 
The CCCMAC meta-analysis confirmed the benefit of CCRT on metastases as 
suggested in the previous reviews (Lukka et al., 2002:203-212 and Green et al., 
2001:781-786). Thus, CCRT may have a systemic effect. Furthermore, the meta-
analysis showed that the benefit of CCRT may not depend on the use of a platinum-
based chemotherapeutic agent. The National Cancer Institute (National Cancer 
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Institute, 1999) recommendations were limited to platinum based CCRT regimen. 
Significant benefits have been noted with non-platinum based CCRT, particularly 
with the use of 5-Fluorouracil and mitomycin C. Although a larger benefit was 
observed in the trials that used additional CT after CCRT, the trials differed in design 
thus the results may not be conclusive. (Chemoradiotherapy for Cervical Cancer 
Meta-analysis Collaboration (CCCMAC), 2010:15) 
In conclusion, the systematic reviews and IPD meta-analysis indicated a significant 
benefit for CCRT in cervical cancer. 
3.5 HIV INFECTION AND CHEMORADIATION 
Currently, HIV positive and HIV negative women with cervical cancer are managed 
in the same way. It is unknown whether the therapeutic ratio for CCRT in HIV 
negative women is maintained or altered in HIV positive women. There is inadequate 
literature available on HIV positive women with invasive cervical cancer regarding 
the response to chemoradiation, side effects, patient adherence and rate of survival. 
Thus, standard treatments for these patients have not been defined. (Formenti et al., 
1995:411-412) Some studies suggest that HIV positive cervical cancer patients are 
known to have poor response to RT and early recurrence, resulting in poorer overall 
survival (Maiman et al., 1990:377).  
A few studies have been conducted to assess the impact of RT on HIV positive 
women with cervical cancer.  A retrospective study by Shrivastava et al. (2005:31-
35) looked at 42 HIV positive women with cervical cancer. Radical RT was 
prescribed for 32 participants, however, only 22 patients completed the prescribed 
RT and only 50% of these patients achieved complete response. Treatment delays 
occurred due to gastrointestinal toxicity in 14% of the patients and skin toxicity in 
27% of the patients. (Shrivastava et al., 2005:34-35) 
Another prospective study by Gichangi et al. (2006:405-411) looked at 218 cervical 
cancer patients who underwent RT. Twenty percent of these participants were HIV 
positive. It was noted that HIV infection was an independent factor that led to 
treatment interruptions. In addition, HIV positive women were six times more likely to 
have residual tumours after RT. A seven fold higher risk of gastrointestinal, skin and 
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genitourinary toxicity was also noted in HIV positive women. (Gichangi et al., 
2006:405-411)  
The immune status influences the response to cervical cancer treatment. Patients 
with CD4 counts greater than 500 cells/mm3 have a more favourable prognosis. If 
HAART is not administered during ICC treatment, the viral load may increase. (Little 
et al., 2000:A11) With the concomitant use of HAART and CCRT, there is no 
increase in viral load during CT. The CD4 count falls by 50% but recovers rapidly 
within a month after treatment. Therefore, improving the immune function of HIV 
positive women through the administration of ARVs should be considered when 
making management decisions in HIV infected women with cervical cancer. 
(Maiman, 1998:49) However, it has been stated that drug interactions and toxicities 
of antiretroviral agents may affect the patient response and adherence to CCRT 
(Powles et al., 2002:535). 
Chemotherapeutic agents have a narrow therapeutic index and inherent toxicity thus 
it is important to be aware of other drugs that may interact with these cytotoxic 
agents. Antiretroviral agents such as didanosine and stavudine may cause 
peripheral neuropathy. The risk of peripheral neuropathy is increased if cisplatin is 
concomitantly administered with these ARVs. Other interactions include 
myelosuppression which is caused by zidovudine and chemotherapeutic agents 
such as cisplatin. Protease inhibitors such as indinavir may induce or inhibit 
enzymes that are responsible for the metabolism of the chemotherapeutic agents 
resulting in pharmacokinetic interactions. Protease inhibitors also cause lactic 
acidosis which may mimic tumour progression. The route of elimination of HAART 
and the effect on the cytochrome P450 (CYP450) system is summarised in Table 
3.8. Potential pharmacokinetic interactions may occur between HAART and 
chemotherapeutic agents (Table 3.9). Interpatient variability can also influence drug 
interactions. Variables such as gender, age, genetics and/or comorbid conditions 
can affect the patients‟ response to treatment and the toxic effects that they might 
experience. (Mounier et al., 2009:10-13) Therefore, close monitoring of HIV positive 
women who are receiving CCRT and ARVs must be instituted (Powles et al., 
2002:531). 
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Table 3.8: Route of elimination of HAART and the effect on the CYP 450 system 
Drug  Elimination  Effect on CYP450 system  
 
Nucleoside and nucleotide reverse transcriptase inhibitors: 
 Zidovudine (ZDV) Hepatic metabolism with 
renal excretion 
None 
 Didanosine (ddI) Renal excretion 50% None 
 Stavudine (d4T) Renal excretion 50% None 
 Lamivudine (3TC) Renal excretion 70% None 
 Abacavir (ABC) Hepatic Minimal 
 Emtricitabine (FTC) Renal excretion 86% None 
 Tenofovir (TDF) Renal excretion 70–80% None 
Non-nucleoside reverse transcriptase inhibitors: 
 Nevirapine (NVP) Hepatic CYP3A4 inducer 
 Efavirenz (EFV) Hepatic CYP3A4 inducer 
Protease inhibitors: 
 Saquinavir (SQV) Hepatic CYP3A4 inhibitor 
 Ritonavir (RTV) Hepatic CYP3A4 and CYP2D6 inhibitor; CYP3A4 
and CYP1A2 inducer 
 Indinavir (IDV) Hepatic CYP3A4 inhibitor 
 Fosamprenavir (f-
APV) 
Hepatic CYP3A4 inhibitor 
 Lopinavir/ritonavir 
(LPV/r) 
Hepatic CYP3A4 and CYP2D6 inhibitor; CYP3A4 
and CYP1A2 inducer 
 Atazanavir (ATZ) Hepatic CYP3A4 inhibitor, CYP1A2, CYP2C9 
inhibitor 
 Darunavir (DRV) Hepatic CYP3A4 inhibitor 
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 Tipranavir (TPV) Hepatic CYP3A4 inducer 
Integrase inhibitors: 
 Raltegravir (RTV) Hepatic None 
Fusion inhibitors: 
 Enfuvirtide (INN) Hepatic None 
Source: Mounier et al., 2009:13 
Table 3.9: Potential pharmacokinetic interactions that may occur between HAART and 
chemotherapeutic agents 
Chemotherapy  
 
Enzymes that mediate 
bio-transformation  
Interaction with NNRTI 
drugs (CYP inducers)  
 
Interaction with PI 
drugs (CYP 
inhibitors)  
 
Alkylating agents: 
 Cyclophosphamide 3A4, 2B6, 2D6 ↑ _ 
 Ifosfamide 3A4 ↑ ↓ 
 Lomustine 3A4 ↑ ↓ 
Anthracyclines: 
 Doxorubicin 3A4 _ ↓ 
 Mitoxantrone 3A4 _ ↓ 
Camptothecins: 
 Irinotecan 3A4 ↓ ↑ 
 Topotecan 3A4 ↑ _ 
Epipophyllotoxins: 
 Etoposide 3A4 ↓ ↑ 
Taxanes: 
 Docetaxel 3A4 ↓ ↑↑ 
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 Paclitaxel 3A4, 2C8 ↓ ↑ 
Vinca alkaloids: 
 Vincristine 3A4 ↓ ↑ 
Kinase inhibitor: 
 Imatinib 3A4 ↓ ↑ 
 Erlotinib 3A4, 1A2 ↓ ↑ 
Proteasome inhibitor: 
 Bortezomib 3A4 ↓ ↑ 
NNRTI, Non nucleoside reverse transcriptase inhibitor; PI, Protease inhibitor. 
Source: Mounier et al., 2009:14 
A randomised study by Msadabwe (2009) compared CCRT against RT as treatment 
of cervical cancer in HIV positive patients. Sixty four patients with stages IB to IIIB 
were recruited to the study, 31 patients in the CCRT arm and 33 in the RT arm 
(Table 3.10). Six patients were on ARVs at the start of treatment, three in each arm. 
(Msadabwe, 2009:37) 
Table 3.10: Characteristics of participants in the trial by Msadabwe (2009) 
Therapy Patients 
randomised 
Patients who 
received treatment 
Regimen 
CCRT 31 25 Cisplatin 30mg/m
3
 weekly 
EBRT 46 Gy in 23 fractions 
Brachytherapy 8 Gy x 3 fractions 
RT 33 28 EBRT 46 Gy in 23 fractions 
Brachytherapy 8 Gy x 3 fractions 
Source: Msadabwe, 2009:30-42 
Response to treatment was classified as complete or incomplete. Complete 
response was defined as the total disappearance of disease at three months and 
incomplete response was defined as the presence of disease based on physical 
examinations. At three months, 25 patients in the CCRT arm and 26 patients in the 
RT arm were evaluated for response. Twenty patients in the CCRT arm and 21 
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patients in the RT arm had complete response. At three, months the response rates 
were similar in both arms and residual disease was noted in 20% of the patients. 
(Msadabwe, 2009:49) 
Twenty five patients completed CCRT treatment and 26 patients completed radiation 
therapy. Three patients had treatment interruptions, two of these patients had 
residual tumour at three months after treatment. Five patients in the CCRT arm and 
four patients in the RT arm died before treatment. None of the patients in the CCRT 
arm died and only one patient in the RT arm died during treatment. At three months, 
one patient in the CCRT arm died of progressive disease and one patient in the RT 
arm died from lung metastasis. (Msadabwe, 2009:50-55) 
The number of chemotherapy cycles received by patients in the CCRT arm varied 
between 0 and 5 cycles. Only 40% of patients received the planned five cycles, 76% 
received four cycles of chemotherapy and 92% received three cycles of 
chemotherapy. This was due to logistical reasons (3 observations), non adherence 
(3 observations), renal toxicity (11 observations) and leucopenia (2 observations). 
(Msadabwe, 2009:57) It has been observed that HIV positive women were more 
likely to have multiple factors that would prevent the safe administration of cisplatin 
based chemotherapy (McArdle & Kigula-Mugambe, 2007:95).  
Most of the toxicity was mild and reversible. Haematological toxicity was the most 
common toxicity followed by skin toxicity, gastrointestinal toxicity and bladder toxicity 
(Table 3.11). (Msadabwe, 2009:42) 
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Table 3.11: Toxicity observed in the Msadabwe trial (2009) 
Toxicity Total  no. of 
patients 
Incidence of toxicity 
in the CCRT arm (31) 
Incidence of toxicity in the 
RT arm (33) 
Leucopoenia 54 29 25 
Skin 44 17 27 
Gastrointestinal (Lower) 28 12 16 
Gastrointestinal (Upper) 15 10 5 
Bladder 15 9 6 
Source: Msadabwe, 2009:44-46. 
The toxicity rates of the HIV positive women in this study were compared to those of 
HIV negative women in other published studies (Rose et al., 1999; Keys et al., 1999 
and Pearcey et al., 2002). The HIV positive patients did not experience greater 
haematological toxicity than that reported in the other three studies. However, 
cutaneous toxicity was higher in HIV positive women who underwent CCRT than HIV 
negative women who underwent CCRT in the other three studies. (Msadabwe, 
2009:51) One theory suggests that HIV positive women have increased sensitivity of 
the normal tissues to RT leading to excessive acute adverse effects of the normal 
tissues (Formenti et al., 1995:411-412 and Gichangi et al., 2006:409).  
In summary, the literature suggests that HIV positive and HIV negative women with 
cervical cancer should be managed using the same principles. However, health 
professionals that are managing HIV positive patients need to be aware of the 
important drug interactions and toxicities of antiretroviral agents when used in 
combination with CCRT. 
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Chapter 4  
METHODOLOGY 
4.1 INTRODUCTION 
The primary aim of the study was to assess how HIV positive women who have been 
diagnosed with cervical cancer responded and adhered to cervical cancer therapy. 
The study also evaluated the effects of the concurrent use of ARVs and CCRT/RT. 
The methodology employed in the research project is discussed in this chapter.  
4.2 LITERATURE REVIEW 
Prior to data collection, a comprehensive literature review was conducted on: the 
course of HPV infection; the relationship between HIV and HPV; HIV and cervical 
cancer statistics of selected developing and developed countries; CCRT and RT as 
treatment options and the evaluation of previous studies and randomised trials which 
investigated the response and adherence to CCRT/RT in HIV positive and HIV 
negative women.  Several electronic online databases such as: PubMed®; Science 
Direct®; Medline®; EBSCOHOST® and Nexus® were used to obtain journal articles. 
The literature search extended from 1999 to 2010, however, where applicable, 
references outside this time frame were consulted.  
4.3 ETHICAL APPROVAL 
The research proposal was submitted to the Faculty of Health Science Research 
Technology and Innovative Committee and to the Research Ethics Committee 
Human at NMMU in order to obtain ethical approval. Permission was also requested 
from the Head of the Oncology department at the study site (Figure 4.1, step 1). 
Confidentiality was maintained at all times during the study. No patient identifiers 
were linked to the data. The study was conducted in accordance with the ethical 
principles of the Declaration of Helsinki (World Medical Association, 2008).  
4.4 STUDY DESIGN 
A historical cohort study design was employed for the study. The study was historical 
or retrospective because the events that were evaluated took place before the onset 
of the study. The main advantage of retrospective studies is that they make use of 
data that have already been collected and can, therefore, be performed quickly and 
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at a low cost. Dawson and Trapp (2001:10) define a cohort as „a group of people 
who have something in common and who remain part of a group over an extended 
period of time‟. Therefore, the cohort consisted of women diagnosed with cervical 
cancer between 2005 and 2008. Cohort studies are the most suitable for studying 
the course of a disease, for instance the course of cervical cancer. They possess the 
correct time sequence to provide the strong evidence for possible causes and 
effects, as in the effect of CCRT/RT in cervical cancer patients. (Dawson & Trapp, 
2001:10-19) 
4.5 STUDY SITE AND SAMPLE 
The study was conducted at the Oncology Department of a tertiary level hospital 
located in the Eastern Cape Province, South Africa. The Oncology Department at the 
study site treats about 200 cervical cancer patients annually (newly diagnosed and 
follow up cases) and provides radiotherapy and chemotherapy for curative or 
palliative purposes. The Eastern Cape has a population of about 6.8 million and over 
95% of the population depends on the state for health care. The Oncology 
Department at the study site is not part of a teaching hospital set up, hence it is not 
funded like other teaching hospitals and cannot provide oncological services to a 
large number of cervical cancer patients. (Reddi, 2003) 
The sample was a total sample in that it consisted of the medical records of all HIV 
positive and HIV negative women diagnosed with cervical cancer between 2005 and 
2008 who were older than 18 years of age at the time of diagnosis and received 
CCRT, CT, curative RT or PRT. 
4.6 DATA COLLECTION 
The data was acquired from the patient records kept at the Oncology Department at 
the study site. The researcher had an introductory meeting with the Head of the 
Oncology Department at the study site (Figure 4.1, step 2). During the meeting, the 
oncologist confirmed that both the electronic and hard copies of the patients‟ medical 
files would be made available to the researcher. 
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Figure 4.1: Flow diagram outlining the methodology of the research study 
A purpose designed researcher completed questionnaire, which was referred to as 
an audit form, was employed as the data collection tool. Data was collected by 
reviewing the patients‟ medical records and capturing the information on an audit 
form (Appendix 4). A retrospective review of case records over a period of two years 
was performed. The records were audited for a two year period from the date of 
diagnosis. Therefore, medical records of the women diagnosed in 2005, were 
audited from 2005 to 2007, the medical records of the women diagnosed in 2006 
were audited from 2006 to 2008, the medical records of the women diagnosed in 
2007 were audited from 2007 to 2009 while the medical records of the women 
diagnosed in 2008 were audited from 2008 to 2010. 
The data that was obtained from the medical records was based on results from 
physical and pelvic examinations, blood counts, chest x-rays, computed tomography 
(CT) scans and ultrasounds as well as clinical notes. Data collection occurred over a 
three month period, from September to November 2010. The study population‟s 
Step 1 
Apply for ethical approval from REC-H and permission from the study site. 
 
 
Step 2 
Design data collection tool: audit form. 
Meet with the Head of the Oncology Department at the study site. 
 
Step 3 
Pilot audit form, review and modify research instrument. 
 
Step 4 
Data collection: Self completion of the audit forms at the study site. 
 
Step 5 
Data analysis and statistical analysis. 
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laboratory test results and the HIV positive women‟s ARV regimen were obtained 
from the National Health Laboratory Service (NHLS) database. The database was 
accessed from the study site. 
4.6.1 Design of the data collection tool 
The audit form (Appendix 3)that was used to analyse the patient records was 
designed using Microsoft® Word. Closed ended questions were used as these types 
of questions are specific and are preferred in self completion questionnaires. Closed 
ended questions are also easier for the researcher to code and incorporate into 
quantitative analyses. (Figure 4.1, step 2) (Smith, 2005: 64)  
The audit form (Appendix 3), was eight pages in total and consisted of seven main 
sections: 
 Patient demographics; 
 HIV status; 
 Cervical cancer status; 
 Response to cervical cancer treatment; 
 Adherence to cervical cancer treatment; 
 Adverse effects; and 
 Mortality. 
4.6.2 Piloting of the data collection tool 
A pilot study was conducted to test the research instrument i.e. the audit form 
(Figure 4.1, step 3). The questionnaire was piloted to test for validity and 
reproducibility. Reliability refers to „the extent to which procedures, measures and 
data are reproducible or internally consistent‟ (Smith, 2005:60). Validity refers to „the 
extent to which the measures (e.g. records maintained by a researcher) actually 
measure what they are designed to measure‟ (Smith, 2005:60). The pilot study 
sample consisted of a convenience sample of ten medical records from the 
Oncology Department.  The pilot study involved the review, using the audit form 
(Appendix 3), of ten files that belonged to women who were diagnosed with cervical 
cancer in 2004. The pilot study was conducted in order to identify any potential 
problems that would occur while collecting data for the main study. 
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The audit form was piloted on the 5th and 6th of August 2010. The pilot study 
revealed that the researcher required 28 + 2 minutes to evaluate each patient file. 
After the pilot study, the researcher reviewed and modified the research instrument 
to ensure that the data acquired in the main study met the study objectives 
(Appendix 4). The following changes were made to the audit form: 
 The audit form used in the main study consisted of six main sections. The 
mortality section was removed from the audit form. The mortality rate of the 
participants could not be determined because most of the patients did not attend 
their follow up visits after treatment. 
 Other sections were also modified, for instance Section E2 which consisted of the 
reasons that led to the non adherence of the patients to cervical cancer 
treatment. The patients‟ risk factors were also included in the modified audit form 
(section C2) (Appendix 4). 
 Originally, the researcher‟s aim was to retrospectively investigate the 
management of women diagnosed with cervical cancer during 2004 and 2005. 
The medical records of the women diagnosed in 2004, were to be audited from 
2004 to 2008 and the medical records of the women diagnosed in 2005 were to 
be audited from 2005 to 2009. However, during the pilot study, the researcher 
realised that this sample would be too small for the main study. “When the 
sample size is too small, errors may occur and this may give rise to a negative 
study.  A negative study means that the results of the study were not statistically 
significant but the results would possibly have been significant if the sample size 
had been larger” (Dawson & Trapp, 2001:124-125). Consequently, the 
researcher decided to increase the sample size. In the main study, the sample 
consisted of the medical records of women diagnosed with cervical cancer 
between 2005 and 2008. The records were audited for a two year period from 
the date of diagnosis as opposed to a five year period as was earlier proposed. 
4.6.3 Administration of the data collection tool 
The researcher completed the audit forms at the Oncology Department located at 
the study site (Figure 4.1, step 4).  
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4.7 DATA ANALYSIS  
Data from the audit form (Appendix 4) was captured on a purpose designed 
Microsoft Excel ® spreadsheet, collated and analysed (Figure 4.1, step 5). The data 
was coded by assigning a number for each response choice, for instance, „Yes‟ =1 
and „No‟ =2. 
4.8 STATISTICAL ANALYSIS   
Microsoft Excel® and StatSoft Statistica® were used for the statistical analysis of the 
data. Descriptive statistics were used in the summarisation of data and where 
appropriate, results were presented as mean ± standard deviation. Minimum and 
maximum values were also reported. The following inferential tests were employed 
in the study: 
4.8.1 The t-test and Cohen’s d Statistic 
The t-test (at a 95% confidence interval) was used to evaluate the differences in 
means between two groups. The practical significance of the differences in the study 
sample was represented by the Cohen‟s d statistic. (Dawson & Trapp, 2001:132) If 
the calculated d-value was found to be ≤ 0.35, the difference was of small practical 
significance, if the d-value was between 0.36 and 0.65, the difference was of 
medium practical significance and a calculated d-value > 0.65, signified a difference 
that was of high practical significance. 
4.8.2 Chi-Square Test of Independence and Cramer’s V statistic 
The Chi-square test was used to evaluate the differences between the three main 
groups in the study sample: the HIV negative patients; the HIV positive patients who 
were on HAART and the HIV positive patients who were not on HAART. The 
Cramer‟s V statistic is a post test used with the Chi-square test and was calculated in 
order to determine the practical significance of a particular result. The degrees of 
freedom (d.f.) are the number of values in the final calculation of a statistic that are 
free to vary. The d.f. for an estimate equals the number of observations (values) 
minus the number of additional parameters estimated for that calculation. For a 
finding to be practically significant, Cramer‟s V needs to be equal to or greater than a 
predetermined value associated with a particular number of degrees of freedom. 
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(Dawson & Trapp, 2001:152) Table 4.1 depicts the minimum values for Cramer‟s V 
(required to denote practical significance) that are associated with a specified 
number of degrees of freedom.   
Table 4.1: Cramer’s V values relative to degrees of freedom 
Degrees of freedom Cramer’s V 
 Small  Medium Large 
1* 0.10** 0.30** 0.50** 
2 0.07 0.21 0.35 
3 0.06 0.17 0.29 
 
* When the degrees of freedom equals one, Cramér‟s V must be ≥ 0.10 in order to depict practical 
significance.  
** The following ranges for Cramér‟s V (when d.f. = 1) are indicative of varying degrees of 
significance: < 0.2 (small); 0.21 - 0.40 (medium); and > 0.40 (large).  
4.8.3 Tukey’s HSD Procedure 
The Tukey‟s HSD (honestly significant difference) was used to compare mean 
differences among HIV negative patients; the HIV positive patients who were on 
HAART and the HIV positive patients who were not on HAART. 
For tests pertaining to statistical significance, a calculated p-value of less than 0.05, 
presented a finding that was significant at the 95% confidence interval. In the current 
study, a result that was found to be „significant‟ was interpreted as being both 
statistically and practically significant. Furthermore, in instances where statistical 
analyses involved „large‟ Cramér's V yield values (Table 4.1), findings were reported 
as being „highly‟ significant.  
4.9 EXCLUSION CRITERIA 
The medical files of patients who: only underwent surgical treatment to manage 
cervical cancer and patients who were younger than 18 years of age at the time of 
diagnosis were excluded from the study. 
4.10 LIMITATIONS OF THE STUDY 
The study was retrospective in nature thus some difficulties arose:  
 The researcher had no control over how the original data was collected. A few of 
the doctors who collected some of the data had been transferred to other 
hospitals thus there was often no way of verifying whether the data was biased or 
incomplete. 
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 Due to the transfer of doctors, the data may be inconsistent. Different doctors 
have different ways of recording data or they may differ in the diagnosis of 
conditions that occur after cervical cancer treatment. This may lead to the 
recording of inconsistent data.  
 The data did not include all the variables pertaining to the objectives of the study 
thus the value of the findings was limited. For instance, the mortality rate of the 
participants could not be determined because some patients did not attend their 
follow up visits after treatment. 
 The patients‟ HPV types could not be established thus it was not possible to 
determine the HPV oncogenic types in HIV positive women and in HIV negative 
women. 
 It could not be determined if the patients had access to the primary and 
secondary prevention strategies. The primary prevention strategies included 
creating awareness, implementing safe sexual practices, smoking avoidance, 
good nutrition and HPV vaccination. Secondary prevention strategies included 
cytology, VIA and HPV DNA testing. (Firnhaber & Michelow, 2009:24) 
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Chapter 5  
RESULTS AND DISCUSSION 
5.1 INTRODUCTION 
In this chapter the results of the study will be presented. Results are reported, where 
applicable, as mean + standard deviation. The results and discussion will be 
presented in the following main sections: 
 Patient demographics; 
 HIV status; 
 Risk co-factors for cervical cancer treatment; 
 Treatment options used at the study site; 
 Prognostic factors in cervical cancer; 
 Response to cervical cancer treatment; 
 Toxicity due to cervical cancer treatment; and 
 Adherence to cervical cancer treatment.  
5.2 ETHICAL CONSIDERATIONS 
Ethical approval to conduct the study was obtained from the Research Ethics 
Committee Human at NMMU on the 5th July 2010 (REF NO H10-HEA-PHA-001) 
(Appendix 1). Permission was also granted by the Head of the Oncology Department 
at the study site (Appendix 2). Confidentiality was maintained at all times during the 
study. No patient identifiers were linked to the data. The study was conducted in 
accordance to the ethical principles of the Declaration of Helsinki (World Medical 
Association, 2008).  
5.3 PATIENT DEMOGRAPHICS 
The study was conducted at the Oncology Department of a tertiary level hospital 
located in the Eastern Cape Province, South Africa. The sample consisted of the 
medical records of 196 HIV positive and HIV negative women diagnosed with 
cervical cancer between 2005 and 2008 who received CCRT, RT or CT and were 
older than 18 years of age at the time of diagnosis. Patients who only received 
surgical treatment and patients who were younger than 18 years of age at the time of 
diagnosis were excluded from the study. 
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Age: The average age of all the patients was 57 + 11.7 years (min = 25 years; max = 
96 years). The average age of the HIV negative women was 58 + 12.0 years (min = 
33 years; max = 96 years) and that of the HIV positive women was 54 + 11.3 years 
(min = 25 years; max = 91 years).  
The results indicated that only one (0.5%; n=196) participant was less than 30 years. 
Nine (4.5%; n=196) participants were between 31 and 40 years, 49 (25%; n=196) 
participants were between 41 and 50 years and 69 (35%; n=196) participants were 
between 51 and 60 years (Figure 6.1). Forty one (21%; n=196) participants were 
between 61 and 70 years, 21 (11%; n=196) participants were between 71 and 80 
years and 2 (1%; n=196) participants were between 81 and 90 years. Three (1.5%; 
n=196) participants were between 91 and 100 years and one participant‟s (0.5%; 
n=196) age was not indicated in the medical file. Therefore, the 51 to 60 years age 
category had the highest (69; 35%; n=196) number of participants. 
 
Figure 5.1: Age distribution of the study population 
The age distribution in this study is in line with data from other developing countries 
where 80% to 90% of cervical cancer cases occurred in women who were 40 years 
and older. The incidence of cervical cancer in most countries was very low in women 
under 35 to 40 years and was highest in women who were aged between 50 and 65 
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years. This is because cervical cancer progresses slowly from precancer to ICC. 
Thus, the high number of patients in the 51 to 60 years age category is expected. 
(Freedman et al., 2006) 
The mean age of the HIV positive women with cervical cancer (54 + 11.3 years) was 
four years lower than the mean age of HIV negative women (58 + 12.0 years). 
Although this result was not significant (t-test = 1.8409; d.f. = 180; p = 0.06728; 
Cohen‟s d = 0.27), three other studies that were also conducted in South Africa 
reported that the mean age of HIV positive women was lower than that of the HIV 
negative women (Lomalisa et al., 2000; Moodley et al., 2001 and Moodley et al., 
2006). These three studies compared the prevalence of cervical cancer in HIV 
positive and HIV negative women (Table 5.1). Lomalisa et al., (2000:460-463) 
reported that the mean age of HIV positive patients was nine years younger than the 
HIV negative patients, Moodley et al. (2001:194-197) noted that the mean age of the 
HIV positive women was 15 years younger than the HIV negative women and 
Moodley et al. (2006:1-6) observed that the HIV positive patients presented with ICC 
six years earlier than the HIV negative patients. This trend was mainly associated 
with immunosuppression caused by HIV infection that lead to the rapid progression 
from precancer to ICC (Strickler et al., 2003:1069). 
Table 5.1: Mean age difference between HIV positive and HIV negative women with 
cervical cancer 
Author Mean age of HIV 
positive women (years) 
Mean age of HIV 
negative women (years) 
Age difference 
Lomalisa et al., 2000 44 53 9 
Moodley et al., 2001 40 55 15 
Moodley et al., 2006 40 46 6 
Current study 54 58 4 
Sources: Lomalisa et al., 2000; Moodley et al., 2001 and Moodley et al., 2006. 
5.4 HIV STATUS 
One hundred participants (51%; n=196) were HIV negative, 83 participants (42%; 
n=196) were HIV positive and 13 women‟s HIV status was unknown (7%; n=196) 
(Figure 5.2). Therefore, most (100; 51%; n=196) of the participants were HIV 
negative. 
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In the literature, a strong association between HIV infection and HPV infection has 
been shown. It has been noted that the changes that occur in the HPV cell are 
related to the functioning of the immune system. Thus, when an individual‟s immunity 
deteriorates or CD4 count lowers the HPV cell changes increase. A rapid 
progression from precancer to ICC in HIV positive women has also been reported. 
(Chirenje, 2005:270 and Holcomb et al., 1998:849). 
It has been reported that in South Africa, up to 30% of cervical cancer patients are 
HIV positive (Mqoqi et al., 2004:22). In the current study, 42% of the patients were 
HIV positive. It is difficult to determine the actual incidence of cervical cancer in HIV 
positive women in countries like South Africa, where the burden of both HIV/AIDS 
and cervical cancer is high because cancer registries are very inadequate. South 
Africa has a National Cancer Registry; however, the cervical cancer statistics were 
last recorded in 2001 and may be outdated. (Bourke, 2007) Therefore, it is quite a 
challenge, in South Africa, to establish the incidence of ICC in HIV positive and HIV 
negative women in order to determine the extent to which HIV infection is associated 
with HPV infection. 
 
Figure 5.2: HIV status of the participants 
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5.5 RISK CO-FACTORS FOR CERVICAL CANCER 
Apart from persistent HPV infection, there are several soci+o-cultural, socio-
economic and biological risk co-factors for HPV infection (Table 2.3). This study 
looked at some of the risk co-factors that were present in the study population. 
These included: socio-cultural co-factors such as high parity; biological co-factors 
such as HIV infection; STIs (chlamydia, gonorrhoea, herpes type 2) and other risk 
co-factors for cervical cancer such as cigarette smoking and long term use of 
hormonal contraception (Firnhaber & Michelow, 2009:23).  
In the current study, 37% (72; n=196) of the participants had no risk co-factors, 41% 
(80; n=196) had one risk co-factor, 20% (39; n=196) had two risk co-factors and 2% 
(5; n=196) of the participants had three risk co-factors for cervical cancer (Figure 
5.3).  
 
Figure 5.3: Number of risk factors presenting in the study population 
5.5.1  Cigarette smoking 
Studies have provided data that cigarette smoking can increase the risk of cervical 
cancer in women with persistent HPV infection. Evidence of nicotine metabolites in 
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the cervical mucus of smokers suggests that cigarette smoking may have a direct 
carcinogenic effect on the cervix. Another theory is that cigarette smoking may 
suppress the local immune response to HPV infection. (Castellasague & Munoz, 
2003:1109-1110) In the current study, 28% (55; n=196) of the participants were 
smokers while 67% (131; n=196) had never smoked a cigarette (Table 5.2). Five 
percent (10; n=196) of the participants were classified as ex-smokers; these were 
patients who had a history of cigarette smoking but did not smoke anymore. 
Therefore, most of the participants were non smokers. 
5.5.2  Sexually Transmitted Infections 
Thirteen percent (25; n=196) of the participants had contracted at least one STI prior 
to their cervical cancer diagnosis (Table 5.2). These infections included chlamydia, 
gonorrhoea and herpes type 2. Eighty seven percent (171; n=196) of the participants 
had never contracted an STI.   
5.5.3  Concurrent HIV infection 
Another important risk co-factor is HIV/AIDS, a sexually transmitted disease. As 
previously reported, 51% (100; n=196) of the participants were HIV negative, 42% 
(83; n=196) were HIV positive and 7% (13; n=196) of the women‟s HIV status was 
unknown (Figure 5.2). Thus, most of the participants had never contracted an STI 
and were HIV negative. 
5.5.4  Long term use of hormonal contraception 
Long term use of oral hormonal contraception can increase the risk of cervical 
cancer among women infected with carcinogenic types of HPV (Schiffman et al., 
2007:893). Hormones may trigger events that could result in the integration of the 
HPV virus into the host's genome. Women who use oral hormonal contraception are 
also less likely to use barrier methods of contraception, which have been shown to 
have a protective effect against cervical cancer. However, the long term use of oral 
hormonal contraception being regarded as a risk co-factor for cervical cancer may be 
due to detection bias because users undergo more frequent gynaecological 
examinations than non users, thus it is easier to detect cervical cancer in its early 
stages in women who use oral hormonal contraception. (Duarte-Franco & Franco, 
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2004:6) Long term use of oral hormonal contraception was reported in 27% (53; 
n=196) of the participants while 72% (141; n=196) of the participants did not use 
hormonal contraception (Table 5.2). The use of oral hormonal contraception could 
not be established for one percent (2; n=196) of the participants because this 
information was not indicated in their medical records. Therefore, the majority of the 
participants had not used oral hormonal contraception.  
5.5.5  Parity 
Parity is the number of times a woman has given birth. It has been suggested that 
women with higher parity are more likely to have cervical cancer than women of 
lower parity (WHO/ICO Information centre on HPV and cervical cancer, 2010:20). 
Multiple pregnancies have a cumulative traumatic or immunosuppressive effect on 
the cervix and this may facilitate the contraction of HPV infection. Pregnancy induced 
hormonal effects on the cervix may also stimulate the immortalization of HPV 
infected cells. (Bayo et al., 2002: 204) Data from case control studies conducted by 
the IARC in four continents, reported that women with HPV infection who had seven 
or more full term pregnancies were four times more likely to develop cervical cancer 
as compared to nulliparous women with HPV infection (Munoz et al., 2002:1096). 
Therefore, using the IARC findings as a guideline, in the current study, women with 
seven or more full term pregnancies were classified under the „high parity‟ category 
and women who had less than seven full term pregnancies or had never given birth 
were classified under the „low parity‟ category.  Fifteen percent (30; n=196) of 
participants were in the „high parity‟ category and 85% (166; n=196) were in the „low 
parity‟ category (Table 5.2). Therefore, most of the participants had low parity.  
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Table 5.2: Risk co-factors in the study population 
Co-factors 
N=196 
Risk co-factors present Risk co-factors absent 
Number Percentage Number Percentage 
Smoking Smoker Ex smoker Smoker Ex smoker  
131 
 
67 55 10 28 5 
STI 25 13 171 87 
HIV infection 83 42 100 51 
Hormonal 
Contraception 
53 27 141 72 
High parity 30 15 166 85 
5.5.6  Summary 
In 2010, the WHO/ICO Information Centre on HPV and cervical cancer published a 
report that listed the risk co-factors for cervical cancer. The prevalence of these risk 
co-factors in four countries has been summarised in Table 5.3. 
Table 5.3: Risk co-factors for cervical cancer in U.S.A., U.K., S.A. and in the current 
study 
Co-factor U.S.A. U.K. S.A. Current 
study (%) 
n=196 
Smoking prevalence (%) women 20.3 31.1 8.9 33 
Total fertility rate (live births per 
women) 
2.0 1.6 2.9 N/A 
Oral contraceptive use (%) 18.3 26.0 11.1 27 
HIV prevalence (%) adults (15-49 
years) 
0.6 0.2 18.1 42 
Source: WHO/ICO Information centre on HPV and cervical cancer, 2010.  
The prevalence of the risk co-factors that were identified in the WHO/ICO South 
African report was compared to that in the current study. The risk co-factor with the 
highest incidence in both the current study (42%) and the WHO/ICO South African 
report (18.1%) was HIV infection (Table 5.3). The high percentage of HIV in the 
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current study (42%) could be due to the fact that the current study was based on a 
sample from the western region of the Eastern Cape Province as opposed to the 
WHO/ICO South African report whose percentage (18.1%) pertained to the 
incidence of HIV in South Africa.  Cigarette smoking ranked as the second highest 
risk co-factor in the current study (33%) as opposed to the WHO/ICO South African 
report which ranked oral contraceptive use (11.1%) as the second highest risk co-
factor for cervical cancer among South African women. The third highest risk co-
factor in the current study was found to be oral contraceptive use (27%) while that of 
the WHO/ICO South African report was cigarette smoking (8.9%). Parity was found 
to be the lowest risk co-factor for cervical cancer in both the current study and in the 
WHO/ICO South African report. (WHO/ICO Information centre on HPV and cervical 
cancer, 2010) 
The majority (63%; n=196) of the participants had at least one risk co-factor for 
cervical cancer and the most prevalent risk co-factor was found to be HIV infection 
(42%). Therefore, HIV positive women were at a high risk of developing cervical 
cancer. 
5.6 THE TREATMENT PROTOCOLS USED AT THE STUDY SITE 
The prescribed treatment options used to treat the different stages of cervical cancer 
at the study site were examined in the current study (Table 5.4). The study 
population consisted of six (3%; n=96) stage I patients, 27 (14%; n=196) stage II 
patients, 106 (54%; n=196) stage III patients and 57 (29%; n=196) stage IV cervical 
cancer patients. Thus, the majority (106; 54%; n=196) of the patients were 
diagnosed with Stage III cervical cancer (Table 5.4). The stage I, II and III patients 
received either curative RT or CCRT and the stage IV patients received palliative 
RT. The patients who only received surgical treatment to treat stage I cervical cancer 
were excluded from this study.  
Curative RT was prescribed for all six of the stage I cervical cancer patients and this 
was also the option that was prescribed to treat majority of the stage II cervical 
cancer patients (14; 52%; n=27) (Table 5.4). Concurrent chemoradiation was the 
recommended treatment of choice for most of the stage III cervical cancer patients 
(55; 52%; n=106). In the majority of the stage IV cervical cancer patients (49; 86%; 
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n=57), RT was prescribed to palliate central disease or distant metastases. The 
adherence patterns of the study population to their prescribed treatment will be 
discussed in Section 5.10.  
Table 5.4: The treatment options used to treat the different stages of cervical cancer 
Stage at 
diagnosis 
Radiation 
therapy 
Chemotherapy Concurrent 
Chemoradiation 
Palliative 
Radiotherapy 
Totals 
 No. % No. % No. % No. %  
I   (n=6) 6 100% 0 0% 0 0% 0 0% 6 
II  (n=27) 14 52% 0 0 12 44% 1 4% 27 
III  (n=106) 44 41% 1 1% 55 52% 6 6% 106 
IV  (n=57) 2 3.5% 2 3.5% 4 7% 49 86% 57 
     196 
The treatment protocols used to treat the different stages of cervical cancer at the 
study site (Table 5.4) were compared to, and were found to be in line with the 
recommendations presented in the 2008 U.K. HIV Association Guidelines for HIV 
Associated Malignancies and the guideline from the U.S.A. National Cancer Institute 
(Bower et. al., 2008:359 and United States National Cancer Institute, 2010) (Table 
2.5). For instance, according to the British and American guidelines, surgical 
treatment such as hysterectomy or conisation is the recommended treatment option 
for stage I cervical cancer patients and radiation therapy should only be considered 
in women who are not surgical candidates. Similarly, in the current study, RT was 
prescribed for only six of the stage I patients who were not surgical candidates. Most 
of the stage I patients at the study site had been managed surgically and these 
patients were excluded from the current study.  
According to the British and American guidelines radiation therapy is the 
recommended treatment option for stage II patients. In the current study, curative RT 
was prescribed for majority (14; 52%; n=27) of the stage II cervical cancer patients. 
Concurrent chemoradiation which was recommended for most (55; 52%; n=106) of 
the stage III cervical cancer patients in the current study, is the treatment option that 
is recommended to treat stage III cervical cancer according to the British and 
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American guidelines. Majority of the stage IV cervical cancer (49; 86%; n=57) 
patients, were prescribed radiation therapy to palliate central disease or distant 
metastases and this is the recommended option used to manage stage IV cervical 
cancer based on the British and American guidelines. (Bower et. al., 2008:359-360 
and United States National Cancer Institute, 2010) 
In summary, most of the patients in the current study were managed according to the 
treatment of choice for the different stages of cervical cancer based on the 
recommendations presented in the 2008 U.K. HIV Association Guidelines for HIV 
Associated malignancies and from the U.S.A. National Cancer Institute guideline. 
(Bower et. al., 2008:359-360 and United States National Cancer Institute, 2010) 
The majority (83%; 163; n=196) of the patients in the current study were diagnosed 
with advanced stage cervical cancer (Stage III and IV). This is in line with a comment 
by Stewart & Kleihues (2003:152), that „It is estimated that over 80% of women with 
cervical cancer in developing countries are diagnosed at advanced stages‟.Other 
studies conducted in developing countries have also reported that a large number of 
women were diagnosed with cervical cancer at its advanced stages due to lack of 
effective screening programmes used to detect and treat the disease in its early 
stages (Wabinga et al., 2003:68 and Sbilinarayanan et al., 2001:10). Most cases of 
ICC can be prevented through regular screening. In 2000, a national cervical cancer 
screening policy was developed and implemented in South Africa. Screening occurs 
by performing three free Pap smears for women at the ages of 30, 40 and 50. 
Statistics have shown that less that 20% of women have used this service. 
(Department of Health, South Africa, 2000:2) Consequently, most women seek 
medical advice only when they have developed symptoms and advanced stages of 
cervical cancer which is difficult to treat. Thus, in this study, the observation that a 
high number (163; 83%; n=196) of patients were diagnosed with advanced cervical 
cancer (stage III and IV) was not surprising.  
5.7 PROGNOSTIC FACTORS IN CERVICAL CANCER 
The prognostic factors that influence the survival of cervical cancer patients include: 
patient characteristics (age and blood Hb level); tumour characteristics (stage); and 
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treatment characteristics (doses and duration of treatment) (Borowsky et al., 
2005:E19).  
In this study, the term „complete response‟ to treatment referred to patients who had 
no recurrence of cervical cancer and no evidence of metastases following RT or 
CCRT and „incomplete response‟  to treatment referred to patients who either had a 
recurrence of cervical cancer or displayed evidence of metastases after receiving RT 
or CCRT. This only applied to patients who had stage I, II or III cervical cancer. 
In patients who received palliative radiotherapy, the term „complete response‟ 
referred to patients who had experienced relief from pain and other symptoms such 
as bleeding or vaginal discharge after receiving PRT and „incomplete response‟ 
referred to patients who did not experience  relief from pain or the other symptoms 
following PRT. This only applied to patients who had stage IV cervical cancer. 
5.7.1  Patient characteristics 
5.7.1.1 Age 
The mean age of all the patients (stage I to IV) who displayed complete response to 
cervical cancer treatment was 56.7 + 12.3 years and the mean age of all the patients 
who displayed incomplete response to treatment was 57.4 + 11.0 years. There was 
no significant difference in the mean age between the women who displayed 
complete response to treatment and those who displayed an incomplete response to 
treatment (t-test = 0.3766; p = 0.7069; Cohen‟s d = 0.05).  
It is believed that cervical cancer in younger patients is more aggressive than in 
older patients (Brewster et al., 1999:1466). However, age is not an independent 
prognostic factor for the survival of cervical cancer patients due to the selection of 
different treatment options for patients of the same age. For instance, women of the 
same age who have small tumours may receive surgical treatment and those who 
have bigger tumours may receive RT or CCRT. Therefore, poor prognosis cannot be 
related to age alone. (Ho et al., 2004:461 and Moore et al., 2010:45) This may 
explain why, in the current study, there was no significant difference in the mean age 
between the women who displayed complete response to treatment and those who 
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displayed an incomplete response to treatment (t-test = 0.3766; p = 0.7069; Cohen‟s 
d = 0.05).  
5.7.1.2 Blood Hb levels 
Anaemia is a disease characterised by low Hb levels. About 30% to 90% of patients 
with cancer experience anaemia. Anaemia may occur as a result of the cancer 
interfering with haematopoiesis or from myelosuppression caused by 
chemotherapeutic agents. Radiotherapy can also have a significant effect on the 
bone marrow, thus worsening haematological toxicity caused by chemotherapy. 
Various studies have suggested that anaemia at diagnosis and/or during treatment 
may affect the prognosis of cervical cancer patients. (Grogan et al., 1999:1532 and 
Dunst et al., 2003:782) An anaemic cervical cancer patient may not be able to 
undergo her scheduled radiotherapy or chemotherapy regimen and this may lead to 
suboptimal outcomes of treatment (Hinkel et al., 2010: S39). Thus, anaemia may 
present a challenge in the management of cervical cancer. In the current study, 
patients with a blood Hb level less than 12g/dl were classified as anaemic. The 
patients‟ Hb levels during and after treatment were investigated rather than the Hb 
levels at presentation as studies have shown that the former is the stronger 
prognostic factor (Grogan et al., 1999:1531 and Obermair et al., 2001:904). 
Eighty four percent (164; n=196) of the patients had anaemia during ICC treatment 
while 16% (32; n=196) of the patients did not have anaemia during ICC treatment 
(Table 5.5). Of the 164 patients who had anaemia, 47% (77; n=164) responded 
favourably to ICC treatment and 53% (87; n=164) did not respond well to ICC 
treatment. Of the 32 patients who did not have anaemia during ICC treatment, 65% 
(20; n=32) responded well to ICC treatment and 35% (12; n=32) did not respond well 
to ICC treatment. Thus the majority (164; 84%; n=196) of patients experienced 
anaemia during treatment and a large number of these anaemic patients (87; 53%; 
n=164) had a poor response to treatment. 
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Table 5.5: Presentation of anaemia in the study participants who experienced a 
‘complete’ or ‘incomplete’ response to treatment 
 Complete response Incomplete 
response 
Totals 
Anaemic 77 47% 87 53% 164 
Not anaemic 20 65% 12 35% 32 
   196 
In the current study, there was no significant difference between the prognosis of the 
anaemic patients and that of the non anaemic patients (Chi2 = 1.46, d.f. = 1, p = 
0.22644, Cramer‟s V = 0.09). However, other studies have reported that anaemia 
was significantly associated with poor prognosis of cervical cancer patients (Grogan 
et al., 1999:1534; Dunst et al., 2003:783 and Obermair et al., 2001:906). These 
studies postulated that anaemia could be linked to poor tumour sensitivity to 
radiotherapy due to decreased oxygen supply. Radiation induced killing of tumours 
increased three-fold in the presence of oxygen. The cytotoxic activity of the alkylating 
agents also appeared to be linked to the oxygen dependent production of free 
radicals. In addition, anaemia might have promoted the transcription of genes that 
were vital for tumour cell adaptation and survival. This resulted in tumour 
aggressiveness, resistance to chemotherapy or radiotherapy and poor prognosis. 
Therefore, low blood Hb levels could be regarded as an independent factor that 
affects the clinical outcome of cervical cancer patients. (Grogan et al., 1999:1534; 
Dunst et al., 2003:783 and Obermair et al., 2001:906) 
Of the 164 patients who had anaemia, 31% (52; n=164) received curative RT, 2% (3; 
n=164) received CT, 39% (64; n=164) received CCRT and 28% (45; n=164) received 
PRT (Figure 5.4). Hence, the highest cases of anaemia were reported in patients 
who received CCRT. 
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Figure 5.4: Relationship between anaemia and treatment options 
(RT= radiotherapy; CT=chemotherapy; CCRT=concurrent chemoradiation; PRT=palliative 
radiotherapy) 
In 1999, the United States National Cancer Institute recommended that CCRT 
should be considered as the standard treatment for advanced cervical cancer. This 
recommendation was based on the results of five randomised controlled trials: Keys 
et al., 1999:1154-1161; Morris et al., 1999:1137-1143; Rose et al., 1999:1144-1153; 
Whitney et al., 1999:1606-1613 and Peters et al., 2000:1606-1613 (Table 3.3). Since 
this recommendation, systematic reviews and meta-analysis conducted by Lukka et 
al. (2002:203-212) and Green et al. (2001:781-786) reported on the effects of CCRT. 
Kirwan et al. (2003:216-226) later evaluated the trials that met the inclusion criteria 
of the Green et al., (2001:781-786) systematic review and meta-analysis in order to 
examine the toxicity of CCRT for cervical cancer. This involved the identification of 
19 trials that were carried out between 1980 and 2000 and included 4580 
randomised patients. Kirwan et al., (2003:216-226) found that there was no 
significant difference in the Hb levels among the CCRT groups and RT groups but 
showed a trend towards more cases of anaemia being reported in the CCRT groups. 
This observation was in line with the current study in that there was no significant 
difference in the Hb levels between the CCRT group and the RT group (Chi2 = 4.83, 
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d.f. = 3, p = 0.18497, Cramer‟s V = 0.16) but more cases of anaemia were reported 
in the CCRT group (64; 39%; n=164) than in the RT group (51; 31%; n=164).  
More severe anaemia develops in patients treated with CCRT than with RT alone, 
because of the additive myelosuppressive effect of chemotherapeutic drugs (Kim et 
al., 2007:199).  Therefore, it is important to effectively manage this condition as it not 
only prevents the administration of chemotherapy but is in itself associated with poor 
treatment outcomes.  
In summary, the current study could not determine whether the presence of anaemia 
could significantly affect the prognosis of the cervical cancer patients despite the fact 
that a large number (87; 53%; n=164) of the anaemic patients had a poor response 
to treatment. There was also no significant difference in the Hb levels between the 
CCRT group and the RT group (Chi2 = 4.83, d.f. = 3, p = 0.18497, Cramer‟s V = 
0.16). However, more cases of anaemia were reported in the CCRT group (64; 39%; 
n=164) than in the RT group (51; 31%; n=164).  
5.7.2  Tumour characteristics 
5.7.2.1 Stage at initiation of treatment 
According to literature, the stage of cervical cancer is not an independent prognostic 
factor but relies on when treatment was initiated. Detection and treatment of cervical 
cancer in its earliest stages significantly improves prognosis. (Committee on Practice 
Bulletins-Gynaecology, 2002:857) 
In the current study, the stage of cervical cancer at initiation of treatment was 
compared to response to treatment. This was done at one month, six months, 12 
months, 18 months and 24 months after treatment. Not all patients returned for 
follow up after each time period so sample size varies at the different periods. 
All of the 196 patients returned to the study site one month after treatment. Complete 
response was noted in 83% (5; n=6) of the stage I patients, 93% (25; n=27) of the 
stage II patients, 61% (65; n=106) of the stage III patients and 4% (2; n=57) of the 
stage IV patients (Figure 5.5). Thus at one month following treatment there was a 
highly significant difference in the incidence of complete response in patients at 
different stages of cervical cancer (Chi2 = 88.9, d.f. = 3, p = 0.0000, Cramer‟s V 
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=0.67). The highly significant difference in response to treatment by patients at 
different stages of cervical cancer was maintained at six months after treatment (Chi2 
= 70.94, d.f. = 3, p = 0.0000, Cramer‟s V = 0.62), 12 months after treatment (Chi2 = 
48.53, d.f. = 3, p = 0.0000, Cramer‟s V = 0.54), 18 months after treatment (Chi2 = 
32.02, d.f. = 3, p = 0.0000, Cramer‟s V = 0.5) and 24 months after treatment (Chi2 = 
18.69, d.f. = 3, p = 0.0032, Cramer‟s V = 0.45). 
At six months after treatment (n=184), complete response was noted in 83% (5; n=6) 
of the stage I patients, 93% (25; n=27) of the stage II patients, 66% (70; n=106) of 
the stage III patients and 1% (2; n=57) of the stage IV patients (Figure 5.5).  
Twelve months after completion of treatment (n=168), complete response was noted 
in 67% (4; n=6) of the stage I patients, 70% (19; n=27) of the stage II patients, 53% 
(56; n=106) of the stage III patients and 5% (3; n=57) of the stage IV patients (Figure 
5.5).  
At 18 months after treatment (n=146), complete response was noted in 50% (3; n=6) 
of the stage I patients, 67% (18; n=27) of the stage II patients, 49% (52; n=106) of 
the stage III patients and 4% (2; n=57) of the stage IV patients (Figure 5.5).  
Twenty four months after treatment (n=139), complete response was observed in 
67% (4; n=6) of the stage I patients, 37% (10; n=27) of the stage II patients, 39% 
(41; n=106) of the stage III patients and 2% (1; n=57) of the stage IV patients (Figure 
5.5).  
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Figure 5.5: Patients diagnosed at various stages of ICC who experienced complete 
response to treatment 
In summary, the study revealed that there was a highly significant difference in the 
response to cervical cancer treatment between the patients with early stage cervical 
cancer (stage I and II) and the patients with advanced stage cervical cancer (stage 
III and IV). These significant differences were observed at each interval: one month 
after treatment (Chi2 = 88.9, d.f. = 3, p = 0.0000, Cramer‟s V =0.67); six months after 
treatment (Chi2 = 70.94, d.f. = 3, p = 0.0000, Cramer‟s V = 0.62); 12 months after 
treatment (Chi2 = 48.53, d.f. = 3, p = 0.0000, Cramer‟s V = 0.54); 18 months after 
treatment (Chi2 = 32.02, d.f. = 3, p = 0.0000, Cramer‟s V = 0.5) and 24 months after 
treatment (Chi2 = 18.69, d.f. = 3, p = 0.0032, Cramer‟s V = 0.45). At each of these 
intervals, the response to cervical cancer treatment was poorer among women with 
advanced stage cervical cancer.  
Cervical cancer is one of the few cancers that can be easily managed if it is detected 
in its earliest stages. The current study showed a trend that patients with stage I and 
stage II disease responded to treatment more favourably than the patients with stage 
III and stage IV. This is due to the fact that the local treatment of cervical cancer in 
Stage
I
Stage
II
Stage
III
Stage
IV
Duration after treatment 
 
N
u
m
b
e
 r
 o
f 
p
a
ti
e
n
ts
 w
it
h
 
c
o
m
p
le
te
 r
e
s
p
o
n
s
e
 
n=196 n=184 n=168 n=146 n=139 
 
93 
 
its earliest stages using surgery or radiotherapy is more effective than systemic 
treatments such as concurrent chemoradiation that is used to manage the advanced 
stages of the disease (Committee on Practice Bulletins-Gynaecology, 2002:857). 
The American Cancer Society has found that, with treatment, the five year relative 
survival rate for the earliest stage of invasive cervical cancer is 92% and the rate for 
all the stages combined is 72%. Approximately, 80% to 90% of women with stage I 
cancer and 50% to 65% of women with Stage II cancer who receive treatment are 
still alive five years after diagnosis. Only 25% to 35% of women with Stage III cancer 
and 15% or less of women with Stage IV cancer are alive five years after diagnosis. 
(American Cancer Society, 2009:22) Although the study carried out by the American 
Cancer Society looked at the relationship between the clinical stage and the five year 
survival rate and this current study looked at the relationship between the clinical 
stage and the response to treatment, it is clear that with treatment, patients who had 
cervical cancer detected at its earliest stages had a more favourable prognosis than 
those patients that were diagnosed with advanced stage cervical cancer.  
In conclusion, most of the participants in the current study (163; 83%; n=196) were 
diagnosed with cervical cancer in its advanced stages (stage III and stage IV). The 
patients with early stage cervical cancer (stage I and II) responded more favourably 
to treatment than the patients with advanced stage cervical cancer. It has been 
shown that the treatment of cervical cancer in its earliest stages using surgery or RT 
is more effective than using systemic treatments such as CCRT that is used to 
manage the advanced stages of the disease (Committee on Practice Bulletins-
Gynaecology, 2002:857). Therefore, it is imperative to detect and treat cervical 
cancer in its earliest stages in order to prevent the disease from progressing into an 
advanced stage.  
5.7.3  Treatment characteristics 
5.7.3.1 Introduction 
At the study site, the prescribed radiotherapy treatment for Stage Ib to III disease 
included EBRT 50 Gray (Gy) in 25 fractions, 2 Gy daily over five weeks and ICT 
brachytherapy 24.8 Gy in four fractions (6.2 Gy/fraction). Carboplatin and cisplatin 
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were the two chemotherapeutic agents that were used at the study site to treat 
cervical cancer. The prescribed dose of carboplatin was between 450 and 600 
mg/m2 weekly and the dose of cisplatin ranged between 50 and 60 mg/m2 weekly. 
The number of cycles received by patients who were in the chemotherapy or 
chemoradiation group ranged between 4 and 7 cycles. In order to minimise cisplatin 
or carboplatin induced nephrotoxicity, one litre of normal saline infusion was used to 
hydrate the patients before they received chemotherapy. The prophylactic 
antiemetics that were administered comprised dexamethasone 8 mg intravenous (IV) 
and granisetron 1 mg (IV). After prehydration and the administration of the 
antiemetics, carboplatin or cisplatin was then added to one litre of normal saline and 
administered to the patients. Cisplatin was withheld in patients with severe 
nephrotoxicity and ototoxicity. 
Radiotherapy was administered to patients with stage IV disease for palliation of 
central or metastatic disease. These patients received 30 Gy in 10 fractions over two 
weeks. These patients also received analgesics and antibiotics as symptomatic 
treatment of advanced disease. 
Since the 1999 National Cancer Institute publication that recommended the use of 
CCRT to treat cervical cancer patients with inoperable disease, oncology 
departments worldwide have adopted this practice in their treatment protocols. The 
widely accepted standard includes EBRT 45 to 50 Gy in 25 fractions, ICT 
brachytherapy 15 to 28 Gy in two to four fractions and weekly concomitant cisplatin 
chemotherapy 40mg/m2 for six cycles (Eifel et al., 2004:1150). The prescribed 
radiotherapy protocols used at the study site were in line with this universally 
acceptable standard, however, the study site prescribed weekly concomitant 
cisplatin chemotherapy 50mg/m2 as opposed to 40 mg/m2 which is more frequently 
prescribed. In the case of palliative treatment, three fractions of 10 Gy is the most 
frequently prescribed dose and this was the dose that was used at the study site 
(Lonkhuijzen & Thomas, 2011:288).  
5.7.3.2 Duration of therapy 
In the current study, in patients who only received curative RT (stage I, II and III), the 
average duration of treatment in patients who had a complete response was 41.9 + 8 
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days (6 weeks) and that of patients who had an incomplete response to RT was 33.2 
+ 16 days (5 weeks). In stage I, II and III patients who received CCRT, the average 
duration of treatment in patients who had a complete response was 64.9 + 12 days 
(9 weeks) and that of patients who had an incomplete response to treatment was 
58.2 + 30.5 days (8 weeks).  
According to literature, the longer the time period over which the prescribed 
treatment is administered (for example, longer periods between doses), the shorter 
the overall survival, disease free survival and local control of the tumour (Waggoner, 
2003:2223 and Taylor et al., 1990:97). The American Brachytherapy Society 
recommends that the total treatment duration for cervical cancer should be less than 
eight weeks. After approximately eight weeks of therapy, the increase in local failure 
is 0.7% to 1.0% per day for everyday of treatment missed. (Nag et al., 2000:202)  
There was no significant difference in the average duration of treatment between the 
patients who had a complete response to CCRT and the patients who had an 
incomplete response to CCRT (t-test = 0.93828 p = 0.35137, Cohen‟s d = 0.3). 
However, a highly significant difference in the average duration of treatment between 
the patients who had a complete response to RT and the patients who had an 
incomplete response to RT was reported whereby the patients who had a complete 
response to RT received treatment over a longer period of time (t-test = 2.91678 p = 
0.00487, Cohen‟s d = 0.79). 
In the current study, the average duration of treatment of the patients who had a 
complete response to RT was less than eight weeks (6 weeks) while the average 
duration of treatment of the patients who had a complete response to CCRT was 
more than eight weeks (9 weeks).  The average duration of treatment of the patients 
who had an incomplete response to RT (5 weeks) and CCRT (8 weeks) was lower 
than that of the patients who displayed complete response to RT (6 weeks) or CCRT 
(9 weeks). The results of the current study, in terms of duration of treatment, are in 
contrast to the recommendation made by the American Brachytherapy Society in 
that the patients who experienced complete response to RT or CCRT received 
treatment over a longer period of time than the patients who experienced an 
incomplete response to RT or CCRT. This was due to the fact that in the current 
study some of the patients who exhibited an incomplete response to RT or CCRT did 
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not complete the prescribed treatment either due to non adherence to the prescribed 
treatment or early termination of treatment by the oncologist. Therefore, in the 
current study a link could not be established between the duration of cervical cancer 
treatment and patient outcome. 
The WHO defines palliative care as „the active total care of patients whose disease 
is not responsive to curative treatment‟ (WHO, 1990). Therefore PRT is not aimed at 
curing cervical cancer but at providing relief from pain and other physical symptoms 
such as bleeding and vaginal discharge. In this study, patients who had a complete 
response to PRT experienced relief from pain and other symptoms and patients who 
had an incomplete response to PRT did not experience pain relief and other 
symptoms. Bleeding was the symptom that was often the reason for palliative 
treatment in women with advanced cervical cancer. The average duration of 
treatment in patients who had a complete response to PRT was 9 + 1 days and that 
of patients who had an incomplete response to PRT was 10.6 + 6 days. There was 
no significant difference in the average duration of treatment between the patients 
who had a complete response to PRT and the patients who had an incomplete 
response to PRT (t-test = 2.61688 p = 0.92613, Cohen‟s d = 0.79).  
5.7.3.3 Doses employed 
Many oncologists, including the ones at the study site, believe that prescribing PRT 
in multiple fraction regimens (20 Gy in five fractions, 30 Gy in 10 fractions, and 45 Gy 
in 20 to 25 fractions) leads to better symptom reduction than administering PRT in a 
large single fraction. In resource constrained countries such as South Africa, where 
there are insufficient trained health care staff and radiation equipment and most 
cervical cancer patients have limited access to treatment facilities due to financial or 
geographical factors, large single fractions of PRT may be preferable if similar 
palliative results could be achieved (Lonkhuijzen & Thomas, 2011:288). This was, 
however, not the practice at the study site. 
Studies have been conducted in order to identify a palliative radiation schedule that 
would provide an optimal palliative effect with the least burden on the cervical cancer 
patients or on the health care system. Lonkhuijzen & Thomas (2011:287-291) 
performed a systematic literature review of eight studies in order to identify an 
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optimal palliative radiation schedule for treatment of patients with advanced cervical 
cancer (Table 5.6). In three of the studies, which used the 30 Gy in 10 fraction 
regimen (multiple fraction regimen), complete cessation of bleeding was reported in 
45%, 31% and 0% of the patients (based on 86, 76 and 41 patients respectively) 
(Boulware et al., 1979:337; Onsrud et al., 2001:1899 and Mishra et al., 2005:212). 
Pain relief was noted in 15% of 86 patients in the Boulware et al. study (1979:333-
338). The 30 Gy in 10 fraction regimen was also used in the current study and when 
the stage IV cervical cancer patients were evaluated one month after treatment, 
complete cessation of bleeding and pain relief was reported in 4% (2; n=57) of the 
patients. In contrast, a study by Patricio et al. (1987:133-135), which used a dose of 
13 Gy in two fractions (low fraction regimen), led to a cessation of bleeding in 46% 
and provided pain relief in 14% of 56 patients. Another low fraction regimen dose of 
10 Gy given in two fractions stopped bleeding in 93% of 15 patients in the study by 
Grigsby et al. (2002:18-21). 
Two studies investigated relief from vaginal discharge as a study outcome (Onsrud 
et al., 2001:1896-1901 and Mishra et al., 2005:208-212). The studies which used a 
multiple fraction regimen of 30 Gy in 10 fractions reported that radiation improved 
this symptom. One study also reported relief from other symptoms such as dysuria, 
ulceration, constipation and tenesmus (Spanos et al., 1996:1479-1482). This 
systematic review drew inconclusive results in that it did not determine a palliative 
radiation regimen that would provide optimal symptom relief and have minimal 
burden on both patients and the health care system. 
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Table 5.6: Studies reviewed by Lonkhuijzen and Thomas (2011) 
Study Number of patients 
(total) 
RT dose Bleeding 
cessation 
Pain relief 
Boulware et al., 1979 86 30 Gy in 10 
fractions 
45% 15% 
Hodson & Krepart, 
1983 
14 30 Gy in 10 
fractions 
  
Halle et al., 1986 42 30 Gy in 10 
fractions 
  
Onsrud et al., 2001 28 30 Gy in 10 
fractions 
31%  
Mishra et al., 2005 100 30 Gy in 10 
fractions 
0%  
Patricio et al., 1987 56 13 Gy in 2 
fractions 
46% 14% 
Spanos et al., 1996 61 14.8 Gy in 4 
fractions 
  
Grigsby et al., 2002 15 10 Gy in 5 
fractions 
93%  
Current study 
(one month after 
treatment) 
57 30 Gy in 10 
fractions 
4% 4% 
Source: Lonkhuijzen & Thomas, 2011:287-291 
5.7.3.4 Summary 
The current study could not determine whether the prolongation of curative RT or 
CCRT would lead to poor patient outcome. This was due to the fact that some of the 
patients who exhibited an incomplete response to RT or CCRT did not complete the 
prescribed treatment either due to non adherence to the prescribed treatment or 
early termination of treatment by the oncologist. In the case of PRT, although the 
average duration of treatment in patients who had a complete response to PRT (9 + 
1 days) was shorter than that of patients who had an incomplete response to PRT 
(10.6 + 6 days), there was no significant difference in the response to treatment 
between these two groups (t-test = 2.61688 p = 0.92613, Cohen‟s d = 0.79). More 
studies need to be conducted in order to find out if large single fractions of PRT, 
rather than multiple fractions of PRT, which provide optimal patient outcome with 
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minimal use of resources may be preferable if similar palliative results could be 
achieved. 
5.8 RESPONSE TO CERVICAL CANCER TREATMENT IN HIV POSITIVE 
VERSUS HIV NEGATIVE WOMEN 
This section will look at the response to cervical cancer treatment in the HIV negative 
women compared to the HIV positive women. The study population consisted of 100 
(51%; n=196) HIV negative participants and 83 (42%; n=196) HIV positive 
participants. This section will exclude 13 of the 196 participants whose HIV status 
could not be determined as the data was not present in the patient files.  
5.8.1 Complete versus incomplete response to cervical cancer treatment 
In this study, the term „complete response‟ referred to patients who had no 
recurrence of cervical cancer and no evidence of metastases and „incomplete 
response‟ referred to patients who either had a recurrence of cervical cancer or 
displayed evidence of metastases. This only applied to patients who received RT 
and CCRT for curative purposes (stage I, II and III patients). In patients who received 
PRT (stage IV patients), the term „complete response‟ referred to patients who had 
experienced relief from pain and other symptoms such as bleeding or vaginal 
discharge and „incomplete response‟ referred to patients who did not experience  
relief from pain or the other symptoms.  
The response of the cervical cancer patients was evaluated one month after 
treatment, six months after treatment, 12 months after treatment, 18 months after 
treatment and 24 months after treatment.  
All the 183 patients with known HIV status returned to the study site one month after 
treatment. Complete response was noted in 65% (65; n=100) of the HIV negative 
patients and in 35% (29; n=83) of the HIV positive patients (Figure 5.6). At one 
month following treatment there was a significant difference in the incidence of 
complete response between the HIV positive patients and the HIV negative patients 
(Chi2 = 16.4, d.f. = 1, p = 0.00005, Cramer‟s V =0.31). The significant difference in 
response to treatment between the HIV positive patients and the HIV negative 
patients was maintained at six months after treatment (Chi2 = 15, d.f. = 1, p = 
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0.00011, Cramer‟s V = 0.34), 12 months after treatment (Chi2 = 20.5, d.f. = 1, p = 
0.00001, Cramer‟s V = 0.37), 18 months after treatment (Chi2 = 9.8, d.f. = 1, p = 
0.00173, Cramer‟s V = 0.28) and 24 months after treatment (Chi2 = 5.0, d.f. = 1, p = 
0.02571, Cramer‟s V = 0.26). 
At six months after treatment (n=171), complete response was noted in 61% (61; 
n=100) of the HIV negative patients and in 34% (28; n=83) of the HIV positive 
patients. Twelve months after completion of treatment (n=155),complete response 
was noted in 60% (60; n=100) of the HIV negative patients and in 27% (22; n=83) of 
the HIV positive patients.  
At 18 months after treatment (n=133), complete response was noted in 54% (54; 
n=100) of the HIV negative patients and in 25% (21; n=83) of the HIV positive 
patients.  
The response of 126 patients was evaluated 24 months after treatment. Complete 
response was noted in 41% (41; n=100) of the HIV negative patients and in 18% (15; 
n=83) of the HIV positive patients.  
In summary, the study revealed that there was a significant difference in the 
response to cervical cancer treatment between the HIV positive patients and the HIV 
negative patients. These significant differences were observed at each interval: one 
month after treatment (Chi2 = 16.4, d.f. = 1, p = 0.00005, Cramer‟s V =0.31); six 
months after treatment (Chi2 = 15, d.f. = 1, p = 0.00011, Cramer‟s V = 0.34); 12 
months after treatment (Chi2 = 20.5, d.f. = 1, p = 0.00001, Cramer‟s V = 0.37); 18 
months after treatment (Chi2 = 9.8, d.f. = 1, p = 0.00173, Cramer‟s V = 0.28) and 24 
months after treatment (Chi2 = 5.0, d.f. = 1, p = 0.02571, Cramer‟s V = 0.26). At each 
of these intervals, the response to cervical cancer treatment was poorer among HIV 
positive women.  
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Figure 5.6: HIV negative and HIV positive patients who experienced complete 
response to treatment 
5.8.2 Recurrence and metastases of cervical cancer 
In this study, „recurrence‟ referred to the detection of disease, following curative RT 
or CCRT, upon physical examination of the cervix by an oncologist. Forty percent 
(40; n=100) of the HIV negative patients and 72% (60; n=83) of the HIV positive 
patients displayed recurrence of cervical cancer after receiving treatment. The 
number of HIV positive patients with recurrence of cervical cancer was significantly 
higher than that of the HIV negative patients (Chi2 = 17.8, d.f. = 2, p = 0.00013, 
Cramer‟s V = 0.31). 
Metastases referred to the detection of cancerous cells in the other parts of the body 
such as: rectum/bladder; lungs; bone; brain; liver; kidney; ovaries and breast. The 
presence of metastases was determined by performing tests such as the ultrasound 
of the kidney and pelvis, bone scans and Magnetic Resonance Imaging (MRI) of the 
brain.  
HIV negative
(n=100)
HIV positive
(n=83)
N
u
m
b
e
r 
o
f 
p
a
ti
e
n
ts
 w
it
h
 
c
o
m
p
le
te
 r
e
s
p
o
n
s
e
 
Duration after treatment 
102 
 
The study revealed that cancer had spread from the cervix to the other parts of the 
body in 14% (14; n=100) of the HIV negative women and in 44% (35; n=83) of the 
HIV positive women (Table 5.7). The number of HIV positive patients with 
metastases of cervical cancer was significantly higher than that of the HIV negative 
patients (Chi2 = 13.6, d.f. = 2, p = 0.00109, Cramer‟s V = 0.28). 
Table 5.7: Metastases observed in the study population 
Area HIV negative (n=100) HIV positive (n=83) 
 Number Percentage Number Percentage 
Bladder/rectum 0 0 2 3 
Lung 4 4 4 5 
Bone 5 5 12 15 
Brain 1 1 3 4 
Liver 2 2 7 8 
Kidney 2 2 4 5 
Ovaries 0 0 1 1 
Breast 0 0 2 3 
Totals 14 14 35 44 
In summary, the study revealed that there were significantly more cases of 
recurrence (Chi2 = 17.8, d.f. = 2, p = 0.00013, Cramer‟s V = 0.31) and metastases 
(Chi2 = 13.6, d.f. = 2, p = 0.00109, Cramer‟s V = 0.28) of cervical cancer among HIV 
positive patients. 
In 1993, the CDC declared cervical cancer an AIDS defining illness after it was 
discovered that HIV infection was associated with an increased risk of developing 
CIN and rapid progression to ICC (Centers for Disease Control and Prevention, 
1993:730). The main treatment options used to manage cervical cancer are RT and 
CCRT. Currently, HIV positive and HIV negative women with cervical cancer are 
managed in the same way. It is unknown whether the therapeutic ratio for CCRT in 
HIV negative women is maintained or changed in HIV positive women. There is 
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inadequate literature available on HIV positive women with invasive cervical cancer 
regarding the response to CCRT, side effects, patient adherence and rate of 
survival. Thus, standard treatments for these patients have not been defined. 
(Formenti et al., 1995:411-412) 
However, some studies have reported similar findings to the current study in that HIV 
positive cervical cancer patients have a poor response to radiotherapy and early 
recurrence, resulting in poorer overall survival. Maiman et al. (1990:377-384) 
assessed 84 women with ICC in terms of disease characteristics, recurrence rates 
and survival rates. Sixteen of these patients were HIV positive and 68 were HIV 
negative. It was found that the response to therapy and prognosis was poorer among 
the HIV positive women, with higher recurrence and death rates compared with the 
HIV negative women. Another study by Maiman et al. (1997:76-80), that investigated 
women with ICC in New York City, also observed that treatment outcomes were 
poorer in HIV positive women than in HIV negative women and 88% of recurrence 
rates were reported among the HIV positive women.  
Gichangi et al. (2006:405-411) prospectively investigated the impact of HIV infection 
on tumour control following radiotherapy for cervical cancer. Twenty percent of the 
218 participants were HIV positive. It was observed that HIV positive women were 
significantly associated with a six fold higher risk of residual tumour after receiving 
radiotherapy than the HIV negative women. 
The findings of Maiman et al. (1990:377-384 and 1997:76-80)and Gichangi et al. 
(2006:405-411) are similar to those of the current study in that the response to 
cervical cancer therapy was poorer among the HIV positive women. Additionally, 
higher recurrence rates were reported in the two studies by Maiman et al. (1990:377-
384 and 1997:76-80) and in the current study. Therefore, HIV infection could 
significantly affect the treatment outcomes of cervical cancer patients. 
5.8.3 Response to cervical cancer treatment in HIV positive women on 
ARVs and HIV positive women who were not on ARVs 
The response to cervical cancer treatment among HIV positive women who were on 
ARVs and the HIV positive women who were not on ARVs was investigated. The 
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CD4 count which is an indicator of the level of immunity in HIV positive women was 
the most important factor that was considered in making the decision to initiate ARV 
therapy in HIV positive women. Classes of ARVs presented included: nucleoside 
reverse transcriptaseinhibitors (NRTIs); non nucleoside reverse 
transcriptaseinhibitors (NNRTIs) and protease inhibitors. The ARVs were used in 
combinations, known as HAART which consists of three active drugs to prevent 
resistance, with initial regimens including combinations of two NRTIs with an NNRTI. 
(Rudek et al., 2011:1) 
Of the 83 HIV positive patients, 87% (72; n=83) were on HAART and 13% (11; n=83) 
were not on HAART. Furthermore, HAART was only initiated in HIV positive women 
whose CD4 count was less than 200 cells/mm3. 
The HAART regimens used were classified as regimen 1a, 1b and 2 according to the 
2004 South African national antiretroviral treatment guidelines. Regimen 1a 
consisted of: stavudine (d4T), lamivudine (3TC) and efavirenz (EFV); regimen 1b 
consisted of d4T, 3TC and nevirapine (NVP) and regimen 2 consisted of zidovudine 
(AZT), didanosine (DDI) and lopinavir (LPV)-ritonavir (RTV). (Department of Health, 
South Africa, 2004:14)  Of the 72 HIV positive women who were on HAART, 81% 
(58; n=72) were on regimen 1a, 5% (4; n=72) were on regimen 1b and 14% (10; 
n=72) were on regimen 2. 
All 83 HIV positive patients returned to the study site one month after treatment. 
Complete response was noted in 38% (27; n=72) of the HIV positive patients who 
were on HAART and in 18% (2; n=11) of the HIV positive patients who were not on 
HAART (Figures 5.7).  
At six months after treatment (n=71), complete response was noted in 39% (28; 
n=72) of the HIV positive patients who were on HAART and in none (0; n=11) of the 
HIV positive patients who were not on HAART.  
Twelve months after completion of treatment (n=55), complete response was noted 
in 29% (21; n=72) of the HIV positive patients who were on HAART and in 9% (1; 
n=11) of the HIV positive patients who were not on HAART.  
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At 18 months after treatment (n=33), complete response was noted in 29% (21; 
n=72) of the HIV positive patients who were on HAART and in none (0; n=11) of the 
HIV positive patients who were not on HAART.  
Twenty four months after treatment (n=26), complete response was noted in 21% 
(15; n=72) of the HIV positive patients who were on HAART and in none (0; n=11) of 
the HIV positive patients who were not on HAART.  
At one month following treatment there was no significant difference in the incidence 
of complete response between the HIV positive patients who were on HAART 
(37.5%; 27; n=72) and the HIV positive patients who were not on HAART (18%; 2; 
n=11) (Chi2 = 1.6, d.f. = 1, p = 0.21071, Cramer‟s V =0.14). However, at six months 
after treatment, a significant difference in the response to cervical cancer treatment 
was observed between the HIV positive patients who were on HAART (39%; 28; 
n=72) and the HIV positive patients who were not on HAART (0%; 0; n=11) (Chi2 = 
0.5, d.f. = 1, p = 0.02546, Cramer‟s V = 0.25). Complete response was significantly 
higher in the HIV positive women who were on HAART.  There was no significant 
difference in the response to treatment between the HIV positive patients who were 
on HAART (29%; 21; n=72) and the HIV positive patients who were not on HAART 
(9%; 1; n=11) at 12 months after treatment (Chi2 = 1.2, d.f. = 1, p = 0.28067, 
Cramer‟s V = 0.13).  At 18 months after treatment and at 24 months after treatment, 
the response to cervical cancer in these two groups could not be statistically 
analysed because the sample size was too small. 
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Figure 5.7: HIV positive patients who were on HAART and HIV positive patients who 
were not on HAART who experienced complete response to treatment 
In summary, a significant difference in the incidence of complete response to cervical 
cancer treatment between the HIV positive patients who were on HAART and the 
HIV positive patients who were not HAART was only noted six months after these 
patients received treatment (Chi2 = 0.5, d.f. = 1, p = 0.02546, Cramer‟s V = 0.25) 
where complete response was observed in 39% (28; n=72) of the HIV positive 
patients who were on HAART and in none (0; n=11) of the HIV positive patients who 
were not on HAART. No significant differences in the incidence of complete 
response between these two groups were noted at the other time intervals: one 
month after treatment (Chi2 = 1.6, d.f. = 1, p = 0.21071, Cramer‟s V =0.14) and 12 
months after treatment (Chi2 = 1.2, d.f. = 1, p = 0.28067, Cramer‟s V = 0.13). The 
number of HIV positive patients who returned to the study site 18 months and 24 
months after they had received treatment was too small to be statistically analysed. 
Therefore, the use of HAART by the HIV positive participants in the current study did 
not have a significant impact in the patient outcome. 
According to the 2004 South African national antiretroviral treatment guidelines, 
ARVs should be commenced in HIV positive patients with a CD4 count of 200 
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cells/mm3 or less. In addition, ARVs should be commenced in patients with WHO 
stage IV disease irrespective of their CD4 count. The WHO stage IV category 
includes ICC. (Department of Health, South Africa, 2004:12)  This implies that 
patients with confirmed diagnosis of ICC should be commenced on ARVs as soon as 
the ICC diagnosis is made whether their CD4 count is above 200 cells/mm3 or less. 
In the current study, only 72 of the 83 (87%; n=83) HIV positive participants were on 
HAART and 11 (13%; n=83) participants were not on HAART. Furthermore, HAART 
was only initiated in HIV positive women whose CD4 count was less than 200 
cells/mm3. Therefore the patients in the current study were not managed according 
to the 2004 South African national antiretroviral treatment guidelines because 13% of 
the HIV positive patients were not on HAART. 
In most hospitals, including the site used for the current study, HIV positive patients 
are treated using the same protocols as HIV negative patients with cervical cancer. 
Standard treatment guidelines for HIV positive patients with cervical cancer have not 
been defined. The cervical cancer treatment modalities (RT and CCRT) have been 
shown to decrease various immunologic parameters such as CD4 counts thus the 
response and tolerance of HIV positive women to these treatment options is of major 
concern. It is also important to identify the impact of HAART on the CD4 count and 
subsequently on the ICC treatment outcomes. (Housri et al., 2010:277) 
The use of HAART has led to an increased life expectancy of HIV positive women 
and an increased incidence of AIDS defining malignancies such as cervical cancer. 
There is limited data available regarding the impact of HAART on ICC and this data 
has produced conflicting results. Some studies suggest that HAART induced 
elevation of CD4 count levels and suppression of HIV viral load has led to improved 
tolerance of full doses of RT or CCRT and improved response to cancer treatment 
(Antoniou & Tseng, 2005:143 and Ntekim & Folasire, 2010:64). In contrast, other 
studies suggest that the use of HAART does not seem to have a significant effect on 
patient outcome (Brunner et al., 2008:2706 and Caceres et al., 2010:73) and some 
ARVs such as protease inhibitors may potentially increase both tumour control and 
toxicity. 
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A study conducted by Ntekim & Folasire (2010:61-66) examined the outcome of 22 
HIV positive patients treated for cancer. Nine of the 22 patients had cervical cancer. 
Three patients had initial CD4 counts of 450, 460 and 500 cells/mm3 respectively 
thus were not on HAART. They were able to complete the prescribed RT and CT. 
These patients were alive and well six months after treatment. Three other patients 
were already on HAART before they were diagnosed with cervical cancer.  Their 
initial CD4 counts were from 350 to 370 cells/mm3.  They continued with HAART and 
were able to complete the prescribed cervical cancer treatment. These patients were 
also alive and well six months after treatment. The other three patients had initial 
CD4 counts between 250 and 320 cells/mm3 and were started on HAART prior to the 
cervical cancer treatment. At six months after treatment, one patient was alive but 
had recurrent cervical cancer and the other two patients had died. Thus the study 
demonstrated that the use of HAART helped to maintain adequate CD4 count levels 
in HIV positive women with cervical cancer thus enabling them not only to be 
managed in the same way as their HIV negative counterparts but also to complete 
their prescribed treatment and achieve the desired treatment outcome indicating the 
possible relevance for the 13% of the HIV positive patients in the current study who 
were not on HAART to be initiated on HAART. 
Shrivastava et al. (2005:31-35) looked at the outcome of 32 HIV positive patients 
with ICC who underwent RT. The information about the patients‟ ARV treatment was 
not available. Only 12 of the 32 patients could complete the full course of RT and 11 
of these 12 patients experienced complete response. Thus, the response of ICC to 
treatment in HIV positive patients is almost the same as that of HIV negative patients 
but the challenge is to ensure that the HIV positive patients complete the prescribed 
treatment and that the modalities are chosen wisely. 
The International Atomic Energy Association (IAEA) has developed a guideline for 
the treatment of cervical cancer in HIV positive women depending on their CD4 
count. If the CD4 count is greater than 200 cells/mm3, they should be managed the 
same way as HIV negative women. If the CD4 count is greater than 50 cells/mm3but 
less than 200 cells/mm3, the standard management protocols should still be followed 
but with caution as the HIV positive women may exhibit intolerance to RT/CCRT or 
may develop opportunistic infections. If the CD4 count is less than 50 cells/mm3 then 
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only palliative RT should be used. (Mallik et al., 2010:433) At the University of Miami, 
dose modifications of CCRT were undertaken in HIV positive patients whose CD4 
count was less than 200 cells/mm3. The daily fraction size was reduced from 2 Gy, 
which is the widely accepted dose to 1.5 Gy and the most frequently prescribed 
cisplatin dose of 40 mg/m2 weekly was reduced to 30 or 35 mg/m2 weekly. These 
dose modifications resulted in tolerance similar to that of HIV negative patients. 
(Housri et al., 2010:277) 
In summary, standard RT and CCRT cervical cancer treatment protocols should be 
used in both HIV negative patients and HIV positive patients so as not to 
compromise tumour control. The use of HAART by the HIV positive participants in 
the current study did not have a significant impact on the patient outcome. However, 
the available literature seems to provide compelling evidence that HAART elevates 
the CD4 count levels and suppresses the HIV viral load leading to improved 
tolerance to full doses of RT or CCRT. Therefore, in accordance with the South 
African ARV treatment guidelines, all HIV positive patients with cervical cancer 
should receive HAART irrespective of their CD4 count.  
5.9 TOXICITY DUE TO TREATMENT IN HIV POSITIVE VERSUS HIV 
NEGATIVE  CERVICAL CANCER PATIENTS 
Toxicity can be classified as acute or late. Acute toxicity is defined as adverse events 
which occur during treatment and up to 90 days after completion of treatment. This 
toxicity occurs in rapidly proliferating cells such as the skin epithelium, mucosal lining 
of the upper digestive tract or the surface lining of the small intestine. Acute adverse 
events are of a short duration and normally diminish with medical management. Late 
toxicity which appears from nine months up to five years after treatment is difficult to 
reverse and may permanently impair the patient‟s quality of life. The slowly 
proliferating tissue such as the vascular endothelium is damaged and this results in 
fibrosis, stricture, necrosis and fistulae. (Green et al., 2001:785) In this section, the 
acute and late toxicity observed in the HIV positive and HIV negative patients will be 
discussed.  
In the current study, toxicity was grouped as: haematological (anaemia, leucopenia, 
thrombocytopenia); gastrointestinal (nausea and vomiting, diarrhoea, constipation); 
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genitourinary (rectovaginal fistula, radiation proctitis), dermatological (skin 
desquamation) and neurological (peripheral neuropathy). Other toxicities that could 
not be grouped included: renal toxicity; weight loss; pain and deep vein thrombosis 
(DVT). 
All of the patients experienced toxicity/side effects during or after treatment except 
for one (1%; n=93) HIV negative woman.  The number of side effects that were 
noted in the rest of the patients ranged from one to ten (Figure 5.8). The most 
common number of side effects per patient was four side effects (46; 27%; n=171).   
On average, HIV negative patients experienced 3.8 + 1.6 side effects per patient, 
HIV positive patients who were on HAART experienced 4.9 + 2.1 side effects per 
patient and HIV positive patients who were not on HAART experienced 4.3 + 1.3 
side effects per patient (Figure 5.9). There was a significant difference in the 
incidence of the number of side effects per patient in the HIV negative patients 
compared to the HIV positive patients who were on HAART (Tukey‟s HSD 
procedure, p = 0.00013). However no significance was noted in the incidence of the 
number of side effects per patient in the HIV positive patients who were not on 
HAART (Tukey‟s HSD procedure, p = 0.50984). 
111 
 
 
Figure 5.8: Distribution of side effects observed in the study population 
 
Figure 5.9: Comparison of the number of side effects in the HIV negative women, HIV 
positive women who were on HAART and HIV positive women who were not on 
HAART 
1, HIV negative patients (n=100); 2, HIV positive patients who were on HAART (n=72); 3, HIV positive 
patients who were not on HAART (n=11) 
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5.9.1  Haematological toxicity 
Haematological toxicity consisted of anaemia, leucopenia and thrombocytopenia. 
Anaemia, which was characterised by Hb levels below 12 g/dl was noted in 95% (87; 
n=92) of the HIV negative patients; 93% (67; n=69) of the HIV positive patients who 
were on HAART and in ten of the HIV positive patients who were not on HAART 
(100%; n=10) (Chi2 = 2.7, d.f. = 2, p = 0.26446, Cramer‟s V = 0.12) (Table 5.8). 
Thrombocytopenia (platelet count less than 100x109/l) occurred in 15% (14; n=92) of 
the HIV negative patients; 36% (25; n=69) of the HIV positive patients who were on 
HAART and in 20% (2; n=10) of the HIV positive patients who were not on HAART. 
Leucopenia (white cell count below 4x109/l) was noted in 41% (38; n=92) of the HIV 
negative patients; 59% (41; n=69) of the HIV positive patients who were on HAART 
and in 20% (2; n=10) of the HIV positive patients who were not on HAART. 
Haematological toxicity was the most common toxicity reported in the study 
population (164; 84%; n=196). This data was in line with the trials that were reviewed 
in the meta analysis conducted by Green et al. (2001:781-786), Lukka et al. 
(2002:203-212) and the Concomitant Chemoradiotherapy in Cervical Cancer Meta-
Analysis Collaboration (CCCMAC) (2010:1-46) (Table 3.3, 3.5 and 3.6) where 
haematological toxicity was also the most frequently reported toxicity in cervical 
cancer patients who received RT or CCRT.  
Although the haematological toxicity that was reported in the current study was 
usually self limiting or was resolved with medical management (blood transfusions or 
colony stimulating factors such as filgrastim), it still had an impact on the patients‟ 
adherence and response to cervical cancer treatment. Thirty three percent (64; 
n=196) of the study population did not complete their prescribed cervical cancer 
treatment or received treatment for a prolonged period due to low blood count (low 
Hb, white blood cell and platelet count) (Table 5.11). In addition, 47% (77; n=164) of 
the patients who had anaemia experienced incomplete response to cervical cancer 
treatment (Table 5.5). 
The highest cases of haematological toxicity were reported among HIV positive 
patients who were on HAART. The incidence of leucopenia and thrombocytopenia 
was significantly highest in this specific group (Chi2 = 9.3, d.f. = 2, p = 0.00948, 
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Cramer‟s V = 0.23 and Chi2 = 10.5, d.f. = 2, p = 0.00535, Cramer‟s V = 0.24 
respectively) (Table 5.8). The majority of the patients who did not adhere to their 
prescribed cervical cancer treatment or who received treatment over an extended 
duration due to haematological toxicity were also HIV positive patients who were on 
HAART (39; 54%; n=72) (Chi2 = 4.0, d.f. = 2, p = 0.01327, Cramer‟s V = 0.15). Thus 
RT or CCRT induced myelosuppression appeared to have been exacerbated by the 
use of HAART. Of the 72 HIV positive women who were on HAART in the current 
study, 81% (58; n=72) were on regimen 1a (d4T; 3TC; EFV); 5% (4; n=72) were on 
regimen 1b (d4T; 3TC; NVP) and 14% (10; n=72) were on regimen 2 (AZT; DDI; 
LPV-RTV). 
This result was expected as cisplatin, carboplatin and ARVs are known to have a 
myelosuppressive effect. In fact, many oncologists avoid the combination of NRTIs 
that cause marked myelosuppression such as AZT with any myelosuppressive 
regimen and many would interrupt HAART for continuous or high dose 
chemotherapy regimens. Therefore, oncologists should monitor the 
myelosuppression that would occur due to the concomitant use of ARVs and 
chemotherapeutic agents. (Rudek et al., 2011:5) 
Table 5.8: Acute and late toxicity observed in the HIV negative patients, HIV positive 
patients who were on HAART and HIV positive patients who were not on HAART 
Toxicity 
(Chi
2
 test) 
HIV negative patients 
(n=92) 
HIV positive patients 
on HAART (n=69) 
HIV positive patients 
not on HAART (n=11) 
 Number (%) Number (%) Number (%) 
Haematological Toxicity  
Anaemia 
p = 0.26446 
87 (95) 67 (97) 10 (100) 
Leucopenia* 
p = 0.00948 
38 (41) 41 (59) 2 (20) 
Thrombocytopenia* 
p = 0.00535 
14 (15) 25 (36) 2 (20) 
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Gastrointestinal Toxicity  
Nausea and 
vomiting 
p = 0.34665 
2 (2) 4 (6) 0 (0) 
Diarrhoea* 
p = 0.04536 
33 (36) 51 (74) 9 (90) 
Constipation 
p = 0.28757 
11 (12) 4 (6) 2 (20) 
Genitourinary Toxicity  
Rectovaginal fistula 
p = 0.16993 
2 (2) 4 (6) 1 (10) 
Radiation proctitis 
p = 0.39907 
8 (9) 3 (4) 0 (0) 
Dermatological Toxicity  
Skin desquamation* 
p = 0.02512 
39 (42) 59 (86) 8 (80) 
Neurological Toxicity  
Peripheral 
Neuropathy* 
p = 0.00029 
3 (3) 15 (22) 0 (0) 
Other 
Renal toxicity 
p = 0.32294 
1 (1) 2 (3) 0 (0) 
Deep vein 
thrombosis 
p = 0.10446 
8 (9) 1 (1) 0 (0) 
Weight loss* 
p = 0.00074 
29 (32) 41 (59) 3 (30) 
Pain 
p = 0.13203 
64 (70) 57 (83) 10 (100) 
*statistically significant (Chi
2 
with Cramer‟s V) 
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5.9.2  Dermatological toxicity 
Radiation induced dermatological toxicity was the next most common toxicity that was 
observed in the study population (106; 54%; n=196) (Table 5.8). Forty two percent (39; 
n=92) of the HIV negative patients; 86% (59; n=69) of the HIV positive patients who 
were on HAART and in 80% (8; n=10) of the HIV positive patients who were not on 
HAART experienced this adverse effect. Dermatological toxicity also had an impact on 
the patients‟ adherence to cervical cancer treatment. Moist desquamation of the 
irradiated areas caused 36% (70; n=196) of the study population either to be non 
adherent to their prescribed treatment or to complete treatment over a period that was 
longer than the prescribed duration (Table 5.11).   
A large number of patients in the study (83%; 163; n=196) had advanced cervical 
cancer (stage III and IV) and thus required larger RT treatment fields. This may have 
lead to the high incidence of cutaneous toxicity in the study population. Cutaneous 
toxicity was significantly higher in HIV positive patients (67; 85%; n=79) than in HIV 
negative patients (39; 42%; n=92) (Chi2 = 4.2, d.f. = 2, p = 0.02512, Cramer‟s V = 0.15).   
Studies on HIV positive patients with Kaposi‟s Sarcoma suggest that the HIV virus 
induces glutathione deficiency that makes HIV positive patients more sensitive to RT 
thus increasing the risk of cutaneous and mucosal toxicity. This results in moist 
desquamation of the skin. (Housri et al., 2010:273) At the study site, the patients who 
had cutaneous reactions in the perianal or groin area were put on bed rest and 
dressings were applied daily until the reactions subsided and the patients could resume 
RT.  
5.9.3  Gastrointestinal toxicity 
Nausea and vomiting, diarrhoea and constipation were classified under gastrointestinal 
toxicity.  
Nausea and vomiting: was recorded in 2% (2; n=92) of the HIV negative patients and in 
6% (4; n=69) of the HIV positive patients who were on HAART (Table 5.8). This result 
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was not statistically significant (Chi2 = 2.1, d.f. = 2, p = 0.34665, Cramer‟s V = 0.11). All 
of these patients were on CCRT. Nausea and vomiting is a very common acute side 
effect of CT. It has been estimated that approximately 70% to 80% of patients receiving 
CT experience nausea and vomiting. The chemotherapeutic agents that were used in 
the current study were cisplatin, which has an emetic risk greater than 90% without anti-
emetic agents and carboplatin, which has an emetic risk of between 30% and 90% 
without anti-emetic agents. (Fiore & Cutsem, 2009:115) However, the low incidence of 
nausea and vomiting that was observed was due to the fact that all the patients who 
underwent CT received dexamethasone 8 mg intravenous (IV) and granisetron 1 mg 
(IV) before receiving the CT. This management of CT induced nausea and vomiting is 
based on the American Society of Clinical Oncology guidelines for antiemetics in 
oncology (Kris et al., 2006:2940). Granisetron was used to prevent acute nausea and 
vomiting that occurs within 24 hours of the initial administration of CT and 
dexamethasone was used to prevent delayed emesis that occurs from 24 hours to 
several days after initial treatment.   
Diarrhoea: was noted in 36% (33; n=92) of the HIV negative patients; 74% (51; n=69) of 
the HIV positive patients who were on HAART and in 90% (9; n=10) of the HIV positive 
patients who were not on HAART (Table 5.8). Radiation therapy induced diarrhoea 
occurs as a result of damage to the jejuna crypt cells in the surface lining of the small 
intestine. It is estimated that 70% of patients who receive RT may experience diarrhoea 
during treatment. (Abayomi et al., 2005:354) At the study site, diarrhoea was managed 
by administering either loperamide or codeine phosphate to the patients. These agents 
form first line therapeutic options for diarrhoea in many oncology centres worldwide 
(Abayomi et al., 2005:359).  In the current study the number of HIV positive patients (60; 
76%; n=79) who experienced diarrhoea was significantly higher than the HIV negative 
patients (33; 36%; n=92) (Chi2 = 1.2, d.f. = 2, p = 0.04536, Cramer‟s V = 0.23). 
Moreover, diarrhoea had an impact on some of the patients‟ adherence to cervical 
cancer treatment. Twenty six percent (26; n=100) of the HIV negative patients, 57% (41; 
n=72) of the HIV positive patients who were on HAART and 64% (7; n=11) of the HIV 
positive patients who were not on HAART did not adhere to their prescribed cervical 
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cancer treatment due to RT induced diarrhoea (Table 5.11). The incidence of non 
adherence was also significantly higher among the HIV positive patients (64%; 7; n=11) 
(Chi2 = 6.9, d.f. = 2, p = 0.03118, Cramer‟s V = 0.19).   
Constipation: occurred in 12% (11; n=92) of the HIV negative patients; 6% (4; n=69) of 
the HIV positive patients who were on HAART and in 20% (2; n=10) of the HIV positive 
patients who were not on HAART (Table 5.8). This result was not statistically significant 
(Chi2 = 2.5, d.f. = 2, p = 0.28757, Cramer‟s V = 0.12).  These patients had stage IV 
cervical cancer thus used analgesics such as paracetamol and codeine for pain relief. 
The constipation that these patients experienced which was caused by codeine was 
relieved by administering agents such as liquid paraffin or senna glycosides.  
5.9.4  Neurological toxicity 
Chemotherapy induced peripheral neuropathy (CIPN) which was classified under 
neurological toxicity was noted in 3% (3; n=92) of the HIV negative patients and in 22% 
(15; n=69) of the HIV positive patients who were on HAART (Table 5.8). All these 
patients were on CCRT. Cytotoxic agents inactivate the components required to 
maintain the metabolic needs of an axon and causes damage to the peripheral, motor, 
sensory, and autonomic neurons. This results in CIPN. Peripheral neuropathy results in 
pain or discomfort and compromises the quality of life of a patient. This condition is also 
of great concern as it can result in chemotherapy dose reductions, treatment delays, or 
discontinuation of treatment. (Rudek et al., 2011:4) Both cisplatin and carboplatin which 
were used to manage some of the patients in the current study have the potential to 
cause CIPN. The incidence of carboplatin induced CIPN is estimated at 5% to 20% and 
cisplatin induced CIPN is estimated at 30% to 100%. The occurrence of CIPN was 
significantly higher in HIV positive patients on HAART (15; 22%; n=69) (Chi2 = 16.3, d.f. 
= 2, p = 0.00029, Cramer‟s V = 0.30). Antiretroviral agents such asDDI and d4T have 
been frequently associated with peripheral neuropathy, which at times may be 
irreversible. The onset is typically weeks to months after ARV therapy is started, 
however patients with pre-existing CIPN might have this toxic effect sooner. (Rudek et 
al., 2011:4)As CIPN is cumulative or dose related, the management of the patients in 
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the current study who developed this toxicity consisted of dose reduction of the 
cytotoxic agent. Amitriptyline was also administered in order to exert an analgesic 
effect.Rudek et al. (2011:1-8) suggests that if a HIV positive patient on DDI or d4T 
based HAART regimens develops a malignancy the options are to: select an alternative 
chemotherapy regimen with no overlapping toxic effects; substitute a different NRTI or 
other appropriate ARV or temporarily discontinue ARV therapy. As cisplatin or 
carboplatin are the first line chemotherapy agents in cervical cancer, substituting ARVs 
such as didanosine or stavudine would be the most viable option. 
5.9.5  Other toxicities 
Weight loss: Thirty two percent (29; n=92) of the HIV negative patients, 59% (41; n=69) 
of the HIV positive patients who were on HAART and 30% (3; n=10) of the HIV positive 
patients who were not on HAART experienced weight loss during and after cervical 
cancer treatment (Table 5.8). Weight loss was as a result of RT induced diarrhoea and 
advanced cervical disease. Weight loss was significantly higher in HIV positive patients 
(44; 56%; n=79) than in the HIV negative patients (29; 32%; n=92) (Chi2 = 14.4, d.f. = 2, 
p = 0.00074, Cramer‟s V = 0.28). This finding is not surprising as HIV/AIDS and cervical 
cancer are individually associated with weight loss thus weight loss may be exacerbated 
in HIV positive cervical cancer patients.   
Pain: occurred in 70% (64; n=92) of the HIV negative patients; 83% (57; n=69) of the 
HIV positive patients who were on HAART and in ten (100%; n=10) of the HIV positive 
patients who were not on HAART (Table 5.8). This result was not significant (Chi2 = 6.9, 
d.f. = 2, p = 0.13203, Cramer‟s V = 0.19). The pain experienced by the patients in the 
current study was caused by: advanced disease and CIPN. Majority (96; 73%; n=131) 
of the patients who experienced pain had advanced cervical cancer (stage III and IV). 
„Symptoms of advanced cervical cancer include back pain and pelvic pain‟ (Lonkhuijzen 
& Thomas, 2011:287). This statement is line with the current study as the participants 
with advanced cervical cancer complained of back pain, leg pain and pelvic pain. Oral 
analgesics (such as paracetamol and/or codeine) or palliative RT was used to manage 
pain that was not related to CIPN. Pain induced by CIPN was also reported in the 
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current study. According to the clinicians‟ notes, patients described the pain as tingling, 
burning or numbing sensations. Dose reduction of the cytotoxic drug and administration 
of amitryptiline seemed to alleviate the pain.  
Renal toxicity: The chemotherapy agents, cisplatin or carboplatin were only 
administered in patients who had an initial creatinine clearance of 60ml/min or greater. 
During the course of treatment, 1% (1; n=92) of the HIV negative patients and 3% (2; 
n=69) of the HIV positive patients who were on HAART experienced creatinine 
clearances of less than 60ml/min which was indicative of mild renal toxicity (Table 5.8). 
All these patients were on cisplatin based CCRT. This result was not significant (Chi2 = 
7.5, d.f. = 2, p = 0.32294, Cramer‟s V = 0.20). The low incidence of renal toxicity in 
patients who received cisplatin, which is highly nephrotoxic was due to the fact that 
saline was administered pre and post chemotherapy in order to prevent nephrotoxicity. 
The renal toxicity was ameliorated by reducing the dose of cisplatin and by intensive 
hydration. 
DVT: Nine percent (8; n=92) of the HIV negative patients and 1% (1; n=69) of the HIV 
positive patients who were on HAART experienced DVT. All of these patients were on 
CCRT (Table 5.8). This result was statistically insignificant (Chi2 = 4.5, d.f. = 2, p = 
0.10446, Cramer‟s V = 0.16). Some studies have reported that the incidence of venous 
thromboembolism (VTE) in patients with cervical cancer ranges from 0% to 34%. The 
use of CCRT has shown an improvement in overall survival in patients with advanced 
cervical cancer however the use of CT has lead to the increase of VTE. Although the 
underlying mechanism is unknown, cisplatin is associated with arterial and venous 
thrombosis, hypertension, myocardial infarction, Raynauds syndrome and stroke. 
(Barbera & Thomas, 2008:54) 
Brachytherapy which is a vital component of curative RT may also be a risk factor for 
VTE. This technique which involves the insertion of a capsule of radioactive material 
through the vagina and directly into the tumour, requires immobilisation of the patient for 
hours or days to deliver treatment thus increases the risk of the patient developing DVT. 
Incidences of VTE reported in patients receiving brachytherapy range from 0% to 17%. 
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(Barbera & Thomas, 2008:57) In the current study, low-molecular-weight heparin 
(LMWH) was administered to patients who developed DVT. This was in line with 
American College of Chest Physicians guidelines which state that for the treatment of 
VTE in cancer the use of LMWH is recommended as it has been shown to be better 
than warfarin. However, no specific or different recommendations have been made for 
patients with cervical cancer. (Buller et al., 2004:425S) 
5.9.6  Genitourinary toxicity 
Genitourinary toxicity consisted of rectovaginal fistula (RVF) and chronic radiation 
proctitis. Radiation proctitis occurred in 9% (8; n=92) of the HIV negative patients and in 
4% (3; n=69) of the HIV positive patients who were on HAART (Table 5.8). This result 
was not significant (Chi2 = 1.8, d.f. = 2, p = 0.39907, Cramer‟s V = 0.10). 
Radiation proctitis: is the inflammation and damage to the lower intestine. Acute 
radiation proctitis frequently occurs during RT and lasts up to three months, with 
symptoms including tenesmus, urgency, diarrhoea and occasional bleeding. Chronic 
radiation proctitis can continue from an acute phase or begin eight to twelve months 
after RT.  Late radiation proctitis can lead to tenesmus, urgency, either diarrhoea or 
constipation, anal sphincter dysfunction, mucus discharge, bleeding, stricture, ulceration 
and fistula formation. (Maher & Denton, 2008:481) In the current study, metronidazole 
was used to manage the symptoms of patients with chronic radiation proctitis. Patients 
who experienced diarrhoea also received oral opioids. There is limited evidence based 
therapy of chronic radiation proctitis. Table 5.9 contains the interventions that are used 
to manage chronic radiation proctitis. A systematic review by Maher & Denton 
(2008:479-487) was conducted to examine the efficacy of these interventions. It was 
found that sucralfate enemas seemed to be the best therapy and were safe and well 
tolerated. Additional use of oral metronidazole 400 mg three times a day for a year may 
have had a synergistic effect. Mesalazine and betamethasone enemas may have had 
some effect, but were less well tolerated and less effective. Thus the use of 
metronidazole in the current study was appropriate. 
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In the minority of cases reviewed by Maher & Denton (2008:479-487), patients did not 
respond to the medical interventions thus hyperbaric oxygen therapy was considered. In 
South Africa, resource constraints may hinder the use of hyperbaric oxygen therapy 
though there are centres linked to academic institutions that can offer these services. In 
the Western Cape, these services are offered at a reduced rate for state patients 
(Simonds, 2009:67). Hyperbaric oxygen therapy services were not availableat the 
current study site which is located in the Eastern Cape Province in South Africa. 
Table 5.9: Interventions used to manage chronic radiation proctitis 
5-aminosalicylates  enemas e.g. mesalazine 
Corticosteroid enemas e.g. betamethasone 
Sucralfate enemas 
Metronidazole oral tablets 
Hyperbaric oxygen therapy 
Rectovaginal fistula: Two percent (2; n=69) of the HIV negative patients; 6% (4; n=69) 
of the HIV positive patients who were on HAART and in 10% (1; n=10) of the HIV 
positive patients who were not on HAART developed RT induced RVFs (Table 5.8). 
This result was not significant (Chi2 = 3.5, d.f. = 2, p = 0.16993, Cramer‟s V = 0.14). A 
fistula is an abnormal communication between 2 epithelialised surfaces. A RVF is an 
abnormal connection between the rectum and the vagina (Simonds, 2009:68). In the 
current study, patients with RVFs complained of passing stools through the vagina. All 
the cases of RVFs were caused by RT. This complication was rectified surgically.  
5.9.7  Summary 
The most common toxicity that was reported in the study population was haematological 
toxicity (164; 84%; n=196). Fortunately, this toxicity tended to be short lived and was 
resolved by appropriate medical treatment. Haematological toxicity (leucopenia and 
thrombocytopenia) and neurological toxicity (CIPN) were predominantly reported among 
the HIV positive women who were on HAART (Chi2 = 9.3, d.f. = 2, p = 0.00948, 
Cramer‟s V = 0.23; Chi2 = 10.5, d.f. = 2, p = 0.00535, Cramer‟s V = 0.24 and Chi2 = 
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16.3, d.f. = 2, p = 0.00029, Cramer‟s V = 0.30 respectively). Radiation induced 
dermatological toxicity (skin desquamation), gastrointestinal toxicity (diarrhoea) and 
weight loss were significantly higher among the HIV positive women (Chi2 = 4.2, d.f. = 2, 
p = 0.02512, Cramer‟s V = 0.15; Chi2 = 1.2, d.f. = 2, p = 0.04536, Cramer‟s V = 0.23 
and Chi2 = 14.4, d.f. = 2, p = 0.00074, Cramer‟s V = 0.28 respectively). Therefore, 
based on the current study, conclusions can be drawn that HIV positive patients have 
increased sensitivity of normal tissues to RT or CCRT resulting in increased adverse 
effects.  
There is limited literature describing the acute and late toxicity experienced by HIV 
positive women with cervical cancer. A randomised study by Msadabwe (2009:1-87) 
compared CCRT against RT as treatment of cervical cancer in South African HIV 
positive patients. Sixty four patients with stages I to III were recruited to the study, 31 
patients in the CCRT arm and 33 in the radiation arm (Table 3.10).The major adverse 
effects in this trial were leucopenia (four in the CCRT arm and one in the RT arm) and 
cutaneous reactions (two in the CCRT arm and six in the RT arm). These adverse 
effects were also the most frequently reported effects in the current study. 
Gichangi et al., (2006:405-411) from Nairobi examined the outcome of cervical cancer 
patients who received RT. Twenty percent of the 208 participants were HIV positive. 
There was a high percentage of toxicity in both HIV negative and HIV positive groups. 
There was no difference in the received dose or duration of treatment for the HIV 
positive group. A seven fold higher risk of gastrointestinal, skin and genitourinary toxicity 
was noted in HIV positive women.  
Mallik et al. (2010:432-441) performed a literature review that explored the issues of 
RT/CCRT and HIV related malignancies in order to determine the optimal management 
of HIV positive patients with AIDS related malignancies. One of the studies reviewed 
was by Oehler-Janne et al. (2006:29) that investigated the toxicity due to CCRT in HIV 
positive patients with anal cancer. In the pre HAART era, side effects were more 
frequent and poorer outcome was associated with CCRT. However, the authors 
concluded that HIV positive patients could be treated in the same way as HIV negative 
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patients with anal cancer as long as special precautions were put in place in order to 
prevent or manage toxicity especially in HIV positive patients with CD4 counts less than 
200 cells/mm3. Another study on HIV positive patients with Non Hodgkin‟s Lymphoma 
revealed that before the HAART era, oncologists often reduced the dose of 
chemotherapy due to poor tolerability to CT. Radiotherapy was also associated with 
higher toxicity rates among HIV positive patients. In the HAART era, unacceptable 
toxicity could be avoided even with standard dose CT however data on RT was not 
available. (Kaplan et al., 2005:1538-1543) 
The data from the current study and from the available literature suggests that HIV 
positive patients are more sensitive to RT/CCRT thus are more likely to experience 
increased toxicity than the HIV negative patients. Haematological toxicity seemed to be 
increased in the HIV positive women who were on HAART. Additionally, radiation 
induced dermatological toxicity (skin desquamation), gastrointestinal toxicity (diarrhoea) 
and weight loss were significantly higher among the HIV positive women. 
The use of HAART has allowed administration of standard doses of RT and even CT 
leading to improved outcomes. Therefore, RT and CCRT protocols should generally be 
used wherever possible, so as not to compromise disease control. All cervical cancer 
patients should be on HAART irrespective of their CD4 count in order to elevate the 
CD4 count levels and to suppress the HIV viral load leading to improved tolerance to full 
doses of RT or CCRT. Reducing the chances of toxicity in the HIV positive patients 
would lead to decreased cases of treatment interruption and thus improved patient 
outcomes. 
The findings of the current study are based on a small patient population and a short 
follow up period. Therefore more extensive studies need to be conducted where 
patients would be followed up over a longer period of time for instance five years so as 
to assess the acute and especially the late toxicity to RT/CCRT in HIV positive patients 
with invasive cervical cancer. These studies will assist in the design of appropriate 
strategies for the management of RT or CCRT induced toxicities in HIV positive cervical 
cancer patients. 
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5.10 ADHERENCE TO TREATMENT IN HIV POSITIVE VERSUS HIV 
NEGATIVE CERVICAL CANCER PATIENTS 
The World Health Organisation defines adherence as „the extent to which a person‟s 
behaviour (medication, diet, lifestyle changes) correspond with the agreed 
recommendations from a health care provider (WHO, 2003). In this study, the term 
„adherence‟ referred to the extent to which the patients followed the prescribed cervical 
cancer treatment plan. Therefore, the term „adherent‟ referred to the patients who 
completed the prescribed cervical cancer treatment plan either within the prescribed 
duration or over a prolonged duration and „non adherent‟ referred to the patients who 
either did not complete the prescribed cervical cancer treatment plan or who did not 
receive any of the prescribed treatment. 
The study revealed that 61 (61%; n=100) HIV negative patients, 52 (72%; n=72) HIV 
positive patients who were on HAART and seven (64%; n=11) HIV positive women who 
were not on HAART were adherent to cervical cancer treatment (Table 5.10). There 
was no significant difference in the adherence patterns between these three groups 
(Chi2 = 10.2, d.f. = 6, p = 0.11805, Cramer‟s V = 0.17).  
Table 5.10: Adherence patterns in the study population 
HIV status Adherent Non adherent Totals  
 Prescribed 
duration 
Prolonged 
duration 
Did not 
complete 
treatment 
Did not 
receive 
treatment 
 
n=183 
HIV negative 8 (8%) 53 (53%) 32 (32%) 7 (7%) 100 
HIV positive 
on HAART 
17 (24%) 35 (48%) 17 (24%) 3 (4%) 72 
HIV positive 
not on HAART 
3 (27%) 4 (37%) 3 (27%) 1 (9%) 11 
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Some of the patients in the study population completed their treatment over a longer 
period than the prescribed duration; others did not complete their prescribed treatment 
while still others did not receive any of the prescribed treatment at all (Table 5.10). 
These observations resulted from a number of reasons that included: missed scheduled 
appointments due to personal reasons; radiotherapy equipment failure; low blood count; 
skin breakdown due to RT; diarrhoea caused by RT or CCRT; and early termination of 
treatment by the doctor (Table 5.11).  
Table 5.11: Reasons for the prolongation of the treatment period or for non adherence in 
the study population 
Reasons for non-
adherence 
HIV negative patients 
(n=100) 
HIV positive patients 
on HAART (n=72) 
HIV positive patients 
who were not on 
HAART (n=11) 
Missed scheduled 
appointments 
p = 0.02385* 
40 (40%) 23 (32%) 9 (82%) 
Equipment failure 
p = 0.41311 
22 (22%) 7 (10%) 0 (0%) 
Low blood count 
p = 0.01327* 
24 (24%) 39 (54%) 1 (9%) 
RT induced skin 
breakdown 
p = 0.04581* 
25 (25%) 37 (51%) 8 (73%) 
RT/CCRT induced 
diarrhoea 
p = 0.03118* 
26 (26%) 41 (57%) 7 (64%) 
Early termination of 
treatment by doctor 
P = 0.09023 
19 (19%) 22 (31%) 
5 (64%) 
*statistically significant (Chi
2 
with Cramer‟s V) 
There was a significant difference in the incidence of treatment prolongation or non 
adherence due to missed scheduled appointments among the HIV negative patients, 
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the HIV positive patients who were on HAART and the HIV positive patients who were 
not on HAART (Chi2 = 2.9, d.f. = 2, p = 0.02385, Cramer‟s V = 0.31) (Table 5.11).  The 
highest percentage of cases was reported in the HIV positive women who were not on 
HAART (82%; 9; n=11). The patients missed their scheduled appointments due to 
various personal reasons that were not indicated in the file. 
The study site was located in an urban area in the Eastern Cape Province, South Africa. 
According to Somdyala et al. (2008), cervical cancer was the most common female 
cancer in the Eastern Cape with an age standardised rate of 20.2 (per 100, 000 
population) and most of the cervical cancer patients were located in the rural areas. 
This finding was in line with data from a study by Anorlu (2008:45) which found out that 
in sub-Saharan Africa, most centres for the management of cervical cancer were 
concentrated in urban areas leaving people in the rural areas with limited access to 
health care. Thus in the current study, some of the patients might have missed their 
scheduled appointments because they lacked money or transportation means to travel 
to the hospital for treatment. In many developing countries, women are the primary care 
givers and bread winners (Anorlu, 2008:46), thus some of the patients in the current 
study might have lacked the time to travel to the hospital for treatment due to work or 
household duties. This might have led to their non adherence to the prescribed cervical 
cancer treatment plan or to receive treatment over an extended period of time. 
Twenty two percent (22; n=100) of the HIV negative patients and 10% (7; n=72) of the 
HIV positive patients who were on HAART received treatment over a prolonged duration 
or were non adherent to the prescribed treatment due to RT equipment failure (Table 
5.11). This result was not significant (Chi2 = 1.8, d.f. = 2, p = 0.41311, Cramer‟s V = 
0.10).  
In South Africa, the increasing incidence of cervical cancer is not matched by the 
facilities that are available to manage the patients. There are six national academic 
radiation centres with a small number of additional satellite units. In total, there are 29 
machines currently available in the public sector to treat cancer patients. These facilities 
are hardly enough to treat the large numbers of cervical cancer patients, which may be 
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more than 600 cases a year in some centres. Moreover, waiting lists are long as some 
centres do not offer chemotherapy due to insufficient resources. (Simonds, 2009:66) 
Thus when the already limited radiation therapy equipment is not functioning properly, 
many of the patients may not be able to complete the prescribed cervical cancer 
treatment plan. This may explain why in the current study, 22% (22; n=100) of the HIV 
negative patients and 10% (7; n=72) of the HIV positive patients who were on HAART 
were either non adherent to their treatment or their treatment was prolonged. 
Low blood count (low Hb, white blood cell and platelet count) caused 24% (24; n=100) 
of the HIV negative patients, 54% (39; n=72) of the HIV positive patients who were on 
HAART and 9% (1; n=11) of the HIV positive patients who were not on HAART to 
complete their treatment over an extended period of time or not to complete the 
prescribed cervical cancer treatment at all (Table 5.11).  A significantly larger number of 
cases was reported among the HIV positive patients who were on HAART (39; 54%; 
n=72) (Chi2 = 4.0, d.f. = 2, p = 0.01327, Cramer‟s V = 0.15).  
Twenty five percent (25; n=100) of the HIV negative patients, 51% (37; n=72) of the HIV 
positive patients who were on HAART and 73% (8; n=11) of the HIV positive patients 
who were not on HAART were either not adherent to treatment or did not complete their 
treatment within the prescribed period due to RT induced skin breakdown (Table 5.11). 
This result was significant (Chi2 = 0.6, d.f. = 2, p = 0.04581, Cramer‟s V = 0.16), with the 
highest percentage of cases noted among the HIV positive women who were not on 
HAART (73%; 8; n=11). 
A significant difference in the incidence of RT induced diarrhoea was observed among 
the HIV negative patients (26; 26%; n=100), the HIV positive patients who were on 
HAART (41; 57%; n=72) and the HIV positive patients who were not on HAART (7; 
64%; n=11) (Table 5.11). The highest percentage of cases was reported in the HIV 
positive women who were not on HAART (64%; 7; n=11) (Chi2 = 6.9, d.f. = 2, p = 
0.03118, Cramer‟s V = 0.19).   
In some of the cervical cancer patients, the doctor terminated the prescribed treatment 
plan if the risks of the treatment outweighed the benefits, that is if the patient 
128 
 
experienced unacceptable toxicity due to the treatment and had poor tumour control. 
This occurred in 19% (19; n=100) of the HIV negative patients, 31% (22; n=72) of the 
HIV positive patients who were on HAART and 64% (7; n=11) of the HIV positive 
patients who were not on HAART (Table 5.11). The highest percentage of cases was 
significantly reported among the HIV positive patients who were not on HAART (64%; 7; 
n=11) (Chi2 = 4.8, d.f. = 2, p = 0.09023, Cramer‟s V = 0.16).  
The longer the time period over which the prescribed treatment is administered (for 
example, longer periods between doses), the shorter the overall survival, disease free 
survival and local control of the tumour (Waggoner, 2003:2223 and Taylor et al., 
1990:97). The American Brachytherapy Society recommends that the total treatment 
duration for cervical cancer should be less than eight weeks. After approximately eight 
weeks of therapy, the increase in local failure is 0.7% to 1.0% per day for every day of 
treatment missed. (Nag et al., 2000:202) Therefore, patients need to adhere to the 
prescribed cervical cancer treatment plan in order to achieve complete response to 
treatment.  
Limited studies have been conducted regarding the patterns of adherence to cervical 
cancer treatment among HIV positive women with cervical cancer. McArdle & Kigula-
Mugambe (2007:94-97) reported that HIV positive patients were more likely to have 
multiple factors that would lead to interruptions of cervical cancer treatment. Another 
prospective study by Gichangi et al. (2006:405-411) noted that HIV infection was an 
independent factor that led to treatment interruptions. In addition, HIV positive women 
were six times more likely to have residual tumours after radiation therapy. The findings 
of the current study did not support those of McArdle & Kigula-Mugambe (2007:94-97) 
and Gichangi et al. (2006:405-411) in that there was no significant difference in the 
incidence of adherence between the HIV negative patients, the HIV positive patients 
who were on HAART and the HIV positive patients who were not on HAART. However, 
there was a significant difference in the incidence of the various reasons (missed 
scheduled appointments, low blood count, RT induced skin breakdown and RT induced 
diarrhoea) for non adherence between the various groups.  
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In summary,  the current study did not find a significant difference in the incidence of 
adherence between the HIV negative patients, the HIV positive patients who were on 
HAART and the HIV positive patients who were not on HAART. However,  there was a 
significant difference in the incidence of the various reasons for non adherence between 
the various groups. These reasons included: missed scheduled appointments (Chi2 = 
2.9, d.f. = 2, p = 0.02385, Cramer‟s V = 0.31); low blood count (Chi2 = 4.0, d.f. = 2, p = 
0.01327, Cramer‟s V = 0.15); RT induced skin breakdown (Chi2 = 0.6, d.f. = 2, p = 
0.04581, Cramer‟s V = 0.16) and RT induced diarrhoea (Chi2 = 6.9, d.f. = 2, p = 
0.03118, Cramer‟s V = 0.19)  Larger studies assessing the adherence of HIV positive 
women with cervical cancer to cervical cancer treatment need to be done. It is vital to 
ensure that cervical cancer patients adhere to their prescribed treatment plan in order to 
achieve tumour control.  
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Chapter 6  
CONCLUSIONS AND RECOMMENDATIONS 
6.1  INTRODUCTION 
The aim of this study was to assess how HIV positive women who have been diagnosed 
with cervical cancer responded and adhered to cervical cancer therapy which includes: 
curative RT; CCRT or PRT. The study also set out to determine the effects of the 
concurrent use of ARVs and cervical cancer treatment. This was done to determine 
whether HIV positive women with ICC could be managed using the same treatment 
protocols as HIV negative women with ICC.   
6.2  CONCLUSIONS 
In this section, an overview of the conclusions drawn from the study will first be 
presented (section 6.2.1) followed by detailed conclusions (section 6.2.2) 
6.2.1  Overview 
The study revealed that there was a significant difference in the incidence of complete 
response to ICC treatment between the HIV positive patients and the HIV negative 
patients (Section 5.8.1 and 6.2.2.5). Cases of both treatment failure and metastases 
were significantly higher in HIV positive women than in HIV negative women (Section 
5.8.2 and 6.2.2.6). In terms of toxicity, haematological toxicity (leucopenia and 
thrombocytopenia) and neurological toxicity seemed to be increased in the HIV positive 
women who were on HAART. Dermatological (skin desquamation) and gastrointestinal 
toxicities (diarrhoea) as well as other toxicities such as weight loss appeared to be 
worse in the HIV positive patients (Section 5.9 and 6.2.2.8).  
Although there was no significant difference in the incidence of adherence between the 
HIV negative women, the HIV positive women who were on HAART and the HIV 
positive women who were not on HAART, there was a significant difference in the 
incidence of the various reasons (missed scheduled appointments; low blood count; RT 
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induced skin breakdown and RT induced diarrhoea) for non adherence between the 
various groups (Section 5.10 and 6.2.2.9).  
Finally, in terms of the 2004 South African national antiretroviral treatment guidelines, 
ARVs should be commenced in patients with WHO stage IV disease irrespective of their 
CD4 count. Patients presenting with cervical cancer would fall into the WHO stage IV 
category of HIV disease. (Department of Health, South Africa, 2004:12)  This implies 
that patients with confirmed diagnosis of ICC should be commenced on ARVs as soon 
as the ICC diagnosis is made whether their CD4 count is above 200 cells/mm3 or less. 
However, in the current study, 13% (n=83) of the HIV positiveparticipants were not on 
HAART.  
In summary, the aims and objectives of the study were fulfilled in that: 
 The patients‟ response to cervical cancer treatment was determined. There was a 
significant difference in the incidence of complete response to ICC treatment 
between the HIV positive patients and the HIV negative patients. The response to 
ICC treatment was poorer among HIV positive women. Cases of both treatment 
failure and metastases were significantly higher in HIV positive women than in HIV 
negative women. 
 The effect of the concurrent use of ARVs and cervical cancer treatment was also 
established. Although, the use of HAART by the HIV positive participants in the 
current study did not have a significant impact in the patient outcome, a higher 
percentage of cases of both treatment failure and metastases were reported in HIV 
positive women who were not on HAART. 
 There was no significant difference in the incidence of adherence between the HIV 
negative patients, the HIV positive patients who were on HAART and the HIV 
positive patients who were not on HAART. However, there was a significant 
difference in the incidence of the various reasons (missed scheduled appointments; 
low blood count; RT induced skin breakdown and RT induced diarrhoea) for non 
adherence between the various groups. 
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6.2.2  Detailed conclusions 
6.2.2.1 Conclusions: Patient demographics 
 Of the 196 participants, 100 participants (51%; n=196) were HIV negative, 83 
participants (42%; n=196) were HIV positive and 13 women‟s HIV status was 
unknown (7%; n=196). 
 The highest (69; 35%; n=196) number of participants were between 51 to 60 years 
old. 
 The mean age of the HIV positive women with cervical cancer (54 + 11.3 years) was 
four years lower than the mean age of HIV negative women (58 + 12.0 years)(t-test 
= 1.8409; d.f. = 180; p = 0.06728; Cohen‟s d = 0.27). 
6.2.2.2 Conclusions: Risk co-factors for cervical cancer 
 Thirty seven percent (72; n=196) of the participants had no risk co-factors, 41% (80; 
n=196) had one risk co-factor, 20% (39; n=196) had two risk co-factors and 2% (5; 
n=196) of the participants had three risk co-factors for cervical cancer. 
 The most prevalent risk co-factor was found to be HIV infection (42%; 83; n=196), 
followed by cigarette smoking (33%; 65; n=196), oral contraceptive use (27%; 53; 
n=196), high parity (15%; 30; n=196) and STI infection (13%; 25; n=196). 
6.2.2.3 Conclusions: The treatment protocols used at the study site 
 The study population consisted of six (3%; n=96) stage I patients, 27 (14%; n=196) 
stage II patients, 106 (54%; n=196) stage III patients and 57 (29%; n=196) stage 
IV cervical cancer patients. Thus, the majority (106; 54%; n=196) of the patients 
were diagnosed with Stage III cervical cancer. 
 Curative RT was prescribed for all six of the stage I cervical cancer patients and for 
most of the stage II cervical cancer patients (14; 52%; n=27). Concurrent 
chemoradiation was the recommended treatment of choice for most of the stage III 
cervical cancer patients (55; 52%; n=106). In the majority of the stage IV cervical 
cancer patients (49; 86%; n=57), RT was prescribed to palliate central disease or 
distant metastases. 
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6.2.2.4 Conclusions: Prognostic factors for cervical cancer 
  Patient characteristics: age and blood Hb levels 
 There was no significant difference in the mean age between the women who 
displayed complete response to cervical cancer treatment (56.7 + 12.3 years) and 
those who displayed an incomplete response to treatment (57.4 + 11.0 years) (t-test 
= 0.3766; p = 0.7069; Cohen‟s d = 0.05).  
 Eighty four percent (164; n=196) of the patients had anaemia (blood Hb level less 
than 12g/dl) during treatment (Table 5.5). Of the 164 anaemic patients, 53% (87; 
n=164) had an incomplete response to cervical cancer treatment. There was no 
significant difference between the prognosis of the anaemic patients and that of the 
non anaemic patients (Chi2 = 1.46, d.f. = 1, p = 0.22644, Cramer‟s V = 0.09).  
 Of the 164 patients who had anaemia, 31% (52; n=164) received curative RT, 2% (3; 
n=164) received CT, 39% (64; n=164) received CCRT and 28% (45; n=164) 
received PRT (Figure 5.4). Hence, the highest cases of anaemia were reported in 
patients who received concurrent chemoradiation. 
Tumour characteristics: stage at initiation of treatment 
 At one month following cervical cancer treatment there was a highly significant 
difference in the incidence of complete response in patients at different stages of 
cervical cancer (Chi2 = 88.9, d.f. = 3, p = 0.0000, Cramer‟s V =0.67). The high 
significant difference in response to treatment by patients at different stages of 
cervical cancer was maintained at six months after treatment (Chi2 = 70.94, d.f. = 3, 
p = 0.0000, Cramer‟s V = 0.62), 12 months after treatment (Chi2 = 48.53, d.f. = 3, p 
= 0.0000, Cramer‟s V = 0.54), 18 months after treatment (Chi2 = 32.02, d.f. = 3, p = 
0.0000, Cramer‟s V = 0.5) and 24 months after treatment (Chi2 = 18.69, d.f. = 3, p = 
0.0032, Cramer‟s V = 0.45). At each of these intervals, the response to cervical 
cancer treatment was poorer among women with advanced stage cervical cancer 
(stage III and IV).  
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Treatment characteristics: duration of treatment 
 A highly significant difference in the average duration of treatment between the 
patients who had a complete response to RT (6 weeks) and the patients who had 
an incomplete response to RT (5 weeks) was reported (t-test = 2.91678 p = 
0.00487, Cohen‟s d = 0.79). 
 There was no significant difference in the average duration of treatment between 
the patients who had a complete response to CCRT (9 weeks) and the patients who 
had an incomplete response to CCRT (8 weeks) (t-test = 0.93828 p = 0.35137, 
Cohen‟s d = 0.3).  
 The average duration of treatment of the patients who had an incomplete response 
to RT (5 weeks) or CCRT (8 weeks) was lower than that of the patients who 
displayed complete response to RT (6 weeks) or CCRT (9 weeks). This was due to 
the fact that some of the patients who exhibited an incomplete response to RT or 
CCRT did not complete the prescribed treatment either due to non adherence to the 
prescribed treatment or early termination of treatment by the oncologist. Therefore, 
the current study could not establish a link between the duration of cervical cancer 
treatment and patient outcome. 
 There was no significant difference in the average duration of treatment between 
the patients who had a complete response to PRT (9 + 1 days) and the patients 
who had an incomplete response to PRT (10.6 + 6 days) (t-test = 2.61688 p = 
0.92613, Cohen‟s d = 0.79).  
6.2.2.5 Conclusions: Response to cervical cancer treatment in HIV positive versus 
HIV negative women 
 There was a significant difference in the response to cervical cancer treatment 
between the HIV positive patients and the HIV negative patients. These significant 
differences were observed at each interval: one month after treatment (Chi2 = 16.4, 
d.f. = 1, p = 0.00005, Cramer‟s V =0.31); six months after treatment (Chi2 = 15, 
d.f.= 1, p = 0.00011, Cramer‟s V = 0.34); 12 months after treatment (Chi2 = 20.5, 
d.f. = 1, p = 0.00001, Cramer‟s V = 0.37); 18 months after treatment (Chi2 = 9.8, 
d.f. = 1, p = 0.00173, Cramer‟s V = 0.28) and 24 months after treatment (Chi2 = 
135 
 
5.0, d.f. = 1, p = 0.02571, Cramer‟s V = 0.26). At each of these intervals, the 
response to cervical cancer treatment was poorer among HIV positive women.  
6.2.2.6 Conclusions: Response to cervical cancer treatment in HIV positive 
women on HAART versus HIV positive women not on HAART 
 Of the 83 HIV positive patients, 87% (72; n=83) were on HAART and 13% (11; 
n=83) were not on HAART and HAART was only initiated in HIV positive women 
whose CD4 count was less than 200 cells/mm3. 
 Of the 72 HIV positive women who were on HAART, 81% (58; n=72) were on 
regimen 1a (d4T; 3TC; EFV), 5% (4; n=72) were on regimen 1b (d4T; 3TC; NVP) 
and 14% (10; n=72) were on regimen 2 (AZT; DDI; LPV-RTV). 
 A significant difference in the incidence of complete response to cervical cancer 
treatment between the HIV positive patients who were on HAART and the HIV 
positive patients who were not on HAART was only noted six months after these 
patients received treatment (Chi2 = 0.5, d.f. = 1, p = 0.02546, Cramer‟s V = 0.25) 
where complete response was observed in 39% (28; n=72) of the HIV positive 
patients who were on HAART and in none (0; n=11) of the HIV positive patients 
who were not on HAART. No significant differences in the incidence of complete 
response between these two groups were noted at the other time intervals: one 
month after treatment (Chi2 = 1.6, d.f. = 1, p = 0.21071, Cramer‟s V =0.14) and 12 
months after treatment (Chi2 = 1.2, d.f. = 1, p = 0.28067, Cramer‟s V = 0.13). The 
number of HIV positive patients who returned to the study site 18 months and 24 
months after they had received treatment were too small to be statistically 
analysed. Therefore, the use of HAART by the HIV positive participants in the 
current study did not have a significant impact in the patient outcome. 
 Since patients presenting with cervical cancer would fall into the WHO stage IV 
category of HIV disease, all patients with confirmed diagnosis of ICC should have 
been commenced on ARVs as soon as the ICC diagnosis was made irrespective of 
their CD4 count. In this study, only 72 of the 83 HIV positive patients were on 
HAART. 
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6.2.2.7 Conclusions: Recurrence and metastases of cervical cancer 
 The number of HIV positive patients (72%; 60; n=83) with recurrence of cervical 
cancer was significantly higher than that of the HIV negative patients (40%; 40; 
n=100) (Chi2 = 17.8, d.f. = 2, p = 0.00013, Cramer‟s V = 0.31). 
 Metastases of cervical cancer was also significantly higher in HIV positive patients 
(44%; 35; n=83) than in HIV negative patients (14%; 14; n=100) (Chi2 = 13.6, d.f. = 
2, p = 0.00109, Cramer‟s V = 0.28). 
6.2.2.8 Conclusions: Toxicity due to treatment in HIV positive versus HIV negative 
cervical cancer patients 
 Only one patient did not experience toxicity/side effects during or after ICC 
treatment. The number of side effects that were noted in the patients ranged from 
one to ten. Most of the patients experienced four side effects (46; 27%; n=171).   
 On average, HIV negative patients experienced 3.8 + 1.6 side effects per patient, 
HIV positive patients who were on HAART experienced 4.9 + 2.1 side effects per 
patient and HIV positive patients who were not on HAART experienced 4.3 + 1.3 
side effects per patient. There was a significant difference in the incidence of the 
number of side effects per patient in the HIV negative patients and in the HIV 
positive patients who were on HAART (Tukey‟s HSD procedure, p = 0.00013). 
However no significance was noted in the incidence of the number of side effects 
per patient in the HIV positive patients who were not on HAART (Tukey‟s HSD 
procedure, p = 0.50984). 
 The most common toxicity that was reported in the study population was 
haematological toxicity (164; 84%; n=196) and the highest cases were reported 
among HIV positive patients who were on HAART. The incidence of leucopenia 
and thrombocytopenia was significantly highest in this specific group (Chi2 = 9.3, 
d.f. = 2, p = 0.00948, Cramer‟s V = 0.23 and Chi2 = 10.5, d.f. = 2, p = 0.00535, 
Cramer‟s V = 0.24 respectively). 
 Radiation induced dermatological toxicity (skin desquamation), gastrointestinal 
toxicity (diarrhoea) and weight loss were significantly higher among the HIV 
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positive women (Chi2 = 4.2, d.f. = 2, p = 0.02512, Cramer‟s V = 0.15; Chi2 = 1.2, 
d.f. = 2, p = 0.04536, Cramer‟s V = 0.23 and Chi2 = 14.4, d.f. = 2, p = 0.00074, 
Cramer‟s V = 0.28 respectively).  
 The occurrence of CIPN was significantly higher in HIV positive patients who were 
on HAART (15; 22%; n=69) (Chi2 = 16.3, d.f. = 2, p = 0.00029, Cramer‟s V = 0.30).  
6.2.2.9 Adherence to treatment in HIV positive versus HIV negative cervical 
cancer patients 
 Sixty one (61%; n=100) HIV negative patients, 52 (72%; n=83) HIV positive patients 
who were on HAART and seven (64%; n=11) HIV positive women who were not on 
HAART were adherent to cervical cancer treatment. There was no significant 
difference in the adherence patterns between these three groups (Chi2 = 10.2, d.f. = 
6, p = 0.11805, Cramer‟s V = 0.17). However, there was a significant difference in 
the incidence of the various reasons for non adherence between the various 
groups. These reasons included: missed scheduled appointments (Chi2 = 2.9, d.f. = 
2, p = 0.02385, Cramer‟s V = 0.31); low blood count (Chi2 = 4.0, d.f. = 2, p = 
0.01327, Cramer‟s V = 0.15); RT induced skin breakdown (Chi2 = 0.6, d.f. = 2, p = 
0.04581, Cramer‟s V = 0.16) and RT induced diarrhoea (Chi2 = 6.9, d.f. = 2, p = 
0.03118, Cramer‟s V = 0.19).   
6.3  RECOMMENDATIONS 
The following recommendations arose from the research study: creating awareness of 
cervical cancer prevention in order to ensure early detection and treatment of the 
disease; using iron supplementation to manage anaemia, a condition that affects the 
prognosis of ICC patients; altering the fractionation of RT which would help to reduce 
machine time and integrating ICC and HIV/AIDS management programmes. 
6.3.1  Creating awareness of cervical cancer prevention 
In the current study, there was a highly significant difference in the response to 
treatment by patients at different stages of cervical cancer. The response to cervical 
cancer treatment was poorer among women with advanced stage cervical cancer (stage 
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III and IV) (Section 5.7.2.1). Cervical cancer is one of the few cancers that can be easily 
managed if it is detected in its earliest stages. However, early detection and treatment 
of cervical cancer is challenging in South Africa because there is a lack of awareness of 
the causes, risk factors, symptoms and prevention strategies. In addition, there is a long 
delay, during referral of patients, between diagnosis and treatment thus the disease 
might progress into an advanced stage. 
Although the South African Department of Health developed a national cervical cancer 
screening policy in 2000, statistics have shown that by 2008, less than 20% of women 
had used this service. This low screening rate was caused by the lack of education 
about cervical cancer in the community. (Maree and Wright, 2007:61) Lack of 
awareness about cervical cancer was associated with low literacy levels (Department of 
Health, South Africa, 2007). Additionally, it has been shown that presenting information 
about HPV infection and cervical cancer as a sexually transmitted disease could 
discourage women from being screened as sexual practices that increase the risk of 
cervical cancer are perceived to be promiscuous and this leads to stigma (Maree and 
Wright, 2007:62). 
A low literacy level in women has been associated with lack of awareness about 
cervical cancer. Schalkwyk et al. (2008:9-17) interviewed 15 South African women with 
advanced cervical cancer in order to understand the routes they followed from the first 
signs and symptoms of disease to receiving treatment. The study showed that the 
women lacked awareness of cervical cancer as a disease. The participants knew that 
something was wrong with them, but lacked the knowledge of what was required to 
prevent the progression of precancer to advanced cervical cancer. Nine of the 15 
participants in the study had less than eight years of education. Similar results were 
reported in other studies not just in developing countries such as Tanzania (Kidanto et 
al., 2002:467-475) but also in the Netherlands which is a developed country (De Nooijer 
et al., 2002:362-369), where there was a link between the low literacy levels of women 
and the lack of knowledge about cervical cancer. 
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In 2007, the South African Department of Health found that eight million of the 
population would not benefit from existing written health promotional material due to low 
literacy levels (Department of Health, South Africa, 2007). In the case of cervical 
cancer, this means that women with low literacy levels would not understand the 
terminology used in the written material aimed at educating women about the 
prevention and management of cervical cancer.  
In addition, presenting cervical cancer as a sexually transmitted disease could 
discourage women from being screened as they may be perceived to be promiscuous 
and this might lead to stigma (Braun and Gavey, 1999:1463-1474 and Markey and 
Markey, 2007:55-65). In South Africa, Maree and Wright (2007:55-65) conducted a 
study to determine if presenting cervical cancer information in a non stigmatising way 
would promote cervical screening. The sample consisted of 105 women and 19% of 
these women had no schooling or only had primary education. The study revealed that 
the target group rejected the information because of the approach. By presenting HPV 
infection and cervical cancer as a sexually transmitted disease, the women felt that they 
would be perceived to be promiscuous. This could result in the avoidance of cervical 
screening because of the possible stigmatisation that they would experience, should 
cervical cancer be diagnosed.  
The study by Schalkwyk et al. (2008:9-17) also revealed that the average number of 
months from the first contact with a health care professional due to the signs and 
symptoms of cervical cancer until diagnosis, was 17.3 months, ranging from 28.4 
months for women living in rural areas to 11.8 months for women living in an urban 
area. The women living in Gauteng Province waited 2.8 months between diagnosis and 
being referred to the hospital for treatment, compared to 6.5 months for those who were 
referred from provincial hospitals outside Gauteng Province. The women were also not 
diagnosed with cervical cancer during their initial sessions with a health care 
professional. This was due to the nature of cervical cancer during the initial stages, the 
lack of insight on the part of the health professionals and some of the women did not 
report their main symptoms.  
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These problems could be addressed in various ways. Awareness programmes that are 
aimed at educating women about cervical cancer prevention and early detection should 
be tailored to the literacy level of women. The target population should be able to 
understand the language used and the content of the literature material. In addition, 
health professionals should be trained to recognise the signs and symptoms of cervical 
cancer. The South African Department of Health should also implement an effective 
referral system so as to decrease the time delay from diagnosis to treatment. 
In summary, cervical cancer prevention and early detection would involve: developing 
appropriate cervical cancer awareness programmes aimed at promoting cervical cancer 
screening; training health professionals to recognise the signs and symptoms of cervical 
cancer and implementing an effective referral system that would support the detection 
and treatment of cervical cancer in its earliest stages thus improving treatment 
outcomes. 
6.3.2  Use of iron supplementation to manage anaemia 
Anaemia at diagnosis and/or during treatment may affect the prognosis of cervical 
cancer patients. In the current study, 164 patients experienced anaemia during 
treatment and of these 164 patients who had anaemia, 53% (87; n=164) had an 
incomplete response to treatment. Furthermore, low blood count (low Hb, white blood 
cell and platelet count) caused 24% (24; n=100) of the HIV negative patients, 54% (39; 
n=72) of the HIV positive patients who were on HAART and in 9% (1; n=11) of the HIV 
positive patients who were not on HAART to complete their treatment over an extended 
period of time or not to complete the prescribed cervical cancer treatment at all (Table 
5.11). 
At the study site, anaemia was corrected by administering blood transfusions to patients 
whose Hb level was below 12g/dl. However, the benefit of blood transfusions in cancer 
patients remains unclear. A randomised trial by Fyles et al. (2000:130-139) that 
investigated the benefits of blood transfusions in cervical cancer patients drew 
unconvincing results. In another study by Sundfor et al. (1997:230-236), only 50% of the 
cervical cancer patients showed an increase in tumour oxygenation after receiving 
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blood transfusions thus suggesting that blood transfusions cannot broadly reduce the 
number of hypoxic tumour cells that are resistant to radiotherapy. Santin et al. (2003:28-
34) reported that the use of routine blood transfusions in anaemic cervical cancer 
patients did not improve the prognosis of the patients. 
Blood transfusions also pose safety and financial challenges. The adverse effects of 
blood transfusions include transmission of infections, allergic and febrile reactions, 
platelet contamination, lung injury and errors relating to incorrect matching of the donor 
and recipient.  Furthermore, the management of blood transfusion services is expensive 
for health care institutions, especially in developing countries such as South Africa in 
terms of the maintenance cost of blood banks and other operational costs such as 
delivering blood to patients. (Hinkel et al., 2010:S42) 
Over the years, alternatives to blood transfusions such as recombinant human 
erythropoietin (rhEPO) and oral or intravenous iron supplementation have been 
developed to maintain Hb levels in patients with cervical cancer.  Despite the existence 
of clinical evidence that supports the use of iron supplementation in cancer patients, this 
approach has not been widely accepted by oncologists. Many oncologists lack 
understanding regarding the use of iron supplementation to treat anaemia in cervical 
cancer patients. (Hinkel et al., 2010:S48) 
Therefore, oncology pharmacists can play a vital role in this area by educating the 
oncologists on the benefits and risks of iron supplementation. This may dispel any 
misconceptions about the safety of iron supplementation. The use of iron 
supplementation may prove to be beneficial in the management of anaemic cervical 
cancer patients in South Africa where many patients have poor access to blood 
transfusion facilities. 
As anaemia can affect the treatment outcomes, it is imperative to ensure that this 
condition is corrected using blood transfusions, rhEPO and oral or intravenous iron 
supplementation. 
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6.3.3  Altered fractionation of radiotherapy 
At the study site, the prescribed radiotherapy treatment for Stage Ib to III disease 
included EBRT 50 Gy in 25 fractions, 2 Gy daily over five weeks and ICT brachytherapy 
24.8 Gy in four fractions, (6.2 Gy/fraction). This is not only labour intensive but with long 
waiting lists for RT machine time, particularly in the public health sector, other options 
should be considered. Further studies need to be conducted in hypofractionation or the 
delivery of radiotherapy in larger fractions per dose. 
Campbell et al. (2002:253-258) examined this concept by randomising 480 patients in 
Nairobi to either conventional fractionation (45 to 50 Gy over five weeks) or 
hypofractionation (45 to 50 Gy over three weeks). Five year survival rates of Stage III 
patients were 42.5% and 40.2% respectively. Early toxicity was similar in both groups 
but there was a higher rate of late toxicity in the hypofractionated group thus the authors 
recommended that caution should be applied in the use of the hypofractionated 
regimen. Muckaden et al. (2002:127-134) from Mumbai retrospectively reviewed 
patients with stage III cervical cancer who received 39 Gy in 13 fractions followed by a 
single ICT brachytherapy treatment of 25 Gy. Of the 62 patients treated, 48 completed 
the regimen.  The three year survival rate was 50%. Six patients had severe acute 
toxicity and five patients had late rectal toxicity. The role that hypofractionated 
radiotherapy plays in treatment of cervical cancer has not been defined and thus further 
studies need to be conducted in order to develop a regimen that maximises tumour 
control and use of resources while limiting toxicities. 
6.3.4  Integration of cervical cancer and HIV/AIDS management 
Although South Africa has a National Cancer Registry, the cervical cancer statistics 
were last recorded in 2001 and may be outdated (Bourke, 2007). Therefore, it is difficult 
to determine the number of South African women with cervical cancer. It has been 
reported that in South Africa, up to 30% of cervical cancer patients are HIV positive 
(Mqoqi et al., 2004:22). In the current study, 42% (83; n=196) of the ICC patients were 
HIV positive. Of the 83 HIV positive patients, 87% (72; n=83) were on HAART.Since the 
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WHO stage IV category of HIV disease includes ICC, all patients with confirmed 
diagnosis of ICC should have been commenced on ARVs as soon as the ICC diagnosis 
was made irrespective of their CD4 count. Therefore, oncologists should ensure that 
HIV positive patients with ICC are started on HAART as soon as ICC diagnosis is made.  
The ideal situation would be for every HIV positive woman with ICC to start HAART as 
soon as diagnosis is made, but the reality is that in sub Saharan African about seven 
out of 10 HIV positive patients who clinically need ARVs do not receive them. South 
Africa has the largest ARV programme in the world. In 2003, the South African 
Department of Health launched the national ARV roll-out with its comprehensive plan for 
the care, management and treatment of HIV and AIDS. The aim of the programme was 
to ensure that in five years time, all HIV positive women in need of ARVs had access to 
this medication. The ARV roll out in the Eastern Cape, where the current study site is 
located began in mid June 2004. By 2006, it was clear that it would take more than 5 
years to fulfil this aim because less than 30% of South African HIV positive women who 
were in need of ARVs had access to ARVs. In 2007, the Department of Health 
published the National Strategic Plan which aimed to achieve access to ARVs for 80% 
of the people who would need them by 2011. Since the implementation of the 2007 to 
2011 National Strategic Plan, the public sector ARV programme has steadily increased 
the numbers of monthly new enrolments on ARVs and decreased waiting times for the 
HIV positive patients eligible for ARVs. However, there are still delays and problems in 
accrediting ARV public health facility sites, providing appropriately trained health 
personnel and registering ARVs. (Uebel et al., 2010:589) Consequently, not every HIV 
positive patient with ICC has access to ARVs thus their CD4 count may deteriorate and 
they may not be able to tolerate ICC treatment and this may lead to unfavourable 
treatment outcomes. 
In South Africa, oncology services are provided in tertiary level institutions. A feasible 
solution would be to test all patients diagnosed with ICC for HIV.  Since patients 
presenting with cervical cancer would fall into the WHO stage IV category of HIV 
disease, oncologists should refer all the newly diagnosed HIV positive patients or HIV 
positive patients who were previously not eligible for HAART to the ARV clinic that is 
144 
 
located at the tertiary level hospital. The patients should continue to receive the ARVs 
from the ARV clinic located at the tertiary level hospital during their course of cervical 
cancer treatment (CCRT/RT). Once treatment is completed, the patients should be 
referred to an ARV clinic which is conveniently located within their area of residence or 
employment where they would continue to receive treatment for the rest of their lives. 
6.4 AREAS FOR FUTURE RESEARCH 
The findings of the current study identified potential areas for future research in the 
fields of HIV/AIDS and cervical cancer. More studies need to be conducted in order to 
find out if large single fractions of PRT, rather than multiple fractions of PRT, which 
provide optimal patient outcome with minimal use of resources may be preferable if 
similar palliative results could be achieved. 
There is mixed evidence concerning the impact of HAART on patient outcome. Some 
studies suggest that the use of HAART has led to improved tolerance of full doses of RT 
or CCRT and improved response to cancer treatment (Antoniou & Tseng, 2005:143 and 
Ntekim & Folasire, 2010:64). In contrast, other studies suggest that the use of HAART 
does not seem to have a significant effect on patient outcome (Brunner et al., 2008: 
2706 and Caceres et al., 2010:73). In the current study, the use of HAART by the HIV 
positive participants did not have a significant impact on the patient outcome, though 
the study was based on a small population and a short follow up period. Therefore, 
more studies still need to be conducted so as to establish conclusive results on the 
impact of HAART on ICC. Larger studies assessing the adherence patterns and the 
acute and late toxicity experienced by HIV positive women undergoing cervical cancer 
treatment also need to be undertaken.  
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APPENDIX ONE 
ETHICAL APPROVAL 
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APPENDIX TWO 
PERMISSION FROM MEDICAL SUPERINTENDENT 
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APPENDIX THREE 
AUDIT FORM USED IN THE PILOT STUDY 
RESPONSE AND ADHERENCE OF HIV POSITIVE WOMEN DIAGNOSED WITH CERVICAL 
CANCER TO CERVICAL CANCER TREATMENT. 
A.  Demographics. 
1. Date of birth at diagnosis: 
 
 
B.  HIV status 
1. HIV positive: 
 
 
 
2. Year of diagnosis: 
 
 
3. CD4 count (cells/mm3): 
 
At diagnosis dd/mm/yy dd/mm/yy dd/mm/yy dd/mm/yy dd/mm/yy 
      
dd/mm/yy dd/mm/yy dd/mm/yy dd/mm/yy dd/mm/yy dd/mm/yy 
      
 
4. ARV treatment:  
Yes No 
 
 
Yes No Unknown 
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5. ARV regimen:         
 
 
 
Diagnosis/initiation 
 
 
During 5 year period 
 
Medication 
 
Date 
 
 
Dose 
 
Date 
 
Dose 
Didanosine (DDI)     
Lamivudine (3TC)     
Stavudine (D4T)     
Zidovudine (ZDV)     
Efavirenz (EFV)     
Nevirapine (NVP)     
Indinavir (IDV)     
Lopinavir (LPV)     
Ritonavir (RTV)     
Other      
     
     
 
C. Cervical cancer status 
1.  Date of diagnosis:  
 
 
2. Stage at diagnosis: 
Stage I IA1 IA2 IB1 IB2 
Stage 2 IIA IIB   
Stage 3 IIIA IIIB   
Stage 4 IVA IVB   
 
 
3. Treatment option: 
178 
 
Radiotherapy Chemoradiotherapy Surgery Palliative 
    
 
4. Treatment: 
Option Dose (Gy) Tmnt 
commenced 
Tmnt 
completed 
No. of 
fields 
Overall time 
(days) 
Radiation GD CD SD     
External beam        
Brachytherapy        
Option  Dose Date/yr of initiation Frequency Number of 
chemotherapy  
or radiation 
cycles 
Chemotherapy Mg/m
2
    
Carboplatin     
Cisplatin     
Dose/agent 
changes if 
applicable 
    
     
     
     
 
*GD= Given dose; CD= Central dose; SD= skin dose 
 
5. Complications present at diagnosis (e.g. recto-vaginal fistula, vesico-vaginal fistula) 
Date Complication 
  
  
 
 
D.  Response to cervical cancer treatment 
1.   Laboratory tests on diagnosis: 
Test Date Result  Normal range 
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FBC and platelets    
WCC   4.0-10.0 x10
9
/l 
RCC   3.80-4.80 x10
12
/l 
Haemoglobin   12.0-15.0 g/dl 
MCV   79.1-98.9 fl 
MCH   27.0-32.0 pg 
MCHC   32.0-36.0 
Red cell distribution width   11.6-14.0 
Platelets   178-400 x10
9
/l 
Differential count    
Neutrophils   2.0-7.5 x10
9
/l 
Monocytes   0.18-0.8 x10
9
/l 
Lymphocytes   1.0-4.0 x10
9
/l 
Eosinophils   0.0-0.45  x10
9
/l 
Basophils   0.0-0.20 x10
9
/l 
Haematology    
Reticulocyte count   0.5-2.0 % 
Absolute reticulocyte count   0.05-0.100 x10
12
/l 
Haematocrit   0.36-0.46 l/l 
Liver function (LFT)    
ALP   <35-130 U/I 
GGT   <70 U/I 
ALT   < 60 U/I 
AST   <35 U/I 
Other    
 
2.   Laboratory tests if repeated: 
Test Date Result  Date Result Date Result Normal range 
FBC and 
platelets 
       
WCC       4.0-10.0 x10
9
/l 
RCC       3.80-4.80 x10
12
/l 
Haemoglobin       12.0-15.0 g/dl 
MCV       79.1-98.9 fl 
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MCH       27.0-32.0 pg 
MCHC       32.0-36.0 
Red cell 
distribution 
width 
      11.6-14.0 
Platelets       178-400 x10
9
/l 
Differential 
count 
       
Neutrophils       2.0-7.5 x10
9
/l 
Monocytes       0.18-0.8 x10
9
/l 
Lymphocytes       1.0-4.0 x10
9
/l 
Eosinophils       0.0-0.45  x10
9
/l 
Basophils       0.0-0.20 x10
9
/l 
Haematology        
Reticulocyte 
count 
      0.5-2.0 % 
Absolute 
reticulocyte 
count 
      0.05-0.100 x10
12
/l 
Haematocrit       0.36-0.46 l/l 
Liver 
function 
(LFT) 
       
ALP       <35-130 U/I 
GGT       <70 U/I 
ALT       < 60 U/I 
AST       <35 U/I 
Other        
 
6. Audiogram test results: 
Date Result 
  
 
7. Ultrasound results: 
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Date Abdominal Pelvic Chest 
    
    
    
 
8. Clinician‟s follow up physical examination: 
Date General Vaginal 
exam 
Rectal 
exam 
Respiratory Skin Abdomen Extremities Other 
         
         
         
         
         
 
9. Other tests (e.g. cystogram) 
Date Test Result 
   
   
 
E.  Adherence to cervical cancer treatment 
1.  Number of missed doses: 
 Total 
prescribed 
Number of 
missed doses 
 
Dates missed 
Radiation      
Chemotherapy      
 
2. Reason for missing dose: 
Patient factors Hospital factors Other factors 
Missed appointment Equipment failure  
Low white blood count at time of 
scheduled treatment 
Other  
Other   
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F.  Adverse effects 
     
Adverse effect Present Radiation and 
carboplatin 
Radiation and cisplatin On ARVs 
Anaemia     
Thrombocytopenia     
Leucopenia     
Nausea and vomiting     
Diarrhoea      
Constipation     
Rectovaginal fistula     
Radiation proctitis     
Skin desquamation     
Peripheral neuropathy     
Renal toxicity     
Deep vein thrombosis     
Weight loss     
Pain     
 
G.  Mortality 
1.  Date of death: 
 
 
 1 year 2 years 3 years 4 years 5 years 
Living      
Deceased      
 
2. Cause of death: 
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Cervical cancer related HIV related Other 
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APPENDIX FOUR 
AUDIT FORM USED IN THE MAIN STUDY 
 
RESPONSE AND ADHERENCE OF HIV POSITIVE WOMEN DIAGNOSED WITH CERVICAL 
CANCER TO CERVICAL CANCER TREATMENT. 
A.  Demographics. 
1. Date of birth at diagnosis: 
 
 
B.  HIV status 
2. HIV positive: 
 
 
 
3. Year of diagnosis: 
 
 
4. CD4 count (cells/mm3): 
 
At diagnosis dd/mm/yy dd/mm/yy dd/mm/yy dd/mm/yy dd/mm/yy 
      
dd/mm/yy dd/mm/yy dd/mm/yy dd/mm/yy dd/mm/yy dd/mm/yy 
      
 
5. ARV treatment:  
Yes No 
 
6. ARV regimen: 
Yes No Unknown 
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Diagnosis/initiation 
 
 
During 2 year period 
 
Medication 
 
Date 
 
 
Dose 
 
Date 
 
Dose 
Didanosine (DDI)     
Lamivudine (3TC)     
Stavudine (D4T)     
Zidovudine (ZDV)     
Efavirenz (EFV)     
Nevirapine (NVP)     
Indinavir (IDV)     
Lopinavir (LPV)     
Ritonavir (RTV)     
Other      
     
     
 
C. Cervical cancer status 
1.  Date of diagnosis:  
 
 
2. Stage at diagnosis: 
Stage I IA1 IA2 IB1 IB2 
Stage 2 IIA IIB   
Stage 3 IIIA IIIB   
Stage 4 IVA IVB   
 
Risk factors: 
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Smoking  
Parity  
Hormonal contraception  
STI  
 
3. Treatment option: 
Radiotherapy Chemotherapy Chemoradiotherapy Surgery Palliative 
     
 
4. Treatment: 
Option Dose (Gy) Tmnt 
commenced 
Tmnt 
completed 
No. of fields Overall time 
(days) 
Radiation GD CD SD     
External beam        
        
        
        
        
Brachytherapy        
Option  Dose Date/yr of initiation Frequency Number of 
chemotherapy  
or radiation 
cycles 
Chemotherapy Mg/m
2
    
Carboplatin     
Cisplatin     
Dose/agent 
changes if 
applicable 
    
     
 
*GD= Given dose; CD= Central dose; SD= skin dose 
 
 
5. Complications present at diagnosis (e.g. recto-vaginal fistula, vesico-vaginal fistula) 
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Date Complication 
  
  
 
 
D.  Response to cervical cancer treatment 
1.   Laboratory tests on diagnosis: 
Test Date Result  Normal range 
Haematology tests    
WCC   4.0-10.0 x10
9
/l 
Haemoglobin   12.0-15.0 g/dl 
Platelets   178-400 x10
9
/l 
Urea, electrolytes, 
creatinine 
   
Sodium   135-147 mmol/l 
Potassium   3.3-5.3 mmol/l 
Chloride   99-113 mmol/l 
Urea   2.6-7.0 mmol/l 
Creatinine   60-100 mmol/l 
Liver function (LFT)    
Bilirubin total   0-21 µmol/l 
Total  protein   60-85 g/l 
Albumin   35-52g/l 
ALP   <40-120 U/I 
GGT   <0-35 U/I 
ALT   < 5-40U/I 
AST   <5-40U/I 
Lactate Dehydrogenase   100-190 U/l 
Chemistry tests    
Calcium   2.05-2.56 mmol/l 
Albumin   35-52 g/l 
Calcium (corrected)   2.05-2.56 mmol/l 
Magnesium   0.65-1.10 mmol/l 
Other    
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2.   Laboratory tests if repeated: 
Test Date Date Date Date  Date  Date Normal range 
        
Haematology 
tests 
       
WCC       4.0-10.0 x10
9
/l 
Haemoglobin       12.0-15.0 g/dl 
Platelets       178-400 x10
9
/l 
Urea, 
electrolytes, 
creatinine 
       
Sodium       135-147 mmol/l 
Potassium       3.3-5.3 mmol/l 
Chloride       99-113 mmol/l 
Urea       2.6-7.0 mmol/l 
Creatinine       60-100 mmol/l 
Liver function 
(LFT) 
       
Bilirubin total       0-21 µmol/l 
Total  protein       60-85 g/l 
Albumin       35-52g/l 
ALP       <40-120 U/I 
GGT       <0-35 U/I 
ALT       < 5-40U/I 
AST       <5-40U/I 
Lactate 
Dehydrogenase 
      100-190 U/l 
Chemistry tests        
Calcium       2.05-2.56 mmol/l 
Albumin       35-52 g/l 
Calcium 
(corrected) 
      2.05-2.56 mmol/l 
Magnesium       0.65-1.10 mmol/l 
189 
 
Other        
        
 
3. Audiogram test results: 
Date Result 
  
 
4. Ultrasound results: 
Date Abdominal Pelvic Chest 
    
    
    
 
5. Clinician‟s follow up physical examination: 
Date General Vaginal 
exam 
Rectal 
exam 
Respiratory Skin Abdomen Extremities Other 
         
         
         
         
         
 
6. Other tests (e.g. cystogram, bone scan) 
Date Test Result 
   
   
 
E.  Adherence to chemoradiotherapy 
1.  Number of missed doses: 
 Total 
prescribed 
Number of 
missed doses 
 
Dates missed 
Radiation      
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Chemotherapy      
 
2. Reason for missing dose: 
Patient factors Hospital factors Treatment factors 
Missed appointment Equipment failure Low white blood count at time of 
scheduled treatment 
  RT induced diarrhoea 
  RT induced skin breakdown 
  Early termination by doctor 
 
F.  Adverse effects 
     
Adverse effect Present Radiation and 
carboplatin 
Radiation and cisplatin On ARVs 
Anaemia     
Thrombocytopenia     
Leucopenia     
Nausea and vomiting     
Diarrhoea      
Constipation     
Rectovaginal fistula     
Radiation proctitis     
Skin desquamation     
Peripheral neuropathy     
Renal toxicity     
Deep vein thrombosis     
Weight loss     
Pain     
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